











This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
• This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
• A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
• This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
• The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
• When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 
 
Characterisation of a novel Rab18 










Thesis submitted for the degree of Doctor of Philosophy 





This thesis is composed of original research undertaken by myself, and where the 










Firstly, I wish to thank Irene for taking me on as a student and starting the project. 
You have had a very difficult few years but have still always been there to provide 
support and guidance whenever needed. It has been an honour to work with you and 
continue this project. 
Thank you to Ian for allowing me to become part of your lab; it has been a fantastic 
group to work for. Thank you for your support and enthusiasm in the project and 
interesting discussions and ideas after every new result. 
Thank you to Mark for your help and guidance and answering questions and queries; 
including those starting with “I know this is a stupid question but...” Thank you for 
your passion in the RAB protein field and science in general, you have showed me 
how great work in this field can be. 
Thank you to the Jackon lab for adopting me and making me feel like part of the 
family. Thanks for all your help and support and sharing reagents and antibodies. In 
particular, thanks to Lisa for all your help with phenotyping and maintenance of the 
mouse colony. Thanks to Lisa and Shalini for all your help with sectioning and 
characterisation of the mouse eye phenotype. Thanks to everyone in C204 office, 
thanks for all the gossips and chats over the last few years, and for being a great 
distraction exactly when needed.  
Thank you to Tom Gillingwater for also taking me in and making me part of your 
lab. Thank you for your interest, enthusiasm and ideas for taking this project forward 
and always making time for me either for brainstorming sessions, paper writing 
meetings or just general discussions. Thank you to Tom Wishart for help with 
analysis of the proteomics and IPA. Thanks to all members of the Gillingwater lab, 
in particular, thank you to Eilidh, Sarah and Sophie for teaching the nerve and 
muscle dissections. Thanks to Derek for coming across to perform the sciatic nerve 
ligation surgery, twice! Thanks to Sarah and Ann for processing the nerves and 
sectioning for EM. 
Thank you to Mike Cousin and Sarah Gordon for your help with the synaptic vesicle 
recycling experiments. 
Thank you to Paul Perry and Matt Pearson for microscope help and support. Thanks 
to Allyson Ross for help with histology. Thank you to Ian McCall and all technical 
staff at the BRF for managing the mouse colony. Thank you to Professor Francis 
Barr for the GFP-RAB18 and GFP-TBC1D20-RA constructs. Thanks also to Harris 
Morrison for performing the OPT processing and imaging. 
Thank you to Dad, Mum, Helen, Bex and Grandma for your continued support and 
patience throughout my studies, you can all breathe a sigh of relief the studies are 
almost over! Thank you for listening to me rant and stress and I hope to spend more 
weekends at home with you all, when this is all completed. 
iv 
 
And last but by no means least, I wish to thank Mike. Thanks for your help with 
illustrator. Thanks for your support and patience over the last eight years, it has 
meant more to me than you could ever know.  Thank you for knowing exactly when I 
needed you there and when I needed peace, and for trying to keep quiet when Cardiff 







I dedicate this thesis in loving memory of Nonno, who was so proud that there could 
one day be a Dr Carpanini but never lived to see it happen. And to Mike, my fiancé, 















Warburg Micro syndrome is a severe autosomal recessive condition characterised by 
abnormalities affecting the ocular, neurological and endocrine systems. Previous 
studies have identified causative loss-of-function mutations in four members of the 
RAB protein network; RAB3GAP1, RAB3GAP2, RAB18 and TBC1D20, causing 
clinically indistinguishable phenotypes. RAB3GAP1 and RAB3GAP2 form a 
heterodimeric complex specifically regulating the RAB3 family of proteins in 
calcium mediated exocytosis of hormones and neurotransmitters. Rab3gap1 deficient 
mice have previously been generated and showed altered short term plasticity in the 
hippocampus and inhibition of Ca2+ mediated exocytosis of glutamate from cortical 
synaptosomes, but failed to recapitulate the characteristic ocular or neurological 
features of Warburg Micro syndrome. Mutations in TBC1D20, a GTPase activating 
protein (GAP) for the RAB1 family, have recently been identified in Warburg Micro 
syndrome patients and the bs (blind sterile) mouse model; although this model 
recapitulated many ocular and endocrine abnormalities of the disease any 
neurological abnormalities have yet to be reported. 
The function and localisation of RAB18 remains to be fully elucidated and its role in 
disease pathogenesis is still unclear. Initially, I have confirmed previous reports co-
localising RAB18 with the cis-Golgi, ER and lipid droplets in mouse embryonic 
fibroblasts and identified a novel localisation in neuronal processes of primary 
hippocampal neurons. To examine the role of RAB18 in vivo a novel Rab18 genetrap 
mouse was generated by MRC Harwell as part of the EUMODIC screen. In this 
study I describe detailed histopathological and neurological characterisation of the 
Rab18-/- mouse model. Rab18-/- mice were viable and fertile. At eye opening they 
presented with dense nuclear congenital cataracts and atonic pupils recapitulating 
major ocular features of Warburg Micro syndrome. Analysis of embryonic eye 
development revealed a delay in lens development in Rab18-/- mice as early as 
embryonic day 12.5. From three weeks of age Rab18-/- mice developed progressive 
hind limb weakness indicative of neurological dysfunction. I have undertaken 
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detailed neuropathological analysis of the observed hind limb weakness and 
identified no abnormalities in synaptic vesicle recycling and no atrophy of peripheral 
muscles or aberrant development or stability of neuromuscular connectivity. 
However, loss of RAB18 resulted in gross accumulations of neurofilament and 
microtubule proteins at the neuromuscular junction and disorganisation of the 
cytoskeleton in peripheral nerves. Investigation of global proteomic profiling in 
peripheral nerve of Rab18-/- mice identified alterations in core pathways regulating 
the axonal cytoskeleton in neurons. 
In summary this thesis describes a novel Rab18-/- mouse model recapitulating the 
characteristic ocular and neurological features of Warburg Micro syndrome. I 
highlight a novel mechanistic insight into Warburg Micro syndrome disease 
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Chapter 1 Introduction 
1.1 Warburg Micro syndrome  
1.1.1 Clinical features 
Warburg Micro syndrome (MIM:600118, 614222, 614225) is a severe 
neurodevelopmental disorder of autosomal recessive inheritance. It was initially 
reported in 1993 by Mette Warburg in two siblings and a male cousin from a 
consanguineous family of Pakistani origin (Warburg et al., 1993). All three affected 
individuals presented with microcornea, congenital cataracts, pinpoint pupils, retinal 
dystrophy and atrophy of the optic nerve. They also displayed hypotonic spastic 
diplegia, agenesis of the corpus callosum, microcephaly and severe developmental 
delay. All three had similar facial features including hypertrichosis, anteverted ears 
and a prominent root of the nose. Additionally the two male subjects had 
microgenitalia with penile hypoplasia, crytorchidism and hypospadius, while the 
female subject exhibited delayed onset of puberty suggestive of hypothalamic 
hypogonadism. 
Over the past two decades multiple case reports and the subsequent gene 
identification of causative mutations in four members of the RAB protein network 
have helped to clearly delineate the clinical features associated with Warburg Micro 
syndrome (Aligianis et al., 2005, Abdel-Salam et al., 2007, Ainsworth et al., 2001, 
Bem et al., 2011, Borck et al., 2010, Derbent et al., 2004, Dursun et al., 2012, 
Graham et al., 2004, Megarbane et al., 1999, Morris-Rosendahl et al., 2010, Yildirim 
et al., 2012, Yuksel et al., 2007).  
Characteristic ocular abnormalities associated with Warburg Micro syndrome 
include bilateral congenital cataracts, microphthalmia, microcornea (<10mm 
diameter), pinpoint atonic pupils that do not respond to dark or mydriatic agents and 
atrophy of the optic nerve. Additionally, congenital ptosis, nystagmus and 
microphakia are occasionally observed. In initial cases patients were subjected to 
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cataract surgery (phacoemulsification) but only minimal light perception was 
achieved, with normal electroretinogram (ERG) and absent visually evoked 
potentials (VEPs) recorded.  
Postnatally, patients go on to develop growth retardation and neurological 
abnormalities including microcephaly (-4 to -6 standard deviations below the mean) 
and severe global developmental delay. While patients may develop early milestones 
such as smiling, most achieve no developmental milestones beyond those associated 
with normal development at 4 months of age: they do not learn to crawl, pull up to a 
standing position, walk or talk.  
Characteristically, patients show congenital hypotonia and lower-limb spasticity 
which progresses to the upper limbs leading to spastic quadriplegia later in life. 
Evidence of a peripheral neuropathy has also been reported. Computerised 
tomography (CT) scans and magnetic resonance imaging (MRI) imaging have 
proven invaluable in characterising the neurological abnormalities of Warburg Micro 
syndrome. Ainsworth et al., 2001 reported 10 affected individuals with pachygyria 
and variable abnormalities of the corpus callosum. Graham et al., (2004) further 
examined 6 Warburg Micro syndrome patients showing a simplified gyral pattern 
with shallow sulci, thickening of the cortex and microgyri and a thin corpus 
callosum. Further analysis of the brain phenotype further delineated the characteristic 
neurodevelopmental abnormalities including: frontal and parietal lobal 
polymicrogyria, hypogenesis of the corpus callosum and broad sylvian fissures. 
Handley et al., 2013 reported a detailed analysis of brain MRI scans from 17 
Warburg Micro or Martsolf syndrome patients and identified bilateral 
polymicrogyria, predominantly within the frontal lobe and extending into Sylvian 
fissures but occasionally within the temporal lobe, partial formation of the corpus 
callosum, enlargement of subdural spaces and hypoplasia of the cerebellum and 
particularly cerebellar vermis (Handley et al., 2013). Patients occasionally suffer 
from seizures and this could be attributable to the array of cerebral anomalies 
observed. 
A characteristic facial appearance of Warburg Micro syndrome patients has also been 
noted with low set ears that are posteriorly angulated, a beaked nose and prominent 
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broad nasal root, deep set eyes, lengthened philtrum, undersized or under developed 
jaw and a high arched palate. 
Bone and joint abnormalities have also been reported in some patients, including; 
micrognathia, scoliosis, congenital hip dislocations and finger anomalies including 
achromachia and clinodactyly. Affected children can additionally show 
hypogonadism, thought to be hypothalamic in origin, with micropenis and 
cryptorchidism in boys and clitoral hypoplasia in girls. However, micropenis is not 
reported in all cases (Warburg et al., 1993, Abdel-Salam et al., 2007, Bem et al., 
2011).  
1.1.2 Differential diagnosis of Warburg Micro syndrome  
To date, there is no accurate information regarding the incidence of Warburg Micro 
syndrome as cases are often misdiagnosed with similar disorders characterised by 
many if not all of the following features; congenital cataracts, microcephaly, growth 
retardation and developmental delay with autosomal recessive inheritance (Graham 
et al., 2004). As a result, detailed phenotypic reports and genetic analysis are 
essential to delineate characteristic Warburg Micro syndrome cases from similar 
disorders, including; Cockayne syndrome, Cerebro-Oculo-Facio-Skeletal syndrome, 
Martsolf syndrome, Congenital Cataracts-Facial Dysmorphism-Neuropathy 
syndrome and Marinesco Schjogren syndrome. Cockayne syndrome (Cockayne 
syndrome A MIM: 216400 and Cockayne syndrome B MIM:133540) is 
characterised by postnatal growth retardation, mental retardation, photosensitivity, 
progressive pigmentary retinopathy, hearing loss and joint contractures, with 
cataracts occasionally observed. Cerebro-Oculo-Facio-Skeletal syndrome (MIM: 
214150) is associated with microcephaly, mental retardation, congenital cataracts, 
joint contractures and facial anomalies. Cogenital Cataracts-Facial Dysmorphism-
Neuropathy syndrome (MIM:604168) is characteristically associated with severe 
developmental delay, skeletal anomalies, hypogonadism, congenital cataracts and 
progressive motor neuropathy. Marinesco Schjogren syndrome (MIM:248800) is 
characterised by infantile cataracts, cerebellar ataxia, progressive muscle weakness, 
developmental delay, growth retardation, hypogonadism and skeletal abnormalities. 
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However, COFs and Cockayne syndrome patients have a worse prognosis that those 
of Warburg Micro syndrome patients and examination of patient cell lines identified 
hypersensitivity to UV irradiation due to defective Nucleotide Excision Repair 
(NER). Whereas, Warburg Micro syndrome patient cell lines do not show 
hypersensitivity to UV or impairment of NER (Graham et al., 2004).  Additionally, 
while cataracts are a characteristic feature of Marinesco Schjogren syndrome reports 
have suggested that they can develop postnatally in some patients rather than 
congenital as observed for Warburg Micro syndrome patients. It should also be noted 
that although the Warburg Micro syndrome phenotype overlaps that of many other 
disorders, its presentation is characteristic irrespective of which gene is mutated. 
1.2 Martsolf syndrome  
Warburg Micro and Martsolf syndromes share a high degree of clinical similarity 
with congenital cataracts, microgenitalia and developmental delay observed in both. 
However, Martsolf syndrome is much rarer in incidence than Warburg Micro 
syndrome. Martsolf syndrome (MIM: 212720) is an autosomal recessive disorder 
that was originally reported in 1978 in two brothers of consanguineous Polish-Jewish 
decent (Martsolf et al., 1978). Patients with Martsolf syndrome present with bilateral 
cataracts (and no other ocular malformations), prominent facial dysmorphism 
(including high forehead, undersized jaw, high palate, and low set and rotated ears), 
microcephaly, microgenitalia, developmental delay, occasional bone/joint 
abnormalities (including scoliosis and contractures) (Sanchez et al., 1985, Hennekam 
et al., 1988, Ehara et al., 2007). Cranial CT and Brain MRI studies of Martsolf 
syndrome patients (Ehara et al., 2007, Handley et al., 2013) identified mild to 
moderate polymicrogyria restricted to Sylvian fissures and frontal lobe. However, 
unlike Warburg Micro syndrome no cerebellar hypoplasias or increase in subdural 
spaces was observed.  
Additionally, patients with Martsolf syndrome are able to support their own heads, 
walk with aids and may speak one or a few words. Thus, the ocular and 
neurodevelopmental features of Martsolf syndrome are milder than those observed in 
Warburg Micro syndrome.  
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1.3 Molecular genetics 
Through linkage analysis, positional cloning and very recently advancements in 
whole exome sequencing causative loss-of-function mutations for Warburg Micro 
syndrome have been identified within approximately 50% of our cohort in one of 
four genes; RAB3GAP1, RAB3GAP2, RAB18 or TBC1D20. 
Aligianis et al., 2005 carried out a 10cM genome wide scan in 12 Warburg Micro 
syndrome individuals and unaffected family members from 8 consanguineous 
families and identified homozygosity between microsatellite markers D2S410 and 
D2S1399. Inactivating mutations were identified in RAB3GAP1 in 5 families. 
Further analysis of both Warburg Micro and Martsolf syndrome cases identified 
mutations in 41% of the cohort, with 18 frameshift, 20 nonsense and 5 splicing 
mutations now reported (Handley et al., 2013). Most of these mutations are predicted 
to affect protein function and/or be a target for nonsense mediated decay (Aligianis et 
al., 2005, Morris-Rosendahl et al., 2010, Dursun et al., 2012, Yuksel et al., 2007, 
Abdel-Salam et al., 2007, Handley et al., 2013). A RAB3GAP1 mutation in two 
siblings with Martsolf syndrome has also recently been reported, and it is suggested 
that residual protein expression is probably responsible for avoiding the more severe 
Warburg Micro syndrome phenotype (Handley et al., 2013). 
An additional 10cM genome wide scan was carried out on 3 affected Martsolf 
individuals and identified homozygosity between GATA124F08 and D1S549 
(Aligianis et al., 2006). All three individuals were found to be homozygous for the 
p.Gly1051Cys mutation in RAB3GAP2. However, RNA obtained from patient 
lymphocytes identified two transcripts, a wild type transcript of reduced intensity 
compared to wild type and a stronger additional transcript skipping exon 28 and 
resulting in a frameshift mutation, thus suggesting some wild type transcript is 
probably produced. An additional p.Arg426Cys missense mutation has also been 
reported that is predicted to disturb protein function (Handley et al., 2013). Borck et 
al., 2011 sequenced Warburg Micro syndrome patients and identified an inframe 
deletion of 9 evolutionary conserved base pairs in exon 6, resulting in loss of 
function and the more severe prognosis (Borck et al., 2010). A further 9 cases of 
Warburg Micro syndrome with RAB3GAP2 mutations have since been reported with 
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RAB3GAP2 mutations now accounting for 7% of Warburg Micro or Martsolf 
syndrome cases (Handley et al., 2013). Warburg Micro and Martsolf syndromes 
therefore appear to represent a phenotypic continuum, whereby mutations in 
RAB3GAP1 and RAB3GAP2 resulting in residual expression and/or function cause 
the milder Martsolf syndrome, and loss-of-function mutations cause Warburg Micro 
syndrome. The outcome (Warburg Micro or Martsolf) therefore appears to be related 
to the nature and severity of the mutation. 
To identify the cause of further genetic heterogeneity, Bem et al., 2011 carried out a 
genome wide linkage scan using the 250K SNP array in 5 consanguineous families 
and identified several homozygous regions. Microsatellite analysis narrowed this to a 
10Mb region between rs943124 to rs3847396. Genetic sequencing and MLPA 
(multiplex ligation-dependent probe amplification) of RAB18 identified a 
homozygous missense mutation c.71T>A, a compound heterozygote inframe 
arginine deletion (p.93Argdel) or an antitermination mutation (p.X207GlnextX20) in 
5 families, all predicted to result in loss of function (Bem et al., 2011). Since this, 
Handley et al., have reported an additional novel p.Thr95Arg mutation in RAB18. 
RAB18 mutations in now been identified in 5% of Warburg Micro syndrome cases 
(Handley et al., 2013).  
Very recently, causative mutations in Tbc1d20 have been identified through linkage 
analysis and positional cloning of the blindsterile (bs) locus and revealed a 416 kb 
region of homogeneity on chromosome 2 between microsatellite markers 
rs27385663 and rs27343710 (Leigel et al., 2013, in press). Sequencing of the 16 
genes encompassing this region identified a c.692_703 deletion in exon 6 of 
Tbc1d20. Given the high degree of similarity between the bs mouse and the Warburg 
Micro syndrome patient phenotype (see below) a cohort of 77 Warburg Micro 
syndrome families negative for mutations in RAB3GAP1, RAB3GAP2 or RAB18 
were screened and five different causative loss-of-function mutations in TBC1D20 
were identified in seven Warburg Micro syndrome patients: c.199C>T, c.292C>T, 
c.352_353delCA, c.672G>A and in one individual a microdeletion of exons 2-8 
(Leigel et al., 2013, in press). 
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To date causative mutations for Martsolf syndrome have not been identified in 
RAB18 or TBC1D20.  
1.4 RAB18 
Mouse models for Rab3gap1 (Sakane et al., 2006) and Tbc120 (Leigel et al., 2013, in 
press) have previously been generated and will be discussed in further detail in 
section 1.9. In this thesis I describe the generation and characterisation of a novel 
Rab18-/-mouse model, I will therefore primarily focus on RAB18. Rab18 was cloned 
in 1993 from mouse pituitary AT-t20 cells and adult mouse kidney (Lutcke et al., 
1994, Yu et al., 1993). RAB18 is a 23 kDa protein encoded by seven exons. An 
additional novel splice variant of 235 aa was reported in 2005, although this is 
predominantly expressed in the testis (Dou et al., 2005). Northern blot analysis on 
adult mouse tissues identified Rab18 mRNA in all tissues examined albeit at 
different levels of intensity with highest levels observed in brain and heart (Lutcke et 
al., 1994).  
RAB18’s cellular localisation and hence function has been the basis of multiple 
reports over the past two decades, with various roles reported in different cell types. 
Following its cloning, initial studies examining RAB18 localisation were undertaken 
on mouse kidney cryosections and identified labelling throughout the cortex, with 
enrichment in proximal tubules (Lutcke et al., 1994). At the subcellular level RAB18 
localised to both vesicles and clathrin positive invaginations, prompting the proposal 
of a role for RAB18 in endocytosis. Further analysis on paraffin intestinal sections 
localised RAB18 to the apical and basolateral portions of intestinal epithelial cells 
(Lutcke et al., 1994). This provided the first insight into RAB18 serving a tissue or 
cell type specific function. In a macrophage cell line (mannose receptor positive) 
RAB18 localised to a distinct vesicular compartment also containing RAB5 where it 
appeared to play a role in the immune evasion of Salmonella phagocytosis (Hashim 
et al., 2000). The most reproducible localisation of RAB18 in variable cell lines is to 
lipid droplets (Vero, 3T3-L1 fibroblasts and differentiated adipocytes and HepG2 
cells) where it is reported to play a role in both lipolysis and lipogenesis (Martin et 
al., 2005, Ozeki et al., 2005, Pulido et al., 2011). One study in these same cell lines 
also reported the localisation of RAB18 to the endoplasmic reticulum and variably to 
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the Golgi apparatus where they reported a role for RAB18 in Golgi to ER trafficking 
via the COPI-independent transport pathway (Dejgaard et al., 2008). However, 
screens of multiple RAB proteins have failed to identify RAB18 within this pathway. 
For example, analysis of Shiga toxin uptake from the cell surface and trafficking to 
the Golgi is dependent on a minimum of 6 RAB-GAPs, none of which show activity 
towards RAB18 (Fuchs et al., 2007). Furthermore, analysis of GTPase activating 
proteins implicated in ER to Golgi trafficking and maintenance of Golgi morphology 
failed to identify RAB18 (Haas et al., 2007).  
RAB18 has also been reported to localise to peroxisomes, preferentially in its GDP-
bound state (Gronemeyer et al., 2013). Studies in both neuroendocrine cells and 
pituitary melanotropes have also identified an interaction of RAB18 with secretory 
granules where it seemingly functions to inhibit their exocytosis (Vazquez-Martinez 
et al., 2007). A similar role has also been reported for RAB3, localising to synaptic 
vesicles and inhibiting calcium mediated exocytosis of hormones and 
neurotransmitters (Fischer von Mollard et al., 1991, Schluter et al., 2002). However, 
examination of RAB18 and RAB3A localisation in PC12 cells failed to identify any 
colocalisation under either basal conditions or stimulation of the secretory pathway 
with potassium, suggesting that RAB18 and RAB3A associate with distinct 
populations and function in different processes of the secretory pathway (Vazquez-
Martinez et al., 2007). Reduced RAB18 levels have been reported in growth 
hormone hypersecretory pituitary adenomas in patients with acromegaly. 
Furthermore, this hypersecretory activity could be reversed upon overexpression of 
RAB18 (Vazquez-Martinez et al., 2008). These studies all point towards a role for 
RAB18 in negative regulation of exocytosis. Interestingly, many studies have 
reported that RAB18 localisation is enhanced upon cellular stimulation. For example, 
in PC12 and AtT20 cell lines RAB18 is found localised to the cytosol but 
redistributes to secretory granules after stimulation with a depolarising K+ pulse to 
activate the secretory pathway (Vazquez-Martinez et al., 2007). Furthermore, in 3T3-
L1 adipocytes RAB18 localises to lipid droplets. This localisation is enhanced upon 
stimulation of lipolysis by isoproterenol activation of β-adrenergic receptor or 
forskolin. Additionally, blockage of stimulation by propranolol prevented this 
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association (Martin et al., 2005). Pulido et al., also reported an increased association 
of RAB18 to the lipid droplet surface upon insulin treatment (Pulido et al., 2011). 
RAB18 has been implicated in disease pathogenesis of various conditions including 
Warburg Micro syndrome and acromegaly (Bem et al., 2011, Vazquez-Martinez et 
al., 2008). In addition, its increased expression was reported in microarray studies of 
high grade prostate adenocarcinoma (True et al., 2006). RAB18 was also identified as 
one of the top hits for genes implicated in pathophysiology of Schizophrenia by 
GWAS (Ayalew et al., 2012) and RAB18 has been identified as being downregulated 
in neuroendocrine gastrointestinal tumour cells upon growth factor treatment to 
induce proliferation (Hofsli et al., 2005). RAB18 has also been found to be 
dysregulated in PaCa 5061- a human pancreatic adenocarcinoma cell line (Kalinina 
et al., 2010). 
1.5 RAB protein activation and function 
RAB3GAP1, RAB3GAP2, RAB18 and TBC1D20 are all members to the RAB 
protein network. RAB18 is a small GTPase of the RAB subfamily, whereas the other 
three proteins have been characterised as regulators of RAB protein function. 
RAB3GAP1 and RAB3GAP2 form a heterodimeric enzyme complex regulating the 
RAB3 cycle (Nagano et al., 1998, Fukui et al., 1997, Sudhof, 2004), and TBC1D20 
functions as a GAP with activity towards the RAB1 and RAB2 subfamilies (Haas et 
al., 2007). It is therefore believed that RAB protein dysfunction underlies Warburg 
Micro syndrome pathogenesis. RAB proteins are small G-proteins of the RAS 
superfamily functioning as master regulators of vesicular trafficking between 
membranous organelles, including the endoplasmic reticulum (ER), Golgi, plasma 
membrane, endosomes and lysosomes. Membrane organelles enclose distinct 
environments serving specific cellular functions that rely on bidirectional membrane 
transport to transfer materials between phospholipid membranes. Membrane 
trafficking can be divided into a series of distinct stages (Grosshans et al., 2006).  
Primarily proteins and protein constituents to be trafficked are selected and bud from 
donor membranes into intermediate vesicles. These vesicles are transported along 
cytoskeletal tracks composed of actin or microtubule filaments responsible for short 
and long range transport respectively to target membranes. When the intermediate 
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vesicle reaches the target membrane of the recipient organelle it is then tethered or 
docked and the intermediate vesicle and target membrane fuse their lipid bilayers to 
transfer material (Stenmark, 2009, Grosshans et al., 2006).  
 
The two major routes of trafficking in secretory organelles are the exocytotic 
pathway, which ends at the plasma membrane, and the endocytotic pathway, which 
begins there. Initially, protein constituents for exocytotic trafficking are formed in 
ribosomes on the surface of the endoplasmic recitulum (ER) where protein 
components for trafficking are synthesised and imported into the ER lumen 
(Grosshans et al., 2006, Brighouse et al., 2010). Within the ER, proteins are post-
translationally modified and folded into correct nascent peptides. Modified and 
folded proteins can then exit the ER at ER exit sites in COPII coated vesicles and are 
transported along microtubules to the cis-face of the Golgi apparatus. Proteins pass 
through the Golgi, where they can be further modified and emerge at the trans-
interface, trans-Golgi network (TGN). Following release from the Golgi, proteins are 
transported in vesicles to the cell surface where they release into the external 
environment (Brighouse et al., 2010). Endocytosis refers to the uptake of cellular 
components from the external environment. Endocytosed molecules are primarily 
transported to early endosomes where they are sorted for either recycling or 
degradation. Those molecules to be recycled are thus transported to recycling 
endosomes and released into the plasma membrane, whereas those for degradation 
are transported to late endosomes and subsequently lysosomes (Grosshans et al., 
2006). 
 
RAB proteins regulate vesicular trafficking through their function as molecular 
switches cycling between GDP bound ‘inactive’ and GTP bound ‘active’ 
conformations (Stenmark, 2009). This reversible activation and the association and 
dissociation of RAB proteins on and off membranes, enables regulation in both a 
temporally and spatially restricted manner. In brief, GDP bound RAB proteins are 
delivered to target membranes. Once attached at the membrane, GDP is exchanged 
for GTP by guanine nucleotide exchange factors (GEFs). GTP bound RAB proteins 
can then interact with multiple effector molecules in vesicular budding, transport, 
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tethering and fusion. Following function, GTPase activating proteins (GAPs) 
accelerate the RAB proteins GTP hydrolysis activity mediating GTP hydrolysis to 
GDP at the nucleotide binding site. The GDP bound RAB protein once again comes 
into contact with GDI and is extracted from the membrane and sequestered in the 
cytosol until the next round of activation (Corbeel and Freson, 2008, Stenmark, 2009). 
The RAB protein cycle is depicted in figure 1.1 and will be discussed in further 
detail below. 
 
Figure 1.1: The RAB protein cycle 
RAB proteins cycle from GDP to GTP bound on and off target membranes. In brief 
GDP bound RAB proteins are sequestered in the cytosol by GDI and targeted to the 
membrane by GDF. GDP is then exchanged for GTP through the action of GEFs. It 
is typically thought to be a GTP bound RAB protein that is ‘active’ and interacts with 
effector molecules. GTP bound RAB is then converted to GDP through the action of 
RAB GAPS that function to stimulate the intrinsic GTPase hydrolysis of the RAB. 
GDP bound RABs are then extracted from the membrane and sequestered in the 




1.5.1 RAB protein structure  
The first report of RAB protein involvement in membrane trafficking came from 
studies in yeast (Salminen and Novick, 1987). Since this study eleven RAB 
homologues have now been identified in yeast (Zerial and McBride, 2001). 
Throughout evolution great expansion of the RAB protein family occurred with 
duplication and diversification of specific RAB protein functions, resulting in more 
than 60 RAB proteins identified in the human genome localising to multiple cellular 
compartments and functioning in diverse steps of membrane trafficking (Pereira-Leal 
and Seabra, 2001). For example, RAB18 has been reported to function in calcium 
mediated exocytosis, lipolysis and lipogenesis (Vazquez-Martinez et al., 2007, 
Martin et al., 2005, Ozeki et al., 2005). 
Phylogenetic analysis of RAB proteins in human, nematode, fly and fission yeast 
have made it possible to track the expansion of the gene family and enabled some 
RABs to be separated into 8 distinct subgroups, labelled I-VIII (Table 1.1) dependent 
on similar reported localisation and/or function (Pereira-Leal and Seabra, 2001). This 
suggests that these 8 subgroups may share a related ancestry or be related in terms of 
function or potentially both. However, it must be noted that a minority of RAB 
proteins, including RAB18, are excluded from these phylogenetic groups suggesting 












Table 1.1: Analysis of RAB phylogenetic function has enabled 
subdivision of the RAB family into 8 distinct domains based on 
localisation and/or function (Pereira-Leal and Seabra, 2001). 
RAB subgroup Contained RABs 
I RAB1A, RAB1B & RAB35 
II RAB2A, RAB2B, RAB4, RAB4B, RAB11a, RAB11B & 
RAB25 
III RAB3A, RAB3B, RAB3C, RAB3D, RAB27A, 
RAB27B, RAB37 & RAB36 
IV RAB19 & RAB30 
V RAB21, RAB5A, RAB5B, RAB5C & RAB22A, 
RAB22B & RAB22C 
VI RAB41, RAB6, RAB6B & RAB6C 
VII RAB7, RAB9 & RAB9B 
VIII RAB13, RAB8, RAB8B & RAB10 
 
Despite their various functions and cellular localisations, all RAB proteins including 
RAB18 share a high degree of structural morphology, sharing a folded structure 
common to members of the RAS superfamily; a core of five parallel and one anti-
parallel beta-sheet flanked by five alpha-helices. The beta-sheets and alpha-helices 
are connected by 5 loops, where the elements responsible for guanine nucleotide 
binding, magnesium binding and GTP hydrolysis are located (Stenmark and 
Olkkonen, 2001, Liu and Storrie, 2012, Dumas et al., 1999). All RABs have two 
switch regions (switch I and switch II) located in loop2 and loop4-α2-loop5 regions 
respectively, that are responsible for binding the gamma phosphate group of GTP 
and alter depending on nucleotide bound state. As a result they are thought to be the 
principle site of RAB effector protein interactions (Stenmark and Olkkonen, 2001). 
The switch regions of GDP bound ‘inactive’ RAB proteins are highly disordered and 
natively unfolded, whereas in GTP bound ‘active’ RABs switch regions show highly 
organised conformations (Lee et al., 2009). Nucleotide binding and the resultant 
conformational change are thus intrinsic to RAB protein function. Additionally, the 
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p.Arg93del and p.Leu24Gln RAB18 mutations abolish nucleotide binding and hence 
lead to a complete loss of protein function (Bem et al., 2011).  
Pereira-Leal & Seabra performed in depth phylogenetic analysis through ClustalW 
alignment of all reported RAB isoforms from mammals and identified five RAB 
specific sequence motifs (RABF) that distinguish RAB proteins from other small 
GTPases (Pereira-Leal and Seabra, 2000). These conserved motifs all localise to 
switch I and switch II regions and to surrounding areas. Furthermore, through 
analysis of the complete mammalian RAB genome they also identified 4 RAB 
subfamily specific regions (RABSF) shared between ‘related’ RAB proteins (see 
table 1.1). These RABSF regions are found throughout the RAB sequence, in both 
loops and the hypervariable domains (Pereira-Leal and Seabra, 2000). Furthermore, 
the crystal structure of RAB3A in complex with rabphilin-3A was reported in 1999 
and identified two interaction sites between the two proteins; one within the switch I 
and switch II regions and the other within a deep pocket which they referred to as 
RAB CDRs (Complementary Determining Region) (Ostermeier and Brunger, 1999). 
These regions of CDR are thought to be composed of highly variable sequences 
within the conserved structural motif of RAB GTPases and are thought to provide 
structural specificity for RAB-effector protein binding. This suggests that other 
components of the RAB protein structure are implicated in effector binding and not 
just the switch domains as previously thought. 
1.5.2 RAB protein post-translational modification 
Despite the highly similar core structure, all RAB proteins including RAB18 contain 
a hypervariable C-terminal domain, with great variations in composition and length 
observed between RABs. This C-terminal domain is the site of post-translational 
modification by RAB geranylgeranyltransferase (RABGGTase) which is essential 
for RAB-membrane targeting. The majority of RAB proteins are prenylated at two 
C-terminal cysteine residues by the covalent attachment of a 20 carbon 
geranylgeranyl isoprenoid through thioether linkages (Pereira-Leal et al., 2001, 
Goody et al., 2005). However, a small subset of RAB proteins (including RAB18) 
instead contain a CAAX box motif (C= cysteine, A= aliphatic residue, X= any amino 
acid) and as a result are geranylgeranylated at only one C-terminal cysteine residue 
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by protein geranylgeranyltransferase type I (CAAX-GGT). Leung et al., showed that 
this small subset of CAAX containing RAB proteins are also modified post-
prenylation by methylation. This methylation has no major impact on membrane 
targeting but RAB mutants that are geranylgeranylated but not methylated show 
abnormalities in membrane/cytosol cycling, thus pointing towards a direct or indirect 
role for RAB methylation in their association with membranes (Leung et al., 2007). 
A RAB18 antitermination mutation has also been reported in Warburg Micro 
syndrome (Bem et al., 2011). The p.X207GlnextX20 mutation extends the C-
terminus of RAB18 by 20 amino acids and thus disrupts geranylgeranylation and 
membrane targeting and hence protein function.  
1.5.3 RAB protein targeting to membranes 
All RABs including RAB18 localise to specific subcellular compartments where they 
function in a diverse array of membrane trafficking steps. Targeting of RAB proteins 
to membranes is coordinated by both REP (RAB Escort Protein) and RAB GDI 
(GDP Dissociation Inhibitor). Immediately following synthesis, newly synthesised 
RAB proteins are recognized and bound by REP and presented to the RAB 
geranylgeranyltransferse (RABGGTase) enzyme for post-translational modification. 
The prenylated RAB protein in contact with REP is then targeted to the membrane. 
The REP protein thus recognizes both prenylated and unprenylated RAB proteins. 
However, REP is only required for initial membrane localisation following 
prenylation, after this the function of membrane targeting and dissociation is taken 
over by GDI proteins (Goody et al., 2005, Pereira-Leal et al., 2001).  
GDI thus functions to bind to GDP-bound RAB proteins and sequester them within 
the cytosol but also target RAB proteins to membranes. The first RAB GDI was 
reported in 1990 by Sasaki et al., as a protein that inhibits GDP dissociation and GTP 
binding (Sasaki et al., 1990). Since this study only three GDI isoforms have been 
identified in the mammalian genome (GDIα, GDIβ and GDIγ) (Alory and Balch, 
2001). Due to the large number of identified RAB proteins functioning in diverse 
intracellular processes, this suggests that RAB GDI proteins serve a general role 
rather than a specific function in RAB protein localisation (Ullrich et al., 1993). 
Additionally, studies of endosomal RABs binding GDI with high affinity, have 
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proposed the involvement of a novel RAB effector called GDF (GDP displacement 
factor) (Dirac-Svejstrup et al., 1997). GDF may function to dissociate the highly 
stable GDI:GDP RAB complex and mediate the association of RAB proteins to 
particular target membranes (Pfeffer and Aivazian, 2004), however it is not yet clear 
whether GDFs participate in the targeting of all RAB isoforms.  
Studies have also suggested that other components in addition to the prenylation 
motif may be implicated in RAB protein localisation. For example exchanging the 
prenylation motif between RAB5 with that of RAB7 and RAB2 with either RAB5 or 
RAB7 showed endosomal localisation reminiscent of the acceptor RAB protein, 
whereas exchange of the C-terminal 34 amino acids, including the cysteine for 
prenylation observed localisation to the donor protein (Chavrier et al., 1991).  
1.5.4 RAB protein activation by GEFs  
Following membrane targeting, all RAB proteins including RAB18 interact with an 
alternative RAB regulatory protein; RAB GEF (Guanine Nucleotide Exchange 
Factor). GEF proteins function by displacing the switch I region implicated in 
nucleotide binding and dislodging the phenylalanine/tyrosine residue that caps 
guanine, thus promoting GDP nucleotide release and exchange for GTP (Barr and 
Lambright, 2010). Stable membrane-association and the majority of reported RAB 
protein interactions mediating downstream events in membrane trafficking occur in a 
GTP bound state. Therefore, RAB GEFs play critical roles in activating RAB 
proteins to mediate membrane traffic. 
The GEFs for RAB18 remains to be identified. GEFs can function as small 
individual proteins or as components of large multimolecular complexes. For 
example the TRAPPI (Transport Protein Particle I) complex is composed of seven 
subunits (Bet3p, Bet5p, Trs20p, Trs23p, Trs31p, Trs33p and Trs85p), and functions 
as a GEF for Ypt1 and Ypt31/32 controlling ER to Golgi transport (Jones et al., 
2000). TRAPP II contains the seven TRAPPI subunits and a further three (Trs65p, 
Trs120p and Trs130p). Delineation of TRAPPI and TRAPPII identified that TRAPPI 
specifically functions as a GEF for Ypt1 functioning in ER to cis-Golgi transport 
whereas the addition of TRAPPII specific subunits (in particular Trs120p and 
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Trs130p) directs GEF activity towards Ypt31/32p in transport mechanisms exiting 
the Golgi (Morozova et al., 2006), thus linking different stages of membrane 
transport. This phenomenon of RAB GEFs mediating links between different stages 
of membrane transport is also observed in the case of RAB5 and RAB7 trafficking 
through early to late endosomes (Rink et al., 2005). Through live cell imaging they 
observed that loss of RAB5 signal (a marker of early endosomes) occurred in 
coordination with the gain of RAB7 (a marker for late endosomes). The authors also 
identified through mass spectrometry that active RAB5 interacted with hVps11, a 
component of the class C VPS/HOPS complex, and an additional subunit Vsp39p has 
GEF activity towards the yeast RAB7 ortholog, Ypt7p. They thus reported an 
essential role of the VPS/HOPs complex on the RAB5 dependent recruitment of 
RAB7 during early to late endosome transport (Rink et al., 2005). Interestingly, a 
recent study has reported a function of RAB GEFs (in particular RABEX-5, DRRA 
and RABIN-8) as a major factor in determining the localisation of specific RAB 
proteins (RAB5A, RAB1A and RAB8A respectively) to correct membrane 
localisations (Blumer et al., 2013). However, to this date they cannot rule out the 
possibility that other RAB regulators and effectors may also mediate membrane 
localisation.  
With regards to the case of RAB18, immunoprecipitation studies performed during 
my masters project identified an interaction specifically between GDP bound RAB18 
and RAB3GAP2 (unpublished data). This suggests that RAB3GAP2 may stabilise 
RAB18 in its GDP bound state and thus could potentially serve as a RAB18 GEF. 
Studies are currently underway with Dr Mark Handley and Prof Francis Barr 
(Oxford) to investigate this potential link and novel function of RAB3GAP2 as a 
RAB18 GEF. 
1.5.5 RAB effector proteins 
RAB protein function is mediated through interactions with specific ‘effector’ 
proteins. Except for a small subset, the majority of these effectors preferentially bind 
GTP-bound ‘active’ RABs. Effector proteins are generally thus recruited from the 
cytosol by activated GTP bound RABs and function to regulate multiple aspects of 
vesicular trafficking including budding, transport, tethering and fusion (Zerial and 
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McBride, 2001). However, despite extensive research aiming to elucidate RAB 
protein effectors, effector proteins for the majority of RAB isoforms are still to be 
reported. This is hindered by the fact that no obvious conservation of structure has 
been identified in the majority of RAB effectors, suggesting that individual effector 
molecules target specific transport mechanisms (Zerial and McBride, 2001). No 
specific effector molecules for RAB18 have been reported. 
The majority of RAB effectors are thought to show specificity for a distinct RAB 
isoform, whereas a small minority show less specificity and interact with a multitude 
of RAB proteins in multiple locations. A recent study performed by Fukuda et al., 
undertook a large scale yeast-2-hybrid screen for novel effectors of 28 RABs and 
identified 27 GTP specific effector proteins. However of the 27 identified, 17 
showed binding to a broad subset of RAB proteins with OCRL (oculocerebrorenal 
syndrome of Lowe) for example binding 16 different RAB isoforms (Fukuda et al., 
2008).  It is possible however that a single effector could bind multiple RAB proteins 
in vitro but only one under physiological conditions.  
The pathogenesis of Warburg Micro syndrome has been linked to dysregulation of 
the RAB3 cycle through RAB3GAP1 and RAB3GAP2 which are implicated in 
RAB3 cycle regulation. RAB3A serves as an example of a RAB protein with several 
identified effectors, including RIM and RABPHILIN. RIM (RAB3-interacting 
molecule) is an evolutionary conserved 1,553 aa protein that specifically binds to 
GTP bound RAB3A (Wang et al., 1997). Subcellular fractionation experiments 
identified RIM to be enriched in the synaptic plasma membrane particularly at the 
presynaptic active zones but absent from synaptic vesicles, where RAB3A is 
reported to be localised (Wang et al., 1997). However, no reduction in the level of 
RIM was identified in RAB3A deficient mice (Wang et al., 1997). RABPHILIN has 
been shown to colocalise with GTP bound RAB3A on synaptic vesicles and RAB3A 
deficient mice show a significant reduction (of approximately 70%) of the levels of 
RABPHILIN (Li et al., 1994). Rabphilin knock out mouse models have therefore 
also been generated to elucidate the role of RABPHILIN in RAB3 localisation and 
function. Rabphilin knockout mice are viable and fertile and show no gross 
phenotypic abnormalities or abnormalities in synaptic plasticity (Schluter et al., 
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1999). Furthermore, no changes in RAB3 protein levels or localisation were 
observed, suggesting RABPHILIN functions as an effector of RAB3 but has no 
impact on regulation or targeting of RAB3 molecules in synaptic vesicle exocytosis 
(Schluter et al., 1999).  
RAB proteins interact with effectors and are capable of mediating various stages of 
vesicular transport. As effector proteins for RAB18 are yet to be identified, examples 
of RAB proteins functioning at different stages will be discussed in more detail 
below. 
Cargo selection and vesicle budding 
The first step of membrane transport involves the selection of specific cargoes to be 
trafficked, the recruitment of coat proteins and vesicle budding (Stenmark, 2009). 
For example, studies have proposed a role for RAB9 in vesicle formation (Carroll et 
al., 2001). GTP bound RAB9 localises to endosomes, where it recruits the effector 
molecule TIP47. In turn RAB9 increases the affinity of TIP47 for its downstream 
cargo mannose-6-phosphate receptors thus mediating endosome to Golgi transport 
(Carroll et al., 2001). 
Vesicle transport  
Following cargo sorting and budding, vesicles are transported along microtubule 
and/or actin cytoskeletal tracks to sites of action, the donor membrane. Vesicular 
transport along actin filaments is driven by myosin motors and along cytoskeletal 
tracks by the molecular motors, kinesin (for anterograde transport) and dynein (for 
retrograde transport). RAB proteins can interact with molecular motors either 
directly or indirectly. For example GTP bound RAB6A directly interacts with 
RABKINESIN thereby regulating the transport of Golgi membranes and vesicles 
(Echard et al., 1998) whereas RAB3A interacts indirectly with KIF1Bβ/KIF1A via 
DENN/MADD (Niwa et al., 2008). 
Tethering and membrane fusion 
Once vesicles have trafficked along cytoskeletal tracks to their target (the donor 
membrane), the next step of the trafficking process involves bringing the vesicle into 
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contact with the target membrane and ‘tethering’ the two together. Tethering has 
been reported to involve either coiled-coil proteins functioning as a bridge to 
physically connect the vesicle and target membrane, or multisubunit protein 
complexes (Grosshans et al., 2006). An example of a RAB effector that acts as a 
tether is EEA1, GTP bound active RAB5 recruits EEA1 to endosomes where it 
functions to mediate the docking and localisation of transport vesicles to early 
endosomes (Christoforidis et al., 1999). 
Once transport vesicles are docked to the target membranes, their lipid bilayers are 
then fused. Vesicular fusion involves the SNARE (N-ethylmaleimide-sensitive factor 
attachment protein receptors) family of proteins, whereby vesicle associated (v-
SNAREs) and target membrane associated (t-SNAREs) form complexes at the target 
membrane, opening a fusion pore and fusing the two membranes together (Grosshans 
et al., 2006).  
1.6 RAB GAPs 
Following effector interactions and function GTP bound RAB proteins interact with 
another set of RAB protein regulators the RAB GAPs (GTPase activating proteins) 
to curb RAB GTPase activity and cease interactions with effector molecules (Barr 
and Lambright, 2010). RAB proteins do naturally possess internal GTPase activity, 
however this occurs at a very slow rate of hydrolysis and as a result RAB proteins 
interact with RAB GAPs to increase the rate of GTP hydrolysis and thus rapidly 
inactivate RAB proteins. To date most of the reported RAB GAP proteins possess a 
TBC (Tre2/Bub2/Cdc16) domain and have aided the identification of novel RAB 
GAPs through sequence homology (Frasa et al., 2012). However, of the 44 identified 
TBC domain containing proteins, approximately only half have been assigned RABs 
(Frasa et al., 2012). Furthermore, a single TBC domain containing RAB GAP may 
inactivate multiple RABs or a single RAB can be modulated by more than one RAB 
GAP (Frasa et al., 2012).  
The GAP for RAB18 is not known. However, the other identified Warburg Micro 
syndrome disease genes comprise two GAPs; TBC1D20 and the RABGAP complex 
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(RAB3GAP1/RAB3GAP2). It has not yet been definitively determined if RAB18 is 
a substrate for either of these GAPs. 
1.6.1 TBC1D20 
TBC1D20 functions as a GAP specifically towards the RAB1 and RAB2 family of 
proteins, however minimal GAP activity has also been reported towards RAB18 
(Haas et al., 2007). TBC1D20 contains the characteristic TBC domain 
(Tre2/Bub2/Cdc16) of RAB GAPs. Haas et al., identified TBC1D20 as one of two 
RAB GAPS (the other being RN-tre) that results in loss of normal Golgi morphology 
upon overexpression and redistribution of Golgi components to the cytosol (Haas et 
al., 2007). Like RAB18, TBC1D20 has also been shown to localise to lipid droplets 
(Nevo-Yassaf et al., 2012). However, in the case of TBC1D20, its recruitment to 
lipid droplets is induced by a viral protein non-structural protein 5A (NS5A), where 
it serves to impact lipid droplet metabolism and endorse hepatitis C viral life cycle 
(Nevo-Yassaf et al., 2012). Recently, RAB18 has also been reported to colocalise to 
NS5A around lipid droplets, preferentially in its GTP bound active form (Salloum et 
al., 2013). In addition, silencing of RAB18 or expression of a dominant negative 
(GDP locked) (S22N) mutant reduced the association of NS5A to lipid droplets, 
suggesting that RAB18 recruits NS5A to lipid droplets, and this recruitment is 
critical for hepatitis C virus genome replication (Salloum et al., 2013). This suggests 
a link between RAB18 and TBC1D20 in that RAB18 recruits NS5A to lipid droplets 
which in turn recruit TBC1D20. A further link has also been observed between 
TBC1D20 and RAB18 in our lab. Investigation of the localisation of EGFP-RAB18 
in human fibroblasts reported an association of RAB18 around lipid droplets, to the 
endoplasmic reticulum (ER) and staining of the perinuclear region consistent with 
the cis-Golgi. However, examination of EGFP-RAB18 in TBC1D20 (p.Gln98*) 
patient fibroblasts identified enhancement of ER staining to the expense of Golgi 
staining. Furthermore FRAP experiments identified that the EGFP-RAB18 ER 
interaction is more stable in TBC1D20 cell lines suggesting that RAB18 may be a 




RAB3GAP (RAB3GAP1/RAB3GAP2 complex) is a novel RAB GAP that to date is 
the only reported RAB GAP to lack the TBC domain. RAB3GAP1/2 has not been 
linked to RAB18 but to the RAB3 family. The RAB3 family are one of the major 
constituents of synaptic vesicles where they cycle on and off vesicles in coordination 
with exocytosis of hormones and neurotransmitters. Four members of the RAB3 
family exist; RAB3A, RAB3B, RAB3C and RAB3D expressed at varying intensities 
in brain and endocrine tissues (Schluter et al., 2002). Of these RAB3A is the most 
abundant, accounting for over 25% of RAB protein binding in synaptosome fractions 
of the brain (Geppert et al., 1994). RAB3A, RAB3B and RAB3C localise to synaptic 
vesicles (Fischer von Mollard et al., 1990, Fischer von Mollard et al., 1994, Schluter 
et al., 2002). RAB3D meanwhile localises primarily to the endocrine pituitary and at 
lower levels in both exocrine cells and adipose tissue (Schluter et al., 2002). All four 
proteins have reported roles in cycling on and off synaptic vesicles in coordination 
with calcium mediated exocytosis of hormones and neurotransmitters (Fischer von 
Mollard et al., 1991, Geppert et al., 1994, Schluter et al., 2002, Sudhof, 2004) 
(Figure 1.2).  
RAB3 preferentially binds with its effector molecules when in a GTP bound state, 
and these include the presynaptic proteins RIM, rabphilin and MUNC-13 (Sudhof, 
2004). Upon vesicle fusion and exocytosis, GTP bound RAB3 is hydrolysed to GDP. 
It is this step in the RAB3 cycle that is regulated by the action of a heterodimeric 
enzyme complex composed of the catalytic subunit RAB3GAP1 and its non-catalytic 
counterpart RAB3GAP2.  Initially Warburg Micro syndrome disease pathogenesis 
was therefore attributed to dysregulation of the RAB3 cycle, with defects in 
neurotransmission seemingly consistent with the observed disease phenotype.  
 
RAB3GAP1 is a 981 aa protein of 130 kDa and has two protein-coding transcripts; a 
major transcript of 24 exons and a minor transcript lacking the first 50 aa encoding 
exons 1-3 but containing an additional N-terminal 3 aa exon. RAB3GAP1 was 
originally isolated as a 130 kDa protein from rat brain containing a C-terminal 
catalytic domain and is ubiquitously expressed in human and zebrafish tissues (Fukui 
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et al., 1997, Aligianis et al., 2005). RAB3GAP1 acts specifically on members of the 
RAB3 subfamily (RAB3A, B, C and D) regulating calcium mediated exocytosis of 
hormones and neurotransmitters (Fukui et al., 1997). RAB3GAP1 has also been 
identified in a novel proteomic screen for interacting partners of ERGIC-53 (Haines 
et al., 2012). Mutations in p97 proteins are observed in neurodegenerative disorders 
including Inclusion Body Myopathy Paget’s disease of the bone and/or 
frontotemporal dementia (IBMPFD) and Amyotrophic Lateral Sclerosis (ALS) and 
are defective at binding UBXD1. UBXD1 interacts with ERGIC-53 and the 
RAB3GAP1/2 complex, however, further analysis of the exact protein constituents 
of this complex remains to be fully elucidated but could point towards the 
involvement of RAB3GAP1/2, UBXD1 and ERGIC-53 complexes in familial 
neurodegenerative diseases (Haines et al., 2012). Recently, a role for RAB3GAP1 
has also been proposed in acquisition of the epidermal barrier during murine 
development (Youssef et al., 2013). Upon knock down of Rab3gap1 by siRNA, 
abnormalities in Claudin-1 (critical component of tight junctions) expression and 
defects in barrier formation were observed. Their results suggest that RAB3GAP1 
controls exocytosis of Claudin-1 to the cell surface and formation of the epidermal 
barrier during gestation (Youssef et al., 2013). 
RAB3GAP2 is a 1,393 aa protein of 150 kDa encoded by 28 exons. RAB3GAP2 was 
originally identified as a 150 kDa protein copurifying with RAB3GAP1 upon column 
chromatography of the synaptic soluble fraction from rat brain (Fukui et al., 1997). 
Rab3gap2 was then subsequently cloned in 1998 (Nagano et al., 1998). Like 
RAB3GAP1, RAB3GAP2 is ubiquitously expressed in human tissues and similar to 
RAB3 enriched in the synaptic soluble fraction of rat brain (Nagano et al., 1998). 
Analysis of rab3gap2 expression during zebrafish development by in situ 
hybridisation revealed restricted expression in the CNS (Aligianis et al., 2006).  
RAB3GAP1 and RAB3GAP2 co-immunoprecipitated as a heterodimeric complex 
from the synaptic soluble fraction from rat brain (Nagano et al., 1998). However, 
RAB3GAP2 showed no GAP activity towards RAB3A, nor did it affect the GAP 
activity or localisation of RAB3GAP1 (Nagano et al., 1998). This suggested that 
RAB3GAP2 may therefore function as a mediator or regulator to maintain 
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RAB3GAP1 stability. However, since this study, research has suggested that 
RAB3GAP1 and RAB3GAP2 may not consistently serve as a complex, with 
RAB3GAP2 serving distinct functions from those reported for RAB3GAP1. For 
example, the RAB3 effector RABCONNECTIN-3 coimmunoprecipitates with RAB3 
GEF and the noncatalytic subunit RAB3GAP2 but not RAB3GAP1 (Nagano et al., 
2002). Further studies identified two subunits of RABCONNECTIN3, alpha and beta 
and showed an interaction of both subunits with RAB3GAP2 but not RAB3GAP1; 
but this interaction was not direct (Kawabe et al., 2003). Additionally, many plant 
species have homologues of RAB3GAP but lack RAB3 isoforms; this suggests that 
the RAB3GAP1/2 complex may serve functions distinct from that of GTPase activity 
(Barr and Lambright, 2010). As mentioned above studies are now underway to 




Figure 1.2 The RAB3 cycle 
GTP bound ‘activated’ RAB3 (A, B, C and D isoforms) are geranylgeranylated at 2 
C-terminal cysteine residues and inserted into the synaptic vesicle membrane. 
Following attachment to the target membrane, RAB3GAP1 and RAB3GAP2 form a 
heterodimeric enzyme complex that specifically stimulates the intrinsic GTP 
hydrolysis activity and converts GTP bound RAB3 to GDP bound, in coordination 
with the exocytosis of neurotransmitters and hormones. GDP bound RAB3 is then 
extracted from the membrane and sequestered in the cytosol by GDI1, where it can 




1.7 RAB GTPases and disease 
RAB proteins function in multiple diverse steps of membrane trafficking and this is 
reflected in the diverse array of human diseases caused by mutations not only in 
RAB proteins but also their regulators and many effector proteins. In particular, 
mutations in RAB proteins give rise to infectious, neurological and endocrinological 
diseases and RAB dysfunction in many types of cancer is also now coming to light 
(Stenmark, 2009). In this section I will focus on the role of RAB proteins in 
pathogenesis of inherited disorders. Loss of function mutations in RAB27A have been 
reported in cases of Griscelli syndrome, type 2 characterised by albinism and 
immunodeficiency with neurological impairment occasionally observed (Menasche 
et al., 2000). Due to the well characterised role of RAB proteins in trafficking of 
synaptic vesicles and neurotransmitters, unsurprisingly mutations in RAB proteins 
have also been implicated in many disorders of neurological impairment. Mutations 
in RAB23 have been associated with autosomal recessive Carpenter syndrome type I 
(Jenkins et al., 2007), characterised by acrocephaly, skeletal abnormalities, heart 
defects, growth retardation, developmental delay and microgenitalia (MIM 201000). 
Loss of function mutations in RAB39B cause mental retardation, X-linked 72 
(Giannandrea et al., 2010) associated with microcephaly, seizures and in some cases 
epilepsy (MIM 300271). Mutations in RAB7 are associated with Charcot-Marie-
Tooth type 2B (Verhoeven et al., 2003) characterised by peripheral sensory 
neuropathy (MIM 600882). Additionally, as described above, loss of function 
mutations in RAB3GAP1, RAB3GAP2, RAB18 and TBC1D20 have been associated 
with Warburg Micro syndrome. Furthermore, mutations have also been identified in 
RAB regulatory proteins and effector proteins. For example, mutations in GDI-alpha 
are associated with mental retardation, X-linked 41 (D'Adamo et al., 1998) 
characterised by moderate to severe mental retardation and dysmorphic facial 
features occasionally noted (MIM 300849). 
In addition to providing insight into genetic disease, as was the aim of this study, 
mouse models of RAB proteins have also proven invaluable to gain insight into 
protein function. For example, mutations in Rab27A (ashen mice), one of its 
regulators, RGGTaseα (gunmetal), a RAB27A effector melanophilin (Leaden) or a 
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motor protein (dilute) all show a similar phenotype of lightened coat colour and 
defects in pigment granule transport (Wilson et al., 2000, Detter et al., 2000, Mercer 
et al., 1991, Matesic et al., 2001), showing that a RAB, an effector, a motor protein 
and a regulator all functioning in the same cellular pathway can and do cause an 
identical phenotype. This also provides further evidence for all four Warburg Micro 
syndrome genes functioning in the same pathway, to cause an identical phenotype. 
Additionally, mutations in Rab38 have been identified in the ‘chocolate’ mouse 
model with partial albinism, a lightened coat colour on C57BL/6J background 
(Loftus et al., 2002). Analysis of melanosome transport identified that trafficking of 
TYRP1 from the trans-Golgi network to melanosomes was impaired in Rab38cht 
mice and thus through characterisation of mouse models they have been able to 
propose Rab38 as a potential target gene for the genetically heterogeneous disorder 
OCA (Oculocutaneous albinism) (Loftus et al., 2002). These studies have brought to 
light two important points; primarily the diseases associated with RAB protein 
dysfunction can be very different, supporting the idea that RAB proteins serve 
distinct functions. Secondly, mouse models can be a very powerful tool in dissecting 
the function of specific RAB proteins. 
1.8 Warburg Micro syndrome disease 
pathogenesis  
No histopathological data is available for Warburg Micro syndrome as patient 
families have declined post mortem. Prior to generation of the Rab18-/- mouse as 
presented in this study, previous studies focused on the RAB3 family of proteins in 
disease pathogenesis. RAB3GAP1 and RAB3GAP2 form a heterodimeric complex 
specifically targeting the RAB3 family of proteins in calcium mediated exocytosis of 
hormones and neurotransmitters, therefore loss-of-function mutations in either 
isoform could result in dysregulation of the RAB3 subfamily. Furthermore, 
mutations in effectors and regulators of the RAB3 subfamily including RAB GDI 
and RIM1 are implicated in neurological impairment and dysfunction of RAB3 could 
therefore potentially explain the cognitive features observed. For example, mutations 
in RAB GDIα cause X-linked mental retardation, type 41 (MIM 300849) and 
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mutations in the RAB3 effector RIM1 have been reported in cases of cone rod 
dystrophy additionally exhibiting enhanced cognition (Miki et al., 2007). 
Additionally, Warburg Micro syndrome patients exhibit microgenitalia, that is 
reported to be hypothalamic in origin. The RAB3B isoform has been reported to 
function in gonadotrophin release in vitro (Tasaka et al., 1998) and could therefore 
potentially explain the microgenitalia defect observed. Warburg Micro syndrome 
patients also present with progressive paralysis and structural brain defects. 
Furthermore, a reduction in RAB3A levels was noted in post-mortem brains of both 
Schizophrenia and Alzheimer disease patients (Blennow et al., 1996a, Blennow et 
al., 1996b), pointing towards an involvement of the synaptic protein in many 
neurodegenerative conditions. 
The majority of studies examining RAB18 function both in vitro and in vivo have 
focused on the localisation of RAB18 to lipid droplets and a role in both lipolysis and 
lipogenesis has been reported (Ozeki et al., 2005, Martin et al., 2005). Recent studies 
have also reported enlarged lipid droplets in RAB18, RAB3GAP1 and TBC1D20 
patient cell lines, suggesting that lipid droplet dysfunction may serve as a link 
between the identified proteins (Leigel et al., 2013, in press). Lipid droplets are the 
primary storage site for neutral lipids, primarily composed of cholesteryl esters 
(Martin and Parton, 2006). Cholesterol metabolism disorders including Smith-Lemli-
Opitz syndrome (MIM 270400) additionally show similar ocular, genital and 
neurological abnormalities to those observed in Warburg Micro syndrome including 
microcephaly, mental retardation, microgenitalia, hypotonia, cataracts, dysmorphic 
facial features and joint and limb abnormalities are occasionally observed. This 
suggests that cholesterol dysfunction may also be implicated in disease pathogenesis 
and should be the basis of future work. 
1.9 Use of mouse models to aid understanding of 
disease 
Animal models have proven invaluable in assigning function to previously 
uncharacterised genes and also dissecting the pathology underlying a vast array of 
human diseases. Experiments are routinely performed using yeast, worm and fly 
29 
 
models to study many aspects of biology. However, these invertebrate models are 
highly diverse from humans, lacking many organ systems and showing great 
variation in genome size. Recent studies have focused on fish models including the 
zebrafish (Danio rerio) due to the transparency of embryos allowing easy 
visualisation of development, short developmental timescale and amenability to 
treatment by pharmacological drugs. However, many genes have been duplicated 
since the divergence of mammalian and aquatic organisms, hindering human genetic 
studies, and fish physiology is very different from that of mammals. The large degree 
of conserved synteny between the human and mouse genomes and their similar size 
has made mouse models an ideal target for the study of human genes and disease. 
Unlike many other mammals, mouse models have an advantage in that they are 
reasonably cheap to maintain, have short gestation times and are amenable to 
colonial life in captivity. Furthermore, congenic lines can be generated by 10 
generations backcross matings which eliminates any background variations that may 
impact on phenotype. 
Studies have focused on mouse mutants generated through ENU (N-ethyl-N-
nitrosourea) irradiation of males, many of which recapitulated human disease 
phenotypes (Rosenthal and Brown, 2007). However this forward genetics approach 
then required time consuming in-depth follow up studies to identify genes of interest 
through positional cloning and candidate gene approaches. As a result the underlying 
genetic mutations for many mutgenised mouse models are still to be identified. 
Following the completion of the mouse genome project there has been a coordinated 
effort to introduce specific mutations into endogenous genes that are transmitted 
through the germline, by homologous recombination in ES cells to knock out genes 
of interest that are then injected into blastocysts. However, this has the disadvantage 
of losing gene function from conception often resulting in embryonic lethality thus 
preventing the examination of late-onset phenotypes. As a result, the Cre/loxP 
system is becoming increasingly popular to generate temporal or tissue specific 
knockouts and thus enable examination upon loss of protein function in particular 
tissues and/or stages of development or adulthood. Additionally, it is now possible to 
knock in patient mutations or overexpress human genes within the mouse. This is 
particularly important for genes whose function is critical for embryonic 
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development and survival and has made it possible to examine phenotypes of a large 
number of human diseases arising from specific mutations altering gene function 
without losing expression in its entirety (Rosenthal and Brown, 2007). Mouse models 
for a variety of human genes are now available and in many cases have provided the 
first insight not only into protein function but also disease pathogenesis (see tables 
6.1 and 6.2). 
However, prior to this study characterisation of available animal models for Warburg 
Micro syndrome have not provided the detailed understanding of disease 
pathogenesis required. For example the Rab3gap1 knockout mouse did not 
recapitulate the characteristic ocular or neurological features of the human disease, 
suggesting potential species specific or functional redundancy of Rab3 isoforms 
(Sakane et al., 2006). Examination of RAB3A levels in the brain identified no 
significant differences in overall levels but accumulations of GTP bound RAB3A. 
Normal synaptic architecture was present in the brains of Rab3gap1 deficient mice, 
and no abnormalities in synaptic vesicle protein levels including syntaxin, SNAP-23, 
synaptotgamin-1 and Munc-18 was reported. However, closer examination of 
synaptic transmission and plasticity by electrophysiology identified inhibition of 
calcium mediated glutamate release in synaptosomes. Altered short term synaptic 
plasticity was noted in the hippocampal CA1 with increased facilitation upon 
repetitive stimulation at a moderate frequency and little to no depression of 
excitatory postsynaptic current (EPSC) and increased paired-pulse facilitation (PPF) 
(Sakane et al., 2006).  
Additionally, flies lacking rab3gap1 were reported in a screen for genes involved in 
homeostatic signalling (Muller et al., 2011). Rab3gap1 fly models showed 
abnormalities in synaptic homeostasis. Synaptic homeostasis refers to the 
upregulation of presynaptic activity when postsynaptic sensitivity is decreased. 
Muller et al., identified abnormalities both in the upregulation of presynaptic activity 
in rab3gap1 knockout flies when treated with PhTX (glutamate receptor antagonist 
philanthrotoxin-433) to block postsynaptic receptors or when crossed to GluRIIA 
mutant flies with persistent expression of synaptic homeostasis. However, synaptic 
efficiency during induction and homeostasis was normal in rab3 mutant flies, and in 
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double rab3gap1/rab3 knockout flies. This suggests that loss of rab3gap1 causes its 
phenotypic effects via RAB3 gain-of-function effect rather than loss-of-function 
(Muller et al., 2011).  
To elucidate the function of RAB3 proteins in development and synaptic plasticity, 
Rab3 knockout mice have been generated (Schluter et al., 2002, Geppert et al., 
1994). Rab3a knockout mice showed normal synaptic transmission and plasticity in 
hippocampal CA1 regions (including paired-pulse facilitation and long term 
potentiation). However, upon repetitive stimulation the depression of excitatory 
postsynaptic currents increased (Geppert et al., 1994). Following this, to examine the 
role of RAB3 proteins and remove the possibility of any potential functional 
redundancy, single, double, triple and quadruple Rab3 knockout mice have been 
generated (Schluter et al., 2004). Upon loss of one or two Rab3 isoforms no impact 
on viability or fertility was observed. However, triple (when Rab3a was knocked 
out) and quadruple Rab3 knockout mice died shortly after birth due to respiratory 
failure. As a result, to examine for any synaptic plasticity abnormalities upon loss of 
all Rab3 isoforms, hippocampal neurons were cultured from quadruple Rab3 
knockout mice. A decrease of approximately 30% in evoked responses was noted 
indicative of a decline in the probability of both synapse and vesicle release and 
suggestive of a critical function of RAB3 in calcium mediated exocytosis as 
previously reported, but not gross exocytosis (Schluter et al., 2006). 
Tbc1d20 bs mice display ocular and genital abnormalities reminiscent of Warburg 
Micro syndrome but neurological impairment has not yet been reported. The bs 
mouse phenotype is characterised by bilateral cataracts, micropthalmia, male sterility 
and glossy coat condition in mice (Varnum, 1983). Further characterisation of the 
male sterility identified normal copulatory behaviour but germ cell depletion with 
little or no sperm observed and a failure of acrosome assembly in the immobile 
sperm that did survive (Sotomayor and Handel, 1986) (Leigel et al., 2013, in press). 
Leigel et al., 2013 identified onset of cataract development from P16 with bilateral 
vacuolar cataracts observed by P28. Microphthalmia was additionally observed, with 
the majority of the ocular phenotype restricted to the lens and lens fibre degeneration 
observed with large vacuoles and rupture of the lens (Leigel et al., 2013, in press). 
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Mouse models deficient for Rab3gap2 have not previously been reported. However, 
given its restricted sites of expression in the developing zebrafish relevant to the 
CNS, it would be of interest to generate Rab3gap2 deficient mice and examine for 
any morphological/degenerative characteristics. However, mice deficient for 
Rab3gap1 also exhibit severe reduction in levels of RAB3GAP2 (Sakane et al., 
2006).  
From the above literature it is evident that generation and characterisation of a 
mammalian model recapitulating the ocular and neurological phenotypes observed in 
Warburg Micro syndrome is critical to understand the pathogenesis of this 
devastating disease. Characterisation of morpholino knockdown of rab18 in 
zebrafish recapitulating ocular and neurological phenotypes including 
micropthalmia, microcephaly and a reduction in overall body size, pointed towards 
an all-important role for RAB18 in disease pathogenesis (Bem et al., 2011). 
Furthermore, analysis of RAB18 in TBC1D20 cell lines and the suggestive link 
between RAB18 and RAB3GAP2 points towards the phenotype of Warburg Micro 
syndrome surrounding that of RAB18 dysfunction. The principle aim of this thesis 
was therefore to undertake detailed ocular and neurological characterisation of a 
novel Rab18-/- mouse model created as part of the EUMODIC screen. 
1.10 Aims and objectives 
Aim 1: Characterise the gross phenotype of Rab18-/-mice taking into consideration of 
the Warburg Micro syndrome patient phenotype 
Aim 2: Examine the localisation of GFP-RAB18 in different cell types to determine 
whether RAB18 localisation may be relevant to a cellular phenotype that is common 
to all cells and results in pathology or serves a cell-specific/specialised localisation 
that is relevant to disease in affected cell types. 
Aim 3: Undertake detailed characterisation of the ocular phenotypes observed in 
Rab18-/- mice through embryogenesis and adulthood 
Aim 4: Undertake detailed neuropathological characterisation of hind limb weakness 
observed in Rab18-/- mice. 
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a) Examination of synaptic vesicle recycling in Rab18-/- mice 
b) Investigate neuromuscular pathology and nerve-muscle connectivity in flexor 
digitorum brevis and lumbrical muscles from the hind paw and the transverse 
abdominal muscle from the abdominal wall. 
c) Analyse axon morphology in the peripheral and central nervous systems 
through electron microscopy 
d) Undertake a detailed proteomics screen to identify alterations in core 
molecular pathways in Rab18-/- mice compared to heterozygote littermates 
that could potentially explain the observed pathology 
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Chapter 2 Materials and Methods 
2.1 Mouse generation and maintenance 
2.1.1 Generation of the Rab18-/- mouse 
The Rab18 mouse (EUCOMM Project; strain C57BL/6 x 129P2/Ola 
(Rab18Gt(EUCE0233a03)Hmgu) was generated as part of the EUMODIC programme by 
MRC Harwell. Rab18 genetrap mice were created using the FlipRosaβGeo cassette 
inserted into intron 2 of Rab18. The genetrap was inserted into 129P2/OlaHsd 
(E14TG2a) embryonic stem (ES) cells, positive ES cell clones were injected into 
blastocysts and transferred to pseudopregnant foster mothers to generate chimeras. 
Mice were bred to 129P2/Ola to retain the ES cell background. Further details of 
genetrap and targeting can be found at 
http://www.informatics.jax.org/javawi2/servlet/WIFetch?page=alleleDetail&key=57
4626 
2.1.2 Breeding and maintenance 
Rab18+/- heterozygote mice on a 129P2/Ola background were obtained from MRC 
Harwell as part of the EUMODIC programme. Most analyses in this thesis were 
performed on Rab18-/- mice and littermate controls from C57BL/6J and 129P2/Ola 
first generation backcrosses. However, mice on pure 129P2/Ola and crossed for 9 
generations to C57BL/6J showed the same overt phenotype. Rab18 mice were 
maintained as heterozygote breeding pairs in the animal care facilities at the 
University of Edinburgh under standard conditions. All animal procedures were 
performed in accordance with Home Office regulations under the personal licence 
60/13012.  
2.1.3 Isolation of DNA from earclips and tailclips 
DNA was isolated from tailclips (embryos and neonates) and earclips (weaned mice) 
using DirectPCR Lysis Reagent tail and ear respectively (Viagen Biotech Inc).  Ear 
or tailclips were digested in 100µl DirectPCR lysis reagent and 4µl 100µg/mL 
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proteinase K. Samples were incubated overnight at 55ºC and proteinase K inactivated 
the next morning at 85ºC for 45 minutes. Samples were vortexed and 100µl H2O 
added to dilute the reaction mix. 1µl was used in genotyping PCR as performed in 
2.1.4. 
2.1.4 Genotyping polymerase chain reaction 
The majority of genotyping was performed using the Bio-X-Act long DNA 
polymerase (Bioline). However, towards the end of my PhD Bioline stopped 
producing Bio-X-Act and their alternative polymerase MyFII was used instead. For 
Bio-X-Act a 20µl reaction was set up containing 15.35µl H2O, 2µl 10x Opti buffer, 
0.6µl MgCl2, 0.2µl each 10µM primer, 0.25µl Bio-X-Act, 0.4µl dNTPs and 1µl 
DNA. For MyFII a 25µl reaction was set up containing 16.5µl H2O, 5µl MyFII 
buffer, 1µl each 10µM primer, 0.5µl MyFII polymerase and 1µl DNA. The following 
PCR programmes were used. 
Bio-X-Act programme   MyFII programme 
1) Denaturation  94ºC 3 minutes 1) Denaturation 95ºC 1 minute 
2) Denaturation 94ºC 30 seconds 2) Denaturation 95ºC 15 seconds 
3) Annealing 58ºC 45 seconds 3) Annealing   58ºC 45 seconds 
4) Extension 68ºC 1 minute 4) Extension   68ºC 1 minute 
5) Cycle to step 2 for 34 more times 5) Cycle to step 2 for 34 more times 
6) Extension 68ºC 2 minutes 6) Extension   68ºC 2 minutes 
7) Hold  15ºC forever  7) Hold   15ºC forever 
 
PCR products were analysed by agarose gel electrophoresis as described in 2.2.1. 
Table 2.1 Primers used in this thesis 
Primer Application Sequence 
Rab18 Intron2 Fwd Genotyping PCR TGCGTTCATGGTTGAGTTTG 
Rab18 Intron2 Rev Genotyping PCR GGCTGTTTTCAAGGACTCCA 
LoxP Rev Genotyping PCR CGATGGTGAAGCTTGGATAAC 
Rab18 Ex1 Fwd RT-PCR AGAGTGGGGTGGGCAAGT 
Rab18 Ex5 Rev RT-PCR CAAAGGTGTCTCTTCTTGTGACAT 
Rab18 Ex3 Fwd RT-PCR AAAACGATTTCAGTGGATGGA 
Rab18 Ex7 Rev RT-PCR GGTTCTCACTTTCCCACAGG 
Rab18 Fwd qPCR GCTGGTCAAGAGAGGTTCAGA 
Rab18 Rev qPCR GGTGTCTCTCTTGTGACATCATAG 
GalT Fwd Cloning GAATTCGAATTCGCCATGAGGCTTCGGGAGCCGCT 
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GalT Rev Cloning GGATCCGGATCCCGGGGCACTGGGACCGAGGTCAA 
Rab18 Fwd Sequencing GCTATTATAGAGGTGCACAGGG 
Rab18 Rev Sequencing TTCGTGCAAATTTCAGGCCT 
 
2.1.5 Agarose gel electrophoresis 
DNA samples were separated by agarose gel electrophoresis and visualised using a 
UV transilluminator (BioDoc-It System, UVP). 5x loading dye (50% sucrose in H2O 
containing phenol red) was added to each PCR sample, to produce a final 1x solution 
and 6µl of each reaction run on an agarose gel. Agarose gels were produced by 
dissolving agarose (Hi-Pure Low EEO agarose, Biogene) in 1x TBE buffer (89mM 
Tris base, 89mM boric acid and 20mM EDTA) in a microwave at full power 
producing final concentrations of 1%, 1.5% and 2% agarose/1xTBE (w/v). Once 
cooled 0.5µg/mL ethidium bromide was added to all gels. A DNA ladder of known 
sizes (Bioline HyperLadder II) was loaded in lane one of each gel for reference 
purposes. All gels were run at 80-150V for 20-45 minutes. 
2.2 RNA protocols 
2.2.1 RNA extraction from tissues 
Intact E11.5 embryos (except for tailclips used in genotyping) were dissected and 
stored in RNAlater, RNA stabilization solution (Qiagen) at 4ºC for short term 
storage. Embryos were homogenised with a Pellet Pestle Cordless Motor (Kontes) and 
individual sterile pestle attachments and homogenate passed through a QIAshredder 
spin column (Qiagen). RNA was then extracted using the QIAamp RNA blood kit 
(Qiagen) according to manufacturer’s instructions. RNA was eluted in 50µl RNase-
free water following centrifugation at 10,000rpm for 1 minute. RNA concentration 
was quantified (see 2.3.2) and samples were stored at -80ºC to preserve RNA quality. 
2.2.2 RNA extraction from cells 
RNA was isolated from 5x105 MEFs plated to 6 well plates and grown to confluency. 
Cells were lysed using buffer RLT (Qiagen) and the lysate added onto QIAshredder 
spin columns (Qiagen). RNA was then extracted using the QIAamp RNA blood kit 
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(Qiagen, following the purification of total RNA from animal cells using spin 
technology protocol) according to manufacturer’s instructions. On column DNAse 
digestion with RNase free DNase (Qiagen) was also carried out. RNA was eluted in 
30µl RNase-free water following centrifugation at 10,000rpm for 1 minute. RNA 
concentration was quantified (see 2.3.2) and samples were stored at -80ºC to preserve 
RNA quality. 
2.2.3 RNA/DNA quantification 
RNA and DNA concentrations were analysed using Nanodrop 1000 UV-Vis 
Spectrophotometer (Thermo Scientific) according to manufacturer’s instructions. 
2.2.4 cDNA synthesis 
cDNA was synthesised from RNA using First Strand cDNA Synthesis Kit for RT-
PCR (AMV) (Roche). 1µg template RNA was used in each reaction. 20µl reaction 
mixes were prepared containing 1x reaction buffer, 50 units RNase inhibitor, 5mM 
MgCl2, 1mM deoxynucleotide mix, 1.6µg Oligo-p(dT)15 primer mix and 20 units 
AMV reverse transcriptase. Samples were incubated in a PCR machine at 25ºC for 
10 minutes, 42ºC for 1 hour, 99ºC for 5 minutes, held at 4ºC and samples stored at     
-80ºC. A negative control minus AMV reverse transcriptase (-RT) was performed 
alongside each reaction to examine for any contaminating DNA. 
2.3.5 RT-PCR 
For RT-PCR experiments, RNA isolated from tissues was carried out as in 2.3.1 and 
cDNA synthesised as in 2.3.3. Intron spanning primers (see table 2.1) were designed 
using Primer 3 software (http://bioinfo.ut.ee/primer3/). 2µl isolated cDNA was used 
in PCR with 6µl Reddymix (Thermo scientific), 0.4µM each forward and reverse 
primer and 3µL H2O and the following PCR programme. 
1) Denaturation  96ºC 5 minutes 
2) Denaturation 96ºC 45 seconds 
3) Annealing 57ºC 45 seconds 
4) Extension 72ºC 45 seconds 
5) Cycle to step 2 for 34 more times 
6) Extension 72ºC 10 minutes 




Minus RT samples were also run as a negative control. 6µl of each reaction was run 
on an agarose gel see 2.2.1. 
2.2.6 Quantitative RT-PCR 
Quantitative RT-PCR was performed using the Roche LightCycler-480 and the 




cDNA isolated from heterozygote and Rab18-/- MEFs (Mouse Embryonic 
Fibroblasts) was diluted 1 in 5 and 2.5µl used in each 10µl reaction containing 
0.2µM each primer, 0.1µM probe #33, 1x Probemaster mix LC-480 (Roche) and 2µl 
H2O. 1 in 2 diluted wild type cDNA was used to create a standard curve by further 
dilutions 1 in 10, 5 times. TBP plasmid (0.1ng/µl) was used as a control gene. The 
following programme was used for qRT-PCR: 
1) Denaturation   95ºC 10 minutes 
2) Denaturation  95ºC 10 seconds 
3) Annealing/Extension 60ºC 30 seconds 
4) Cycle to step 2 for 44 more times 
5) Extension  40ºC 30 seconds 
 
2.3 Protein protocols 
2.3.1 Protein extraction from tissues 
Sciatic nerves and lenses were dissected from Rab18-/- mice and littermate controls. 
Nerves and lenses were homogenised in 1x RIPA buffer (Thermo scientific) 
containing 1x protease inhibitor cocktail (Roche), using a Kontes handheld Pellet 
Pestle Cordless Motor.  Samples were sonicated for 3 x 30 second pulses (Bioruptor, 
Diagenode) and centrifuged at 15,000 RPM, 4ºC for 15 minutes. The supernatant 
was then collected and stored at -20 or -80ºC. 
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2.3.2 Preparation of crude synaptosomes 
Brains from wildtype, heterozygote and Rab18-/- mice were rapidly dissected and 
homogenised in isotonic sucrose solution on ice (5mM Tris-HCl, 1mM EDTA, 
320mM sucrose, pH 7.4). Homogenates were centrifuged at 900g for 10 minutes and 
the supernatant collected. Resultant pellets were resuspended in isotonic sucrose 
solution and centrifuged at 900g for 10 minutes and the supernatant collected. The 
resultant supernatants were centrifuged at 20,000g for 15 minutes and the pellets 
combined in buffer A (20mM Tris-HCl, 1M KCl, 250mM sucrose, 2mM MgCl2, 
1mM DTT, pH 8.0), further centrifuged at 14,000 RPM for 1 hour and supernatants 
collected- cytosolic fraction. The resultant pellets were resuspended in detergent 
containing buffer B (10mM HEPES, 100mM KCl, 2mM MgCl2, 1mM DTT, 5% 
CHAPS, pH 7.8), rotated for 45 minutes, centrifuged at 14,000 RPM for one hour 
and supernatants collected- membrane fraction. Cytosolic and membrane fractions 
were combined, and clarified by dialysis overnight in 25mM Tris-HCl, 50mM KCl, 
1mM DTT, 0.1% CHAPS, pH 7.8. 
2.3.3 Calculating protein concentration 
Protein concentration was calculated using the bicinchoninic acid Protein Assay kit 
(Pierce). 10µl of each sample was mixed with 180µl reagent (50 parts reagent A to 1 
part reagent B) and incubated for 30minutes at 37ºC. Samples were then cooled to 
room temperature and absorbance read at 562nm using the Thermo Multiskan 
Spectrum platereader. Bovine Serum Albumin (provided in BCA kit) was used to 
create a standard curve to calculate protein concentration. 
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Table 2.2: Antibodies used in this thesis 
Antibody Company (catalogue number) Species Dilution Application 
NEFM DSHB (2h3) Mouse 1 in 200 IF 
β3 tubulin Abcam (ab18207) Rabbit  1 in 2000 IF 
GM130 BD biosciences (558712) Mouse 1 in 200 IF 
hypophosphorylated NEFH Abcam (ab82259) Mouse 1 in 200 IF 
NEFL Chemicon internation (AB9568) Rabbit 1 in 1000 IF 
NEFH Abcam (ab8135) Rabbit 1 in 1000 IF 
Periaxin Sigma (HPA001868) Rabbit 1 in 150 IF 
sv2 DSHB (sv2) Mouse 1 in 100 IF 
ApoD Sigma (SAB2700764) Rabbit 1 in 1000 WB 
APP abcam (ab2072)  Rabbit  1 in 5000 WB 
β3 tubulin Sigma (T8578) Mouse 1 in 5000 WB 
KIF5A abcam (ab5628) Rabbit  1 in 200 WB 
Rab3a cell signalling (3930) Rabbit 1 in 1000 WB 
Rab3gap1 Bethyl laboratories (A310-750A) Rabbit  1 in 250 WB 
Rab3gap2 Abgent (AP9635b) Rabbit  1 in 250 WB 
Rab18 Eurogentec custom made , peptide CESENQNKGVKLSHRE Rabbit 1 in 200 WB 




25μg crude synaptosomes, 3μg or 10μg sciatic nerve or 10μg lens samples were 
prepared in 1x sample loading buffer (Invitrogen) and 1x reducing agent (Invitrogen) 
and heated at 70ºC for 10 minutes. Samples were then loaded on a Novex 4-12% Bis-
Tris pre-cast gels (Life Technologies) using the XCell surelock mini system with a 
ladder of known protein sizes in lane one (Novex Sharp protein ladder). Proteins 
were separated by running the gel at 200V for 55minutes in 1x MOPS running buffer 
(Invitrogen) plus 1x antioxidant (Invitrogen). 
2.3.5 Western blotting 
Following SDS-PAGE, the gel was removed from the cassette and proteins were 
electrophoretically transferred to Hybond nitrocellulose membranes (Hybond ECL, 
Amersham Biosciences) again using the Invitrogen XCell surelock Mini system. In 
brief the transfer system was prepared by pre-soaking Whatman filter paper and 5 
sponges in transfer buffer (1x transfer buffer (Invitrogen), 10% methanol and 1% 
antioxidant in H2O). The system was then prepared in the following order; 2x 
sponges, Whatmann paper, gel, membrane, Whatman paper, 3x sponges in transfer 
buffer and transfer carried out at 30V for 60 minutes. Membranes were blocked in 
4% Marvel milk (w/v) (Premier foods) in 1xTBST (TBS containing 0.2% tween-20) 
for one hour at room temperature or overnight at 4ºC. Membranes were then 
incubated in primary antibody solutions (see Table 2.2 for concentrations) rolling 
overnight at 4ºC. For loading control experiments, where βIII tubulin was used, 
membranes were incubated in primary antibody rolling for 1 hour at room 
temperature. Membranes were then washed for 5 x 5 minutes in 1x TBST and 
incubated with relevant HRP conjugated secondary antibodies; donkey anti-rabbit 
and donkey anti-mouse HRP (Amersham ECL western blotting reagent pack) 
1:10,000 for 1 hour rolling at room temperature. Membranes were then washed again 
in 1x TBST for 5 x 5 minutes and proteins detected with Amersham ECL plus 
western blotting detection system (GE Healthcare). Solutions A and B were mixed at 
a 40:1 ratio respectively and added to the membrane for 5 minutes at room 
temperature. Membranes were then passed through water and blotted to remove any 
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excess solution and exposed to photographic film (GE Healthcare, Amersham 
Hyperfilm ECL) which was developed using Konika SRX-101A developing system. 
2.3.6 Coomassie staining 
Alternatively, after SDS-PAGE, the gel was removed from the cassette and incubated 
in Coomassie (Expedeon, Instant Blue) for one hour rocking at room temperature. 
The gel was then rinsed in dH2O and washed overnight in dH2O at 4ºC. The gel was 
then imaged using ImageQuant LAS4000. 
2.3.7 Densitometry 
After Western blotting, membranes to be quantified via densitometry were exposed 
using the ImageQuant LAS4000 software rather than photographic film. Blot images 
were imported into ImageQuant TL software (GE Healthcare Life Sciences) and 
densitometry performed for 1-D gel analysis. Briefly, lanes were manually outlined 
and the background subtracted. Bands were then detected (with nonspecific bands 
removed from further analysis) and band intensities calculated. In some experiments 
band intensities were normalisied to that of βIII tubulin (where stated). 
2.3.8 iTRAQ proteomics 
The sciatic nerve from three 6week old heterozygote and Rab18-/- littermate controls 
was dissected in PBS and snap frozen in liquid nitrogen. Nerves from each genotype 
were pooled and homogenized using Kontes pellet pestle cordless motor in 1:40 
weight/volume ratio of 0.5M triethylammonium bicarbonate pH8.5, 1% SDS and 
1mM PMSF, sonicated for 3 x 30 second pulses and centrifuged at 14,400 RPM, 4ºC 
for 10 minutes and supernatant collected for iTRAQ undertaken by Dundee Cell 
Products. The following iTRAQ protocol was provided by Dundee Cell Products. 
Protein digestion FASP 
FASP Procedure - adapted from  (Wisniewski et al., 2009). In total, 50µg of each 
sample was used for this analysis. Based on the capacity of the filters, 7.5mg of 
protein lysate were diluted 5 times in 3mL FASP 1 (8M urea, 20mM DDT in 100mM 
Tris/HCL pH 8.5) and the equivalent of 2.5mg of protein lysate transferred to three 
Vivacon 500, 30k MWCO HY filters (Sartorius Stedim Biotech, VN01H22). The 
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sample was buffer exchanged using FASP1 several times by spinning the tube at 
7000g to remove detergents. The protein lysate was concentrated by centrifugation 
and diluted in FASP 2 (100mM Tris/HCl pH 8.5) ready for trypsin digestion. The 
sample was reduced using 50mM fresh iodoacetamide (IAA) in FASP 2 in the dark 
for 30 minutes. Lysates were spun down to remove excess IAA and buffer 
exchanged into FASP 3 (100mM TEAB (triethyl ammonium bicarbonate). Trypsin 
(Roche) was dissolved in FASP 3 to give a 1:200 enzyme to protein ratio and added 
in a volume of at least 100µL for 4-6 hrs.  This was repeated with fresh trypsin for a 
further overnight incubation. Lysates were spun down and washed with 0.5M NaCl 
and 150µL 10% trifluoroacetic acid (TFA) added to reduce the pH. Samples were 
desalted and then dried as described in (Thingholm et al., 2006).  
iTRAQ procedure      
1. iTRAQ labelling  
iTRAQ labeling was performed using the iTRAQ Reagents Multiplex kit - 4 plex 
(AB Sciex, UK Ltd). 70µL ethanol was added to each vial of labelling reagent, i.e. 
labels 114, 115, 116 and 117, vortexed and centrifuged. A two way comparison was 
undertaken with samples run in duplicate; Rab18 114 and 116, het 115 and 117. 
Dried samples were re-suspended in 50 µl Dissolution buffer supplied by the kit 
manufacturer.  25µl of the contents of one vial of label was added to an equivalent 
volume of sample, vortexed then centrifuged. Samples were incubated with shaking 
at room temperature for one hour. After incubation, 100µl of water was added to 
each vial to quench the experiment and left for a further hour on the shaker. The four 
vials of labels with samples were pooled into one vial then speed vacuumed to 
dryness. Samples were desalted using as recommended by the iTRAQ kit 
manufacturer. 
2) Offline strong cation exchange (SCX) fractionation 
Samples were re-suspended in 100µL of 5mM KH2PO4 in 25% ACN (Buffer A), 
vortexed well and centrifuged for 10 minutes. The system set-up was as follows: 
Buffer A as above, Buffer B- 500mM KCl in 25% ACN. Gradient: 0-50 % B in 31 
minutes, 50% B-100% B in 7mins, flow rate: 200µl/min. Column size was 2 x 
200mm, 5µm (Poly LC). 90 µL of sample was injected into the fractionator and 
samples were collected in separate vials, every 3 minutes for the first two fractions, 
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then every minute for the remainder of the fractions. All fractions were dried down in 
a speedvac.  Samples were then re-suspended in 1% fluoroacetic acid (FA). 
Mass spectrometry analysis 
Trypsin-digested peptides were separated using an Ultimate 3000 RSLC (Thermo 
Scientific) nanoflow LC system. 15µl of sample was loaded with a constant flow of 
5µl/min onto an Acclaim PepMap100 nanoViper C18 trap column (100 µm inner-
diameter, 2cm; Themro Scientific). After trap enrichment, peptides were eluted onto 
an Easy-Spray PepMap RSLC C18 column (75 µM x 50cm) (Thermo Scientific) 
with a linear gradient of 2–45% buffer B (80% acetonitrile with 0.08% formic acid) 
over 85 minutes with a constant flow of 300nl/min. The HPLC system was coupled 
to a linear ion trap Orbitrap hybrid mass spectrometer (LTQ-Orbitrap Velos Pro, 
Thermo Scientific) via a nanoelectrospray ion source (Thermo Scientific). The spray 
voltage was set to 1.9 kV, and the temperature of the heated capillary was set to 
50°C. Full-scan MS survey spectra (m/z 335–1800) in profile mode was acquired in 
the Orbitrap with a resolution of 60,000 after accumulation of 1,000,000 ions. The 
ten most intense peptide ions from the preview scan in the Orbitrap were fragmented 
by higher-energy collisional dissociation (HCD) (two-step (6%) collision energy, 
40%; activation Q, 0.250; and activation time, 0.1ms) in the LTQ after the 
accumulation of 10,000 ions. Maximal filling times were 1,000 ms for the full scans 
and 200ms for the MS/MS scans. Precursor ion charge state screening was enabled, 
and all unassigned charge states as well as singly charged species were rejected. The 
lock mass option was enabled for survey scans to improve mass accuracy (Olsen et 
al., 2004). Data were acquired using the Xcalibur software. 
Quantification and bioinformatics analysis 
The raw mass spectrometric data files obtained for each experiment were collated 
into a single quantitated data set using Proteome Discoverer (Thermo Scientific) and 
the Mascot search engine. Enzyme specificity was set to that of trypsin, allowing for 
cleavage N-terminal to proline residues and between aspartic acid and proline 
residues. Other parameters used were: (i) variable modifications, methionine 
oxidation, protein N-acetylation, gln  pyro-glu; (ii) fixed modifications, cysteine 
carbamidomethylation; (iii) database: IPImouse_20130120; (iv) iTRAQ labels: 
standard iTRAQ 4-plex quant method with labels 114-117; (v) MS/MS tolerance: 
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FTMS- 10ppm, ITMS- 0.6Da; (vi) maximum peptide length, 6; (vii) maximum 
missed cleavages, 2; (viii) false discovery rate, 1%. Peptide ratios were calculated 
using the averaged ratios of 114 and 116 and 115 and 117 for samples Het/Rab18 
and Rab18/Het. Protein ratios for all labelled peptides sequenced for each protein 
were normalized on the protein median ratio.  
In Silico Protein Network Analysis: 
To obtain further insight into potential cellular pathways that may be modified as a 
result of protein changes identified by our iTRAQ proteomic screen, the Ingenuity 
Pathways Analysis (IPA) application (Ingenuity Systems) was used. IPA 
dynamically generates networks of gene, protein, small molecule, drug, and disease 
associations on the basis of hand-curated data held in a proprietary database as 
previously described (Wishart et al., 2007) Filtered iTRAQ data was input into IPA. 
Networks generated by IPA were limited to a maximum of 35 members and 
experimentally observed relationships. Networks were ranked according to a score 
calculated via a right tailed Fisher¹s exact test. This test outputs a value that takes 
into account the original input proteins of interest and the size of the network 
generated. Further information on the computational methods implemented in IPA 
can be obtained from Ingenuity Systems (Wishart et al., 2010, Wishart et al., 2007, 
Wishart et al., 2012). 
2.4 Bacterial cloning and DNA methods utilised 
during cloning 
2.4.1 Plasmids used in this thesis 
Plasmid Source 
GFP-RAB18 Gift from Prof. Francis Barr, Oxford and sequence verified 
mCherry-RAB18 Subcloned from GFP-RAB18, Mark Handley 
GFP-TBC1D20-RA Gift from Prof. Francis Barr, Oxford 





2.4.2 PCR for cloning 
High-fidelity PCR for cloning reactions was carried out using KOD polymerase 
(Novagen). A 50µl reaction was set up containing 0.5µl human brain cDNA, 5µl 10x 
KOD buffer, 2µl MgSO4, 5µl dNTP, 10µl 5M betaine, 1.5µl of each forward and 
reverse primers, 0.5µl KOD polymerase and 24µl H2O. The following PCR 
conditions were used; 
1) Denaturation  98ºC 30 seconds 
2) Denaturation 98ºC 10 seconds 
3) Annealing 55ºC 45 seconds 
4) Extension 72ºC 90 seconds 
5) Cycle to step 2 for 19 more times 
6) Extension 72ºC 10 minutes 
7)  Hold  4ºC forever 
 
2.4.3 Gel extraction 
PCR reactions for cloning were run on 1% agarose gels as in 2.1.5 and DNA 
fragments of interest excised from the gel under UV light. DNA was then extracted 
using NBS biological DNA spin column gel extraction kit according to 
manufacturer’s instructions.  
2.4.4 Transformation of chemically competent cells 
For high-fidelity GalT-CFP cloning Top10 cells (Life Technologies) were used for 
transformations. In brief, 2µl of PCR product was added to 0.5µl salt solution and 
0.5µl D-Topo vector and incubated for 10 minutes at room temperature. The reaction 
mix was then transferred to 14ml round bottom falcon tubes and 25µl Top10 cells 
added and incubated on ice for 30 minutes. Cells were then heat shocked at 42ºC for 
30 seconds and allowed to briefly recover on ice. 125µl of room temperature SOC 
media was then added and cells were shaken at 225rpm, 37ºC for 1 hour before 
spreading on antibiotic specific agar plates. Plates were incubated overnight at 37ºC.  
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2.4.5 Purification of DNA from bacterial cells by miniprep and 
maxiprep 
For miniprep purification of DNA, a single bacterial colony was picked and added to 
4ml L-broth containing the appropriate antibiotic and incubated overnight shaking at 
225rpm and 37ºC. NBS biologicals spin column plasmid DNA miniprep kit was then 
carried out according to manufacturer’s instructions. 
For maxiprep purification of DNA, two colonies were picked from a transformed 
agar plate and used to inoculate 200mL L-Broth containing the appropriate 
antibiotic. Cultures were incubated overnight shaking at 225rpm and 37ºC. Qiagen 
hispeed maxiprep kit was then carried out according to manufacturer’s instructions. 
2.4.6 Restriction enzyme digestion 
To confirm correct insertions, and cut eCFP-N1 destination vectors restriction 
enzyme digestions were performed. Restriction endonucleases (in this case BamHI 
and EcoRI, New England Biolabs) were incubated with their corresponding reaction 
buffers at 37ºC for 4 hours. The reaction mix contained 1µl miniprep, 0.25µl each 
restriction enzyme, 7.5µl H2O and 0.1µl BSA where appropriate. Following 
incubation reactions were run on a 1% agarose gel. 
2.4.7 Cloning of GalT-CFP 
GalT was directionally cloned from wild type human fibroblast cDNA (first strand 
AMV kit, Roche). Primers were designed to include EcoRI and BamHI restriction 
sites for subsequent in frame insertion into ECFP-N1 vectors (see table 2.1). Inserts 
were initially cloned into pENTR/D-TOPO and used to transform Top-10 cells 
Invitrogen).  The insert was then cloned into EcoRI and BamHI sites of CFP-
N1vectors and used to transform XL-1 blue cells (Stratagene) according to 
manufacturer’s instructions and plated on Kanamycin plates. 
2.4.8 GFP-RAB18 
GFP-RAB18 was a kind gift from Professor Francis Barr, University of Oxford. 
GFP-RAB18 was used to transform subcloning efficiency DH5α cells (Invitrogen). 
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1µl of GFP-RAB18 was added to 50µl DH5α cells and incubated on ice for 30 
minutes. Cells were then heat shocked at 42ºC for 20 seconds and allowed to briefly 
recover on ice. 450µl of room temperature SOC media was then added and cells 
were shaken at 225rpm, 37ºC for 1 hour before spreading on agar plates containing 
kanamycin. Plates were incubated overnight at 37ºC. Constructs were then used to 
transform L-broth containing kanamycin and DNA purified by maxiprep. GFP-
RAB18 was then sequence verified at the MRC Human Genetics Unit. 
2.5 Cell culture 
2.5.1 Preparation and maintenance of mouse embryonic 
fibroblasts (MEFs) 
MEFs were isolated from E12.5 embryos from a HET x HET cross. Embryos were 
dissected in prewarmed MEF media (DMEM (Gibco, Invitrogen) containing 10% 
fetal calf serum (FCS), 1% penicillin/streptomycin (P/S) and 3.5µl β-
mercaptoethanol (Sigma-Aldrich). Tails were removed for genotyping and head and 
abdominal organs removed and disposed of. Under sterile tissue culture conditions 
embryos were minced with a sterile scalpel and transferred to 25cm3 flasks and 
cultured at 37ºC, 5% CO2 and 3% O2. After 3 days clumps of tissue were removed 
and MEFs were transferred to 75cm3 flasks, where they were passaged every 2-3 
days until passage 8 or earlier if differentiation occurred. Cells were plated at a 
density of 5x105 in 6 well plates for RNA extraction and at a density of 1x105 on acid 
treated coverslips (heated at 50-60ºC for 4-16 hours in 1M HCL, cooled to room 
temperature, rinsed in dH2O and washed in 50-70-100% ethanol, for a minimum of 
10 minutes per wash) or glass bottom 24 well plates for transfection and 
immunofluorescence.  
2.5.2 DNA transfection of MEFs with lipofectamine 
For transfection experiments, MEFs were plated at a density of 1x105 in 24 well 
glass bottom plates and transfected using lipofectamine 2000 (Invitrogen). Briefly, 
16-24 hours post plating 3µl of lipofetamine per well was added to 50µl of Opti-
MEM (Invitrogen) and incubated for 5 minutes at room temperature. Meanwhile, 
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0.5µg of the desired DNA construct was added dropwise to 50µl of Opti-MEM per 
well and incubated for 20-30 minutes at room temperature. Media was removed from 
all wells and replaced with 400µl of Opti-MEM and 100µl of desired DNA 
construct/Opti-MEM/lipofectamine mix and incubated for 4-6 hours at standard 
tissue culture conditions. Following incubation, the transfection mixture was 
removed and replaced with complete media. Cells were returned to standard culture 
conditions for 16-24 hours prior to microscopic imaging. 
2.5.3 Lipid loading of MEFs with oleic acid 
For lipid loading experiments, MEFs were plated at a density of 1x105 in 24 well 
glass bottom plates. 48 hours post plating; MEFs were loaded with 400µM oleic acid 
for 24 hours. Cells were then fixed in 4% PFA/PBS for 30 minutes and labelled with 
BODIPY (Life Technologies) in 150mM NaCl in H2O for 20 minutes at room 
temperature. Cells were then washed 3 x in PBS and mounted in mowiol containing 
DAPI. 
For live cell imaging of lipids, MEFs were plated at a density of 1x105 in 24 well 
glass bottom plates. 24 hours post plating, MEFs were loaded with 400µM and 6µM 
BODIPY558/564 C12 (Life Technologies) in complete media. 24 hours later the media 
was removed and replaced with complete media prior to microscopy on Nikon A1R. 
2.5.4 Mouse hippocampal neuron culture conditions 
Primary hippocampal neuron cultures were prepared from E17.5 wild type embryos. 
Brains from E17.5 embryos were dissected in ice cold dissection buffer (HBSS 
(Gibco) containing 0.7% HEPES (Invitrogen) and 1% Glutamax (Invitrogen). 
Hippocampai were then dissected from each brain into DMEM (Gibco) containing 
10% FBS (Invitrogen) and 1% P/S (Invitrogen). Hippocampai were then pooled and 
dissociated in 0.1% TrypLE (Invitrogen, diluted 2:3 in dissection buffer) for 45 
minutes at 37ºC. TrypLE solution was then aspirated and cells resuspended in 5ml 
complete DMEM before passing through a 40µm cell strainer. Cells were then spun 
for 5 minutes at 1500RPM and pellets resuspended in Neurobasal media (Gibco) 
containing 2% B27 (Invitrogen) and 1% glutamax (Invitrogen). 2.5x105 or 5x105 
cells were plated on poly D-lysine (Sigma Aldrich) coated glass bottom 24 well 
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plates and cells maintained under standard conditions (37ºC, 5% CO2), with half 
media changed every 3-4 days. 
2.5.5 DNA transfection with Lonza Amaxa AD1 system 
After 12-14 days in vitro (DIV) differentiated hippocampal neurons were transfected 
with GFP tagged RAB18 using the Lonza Amaxa AD1 system. Briefly, 17.5µg GFP-
RAB18 was added to AD1 solution, producing a final volume of 350µl. The media 
was removed from all wells and kept and replaced with 350µl AD1/GFP-RAB18 
construct mix. Cells were then transfected using the Amaxa AD1 system (Lonza) for 
24 well plates and the IF-100 programme, chosen during optimisation for optimal 
transfection of GFP-RAB18 and neuron viability. Following transfection, the 
transfection mixture was removed and replaced with 700µl conditioned media. Cells 
were returned to the incubator and imaged 24 hours later. 
2.5.6 Immunocytochemistry 
Wild type, heterozygote and Rab18-/- MEFs were plated on acid coated coverslips in 
24well plates at a density of 1x105 cells per well. After 24 hours, cells were rinsed in 
PBS and fixed in 4% PFA/PBS for 10 minutes at room temperature. Cells were then 
permeabilised in 1x TBST (containing 0.1 Triton-X) for 10 minutes at room 
temperature before blocking in 10% donkey serum in 1x TBST for 1 hour at room 
temperature. Cells were then incubated in primary antibodies (see table 2.2) in 
blocking solution overnight at 4ºC. The next morning, cells were washed 3 x 5 
minutes in 1x TBST and incubated in AlexaFluor conjugated secondary antibodies 
(Invitrogen) at a concentration of 1:500 in blocking solution for 1 hour at room 
temperature. Cells were then washed for 3 x 5 minutes in 1x TBST and mounted 
with mowiol containing DAPI. 
Wild type primary neuron cultures after 12-14 DIV were rinsed in PBS and fixed in 
4% PFA/PBS for 10 minutes at room temperature. Cells were then permeabilised in 
1x TBST (containing 0.1 Triton-X) for 10 minutes at room temperature before 
blocking in 10% donkey serum in 1x TBST for 1 hour at room temperature. Cells 
were then incubated in primary antibodies (see table 2.2) in blocking solution 
overnight at 4ºC. The next morning, cells were washed 3 x 5 minutes in PBS and 
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incubated in AlexaFluor conjugated secondary antibodies (Invitrogen) at a 
concentration of 1:400 in blocking solution for 1 hour at room temperature. Cells 
were then washed for 3 x 5 minutes in PBS and mounted with mowiol. 
2.6 Muscle dissections and 
immunohistochemistry 
2.6.1 Muscle preparation 
Lumbrical and flexor digitorum brevis (FDB) muscles from the hind paw and the 
transverse abdominus (TVA) from the anterior abdominal wall were dissected in 
PBS. All muscles were fixed rocking in 4% PFA/PBS at room temperature for 15 
minutes (mid/late symptomatic mice) or 10 minutes (early symptomatic mice). 
Muscles were then rinsed several times in PBS and carefully subdissected to remove 
individual muscles from tendons and the TVA from the abdominal wall. All muscles 
were then processed for immunohistochemistry. 
2.6.2 Immunohistochemistry 
All muscles were permeabilised in 4% Triton-X in 1 x PBS for 1.5 hours (mid/late 
symptomatic) or 0.5 hours (early) and blocked in 4% bovine serum albumin and 2% 
Triton-X in PBS for 0.5 hours. Muscles were then incubated with primary antibodies 
in blocking solution (see table 2.2) for either two nights (mid/late) or one night (early 
symptomatic) rocking at 4ºC. After 4 x 30 minutes washing in PBS, muscles were 
incubated for 10 minutes in α-bungarotoxin solution conjugated to either TRITC or 
Alexa647 (5mg/ml, Biotium Inc.). Muscles were then exposed to secondary 
antibodies for 2.5 hours (swine anti-mouse 488, swine anti-rabbit 488 or swine anti-
rabbit 594, all 1:50 Dako). Muscles were then mounted in Mowiol (Calbiochem) on 
glass slides and coverslips. 
2.6.3 Quantification and statistics 
Where possible at least 90 endplates from each muscle preparation, chosen at 
random, were assessed. For occupancy counts individual motor neuron endplates 
were classified as being fully occupied (neurofilament stain entirely covers the 
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endplate), partially occupied (neurofilament partially occupies the endplate) or 
vacant (no neurofilament present in the endplate). To calculate motor endplate area, 
images of motor endplates were imported into ImageJ and manually outlined. To 
calculate muscle fibre diameter, three diameter measurements from isolated muscle 
fibres were measured using ImageJ and the average taken. For G-ratio calculations 
TEM images were imported into ImageJ and the area of every intact axon and axon 
plus myelin calculated. From this the diameters were measured and g-ratio calculated 
(diameter axon/diameter axon plus myelin).  
2.7 Histology 
2.7.1 Eye histology 
Eyes were dissected from neonates and E17.5 embryos and fixed in Davidson’s 
solution (3ml 95% ethanol, 2ml 10% neutral buffered formalin (500μl formalin and 
4.5ml phosphate buffer), 1ml glacial acetic acid and 3ml dH2O)) rolling overnight at 
4ºC. Whole embryos (E12.5) or embryo heads (E15.5) were fixed in 4% PFA in PBS 
overnight rolling at 4ºC. All samples were dehydrated through an ascending ethanol 
series of 30-50-70% ethanol and stored in 70% ethanol at 4ºC. 
2.7.2 Wax embedding 
Tissue samples in 70% ethanol were wax embedded using the VIP Tissue Processor. 
E12.5 embryos, E15.5 heads and P1.5 eyes were subjected to 30 minute cycles, E17.5 
eyes to 15 minute cycles and adult eyes to 45 minute cycles. In brief, processing 
involved 85% ethanol, 95% ethanol, 2 cycles at 100% ethanol, 2 cycles in xylene and 4 
cycles in molten paraffin wax at 58ºC. Samples were then embedded in paraffin in 
plastic cassettes and allowed to set. Samples were cut using a microtome to 7µm sections 
and mounted on Superfrost glass slides. Slides were then dried at 60ºC overnight prior to 
staining. 
2.7.3 Haematoxylin and eosin staining of paraffin sections 
Slides were dewaxed through 3 x 5 minute changes in xylene and 2 x 5 minute 
changes in 100% ethanol, followed by 2minutes in each of 90%, 70%, 50% and 30% 
ethanol and rinsed in H2O. Slides were then stained in Harris’ haematoxylin for 5 
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minutes, differentiated in acid/alcohol (1M HCl in 70% ethanol) for 5 seconds and 
washed in saturated lithium carbonate solution for 15 seconds. Slides were then 
counterstained in eosin for 3-5 minutes, quickly rinsed and then washed in 100% 
ethanol. Slides were then incubated for 3 x 5 minutes in 100% ethanol followed by 3 
x 5 minutes in xylene and mounted with DPX (Sigma). 
2.7.4 Immunohistochemistry on paraffin sections 
Slides were dewaxed through 3 x 5 minute changes in xylene and 2 x 5 minute 
changes in 100% ethanol, followed by 2 minutes in each of 90%, 70%, 50% and 30% 
ethanol and rinsed in H2O. Meanwhile, sodium citrate buffer for antigen retrieval 
was prepared containing 10mM sodium citrate, pH 6.4 and heated for 10 minutes in a 
microwave oven. Slides were then added to the sodium citrate buffer and heated for a 
further 2 x 10 minutes and allowed to cool to room temperature. Slides were blocked 
in 10% donkey serum (Sigma) in 1x TBST (TBS containing 0.1% triton-X) for 1 
hour at room temperature. Slides were then incubated in primary antibodies diluted 
in blocking buffer (see table 2.2 for antibody concentrations) overnight at 4ºC. Slides 
were then washed for 3 x 5 minutes in 1x TBST in a coplin jar, rocking at room 
temperature. Alexafluor conjugated secondary antibodies (Invitrogen) were added at 
a concentration of 1:500 in 1x TBST, for 1 hour at room temperature in the dark. 
Slides were washed 3 x 5 minutes in 1x TBST and mounted in Vectashield plus 
DAPI (Vector labs). 
2.7.5 LacZ staining using X-gal  
E11.5 embryos were dissected in PBS and fixed in 4% PFA/PBS at 4ºC for 30 
minutes. Samples were then washed in PBS followed by 3 x 20 minute washes in 
detergent wash solution (0.1M phosphate buffer pH 7.3, 2mM MgCl2, 0.1% sodium 
deoxycholate and 0.02% NP40). Samples were then stained with X-Gal staining 
solutions (detergent wash containing 0.085% NaCl, 5mM K4Fe, 5mM K3Fe and 
50mg/mL X-Gal) overnight at 37ºC wrapped in foil. The next morning the staining 
solution was removed and samples were washed 3 x 20 minutes in detergent wash 
solution and post-fixed in 4% PFA/PBS overnight at 4º. Stained embryos were then 
imaged with a macroscope see 2.8.3. 
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2.7.6 Optical projection tomography 
Optical projection tomography (OPT) was performed by Harris Morrison. OPT was 
carried out on PFA fixed, albino, adult eyes which were mounted in 1% LMP 
agarose, dehydrated in methanol and then cleared overnight in BABB (1 part benzyl 
alcohol: 2 parts benzyl benzoate) as per (Sharpe et al., 2002). The eye was then 
imaged using a Bioptonics OPT Scanner 3001 (Bioptonics, Edinburgh, UK) using 
tissue autofluorescence (excitation 480 nm/emission 510nm). The scans were 
reconstructed using Bioptonicsproprietary software and then rendered using Drishti 
software (Ajay Lamaye, ANU, Canberra, Australia). Movies and stills were created 
using the same software. 
2.8 Synaptic vesicle recycling assays 
2.8.1 FM1-43fx staining of synaptic vesicle recycling 
For synaptic vesicle recycling assays lumbrical muscles were dissected in 
oxygenated mammalian Ringer solution (120mM NaCl, 5mM KCl, 2mM CaCl2, 
1mM MgCl2, 0.4mM NaH2PO4, 23.8mM NaHCO3 and 5.6mM D-glucose bubbled 
with 95% O2/5% CO2). Post-synaptic acetylcholine receptors were stained with 
TRITC conjugated α-bungarotoxin (5mg/ml, Biotium, Inc.) for 5 minutes and 
muscles further washed in oxygenated Ringer solution for 5minutes. Synaptic vesicle 
recycling was then stimulated using a high potassium Ringer solution (75mM NaCl, 
50mM KCl, 2mM CaCl2, 1mM MgCl2, 0.4mM NaH2PO4, 23.8mM NaHCO3 and 
5.6mM D-glucose bubbled with 95% O2/5% CO2) and vesicles labelled with the 
fluorescent styryl dye FM1-43fx (Molecular probes, 2.5μg/ml in high potassium 
Ringer) for 15 minutes. Following labelling of synaptic vesicles, mucles were 
washed for a further 15 minutes in oxygenated Ringer solution and fixed in 4% 
PFA/PBS for 5 minutes. Muscles were then further washed in PBS for 10 minutes to 
remove fixative and mounted in mowiol (Calbiochem). 
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2.8.2 Mouse cortical neuron culture and fluorescent imaging 
with pHluorin reporter (protocol provided by Dr Sarah 
Gordon) 
Primary dissociated cortical neuronal cultures were prepared from E17.5 Rab18-/- 
(KO) and wild-type (WT) embryos and plated at a density of 1.0 x107 cells/coverslip 
on poly-D-lysine and laminin-coated coverslips. Cells were maintained in 
Neurobasal media containing B27, 0.5mM L-glutamine and 1% v/v 
penicillin/streptomycin. After 72 hours cells were supplemented with 1µM cytosine 
β-d-arabinofuranoside to inhibit glial proliferation.  
Fluorescent imaging with sypHy was undertaken as reported previously (Gordon et 
al., 2011). Cortical neurons were transfected after 7 DIV with 1µg synaptophysin-
pHluorin (sypHy, gift from L. Lagnado, LMB Cambridge) using lipofectamine 2000 
and imaged after 14-16 DIV. SypHy-transfected cortical cultures were mounted in a 
Warner imaging chamber with embedded parallel platinum wires (RC-21BRFS) and 
visualised at 480 nm (>525 nm emission) using a x40 oil immersion objective on a 
Zeiss Axio Observer D1 epifluorescence microscope. Cultures were subjected to 
continuous perfusion with imaging buffer (in mM: 136 NaCl, 2.5 KCl, 2 CaCl2, 1.3 
MgCl2, 10 glucose, 10 HEPES, pH 7.4) and were stimulated with a train of 300 
action potentials delivered at 10 Hz (100 mA, 1 ms pulse width). Cultures were then 
subjected to alkaline imaging buffer (50 mM NH4Cl substituted for 50 mM NaCl) to 
reveal total sypHy fluorescence (total vesicle pool). Fluorescent images were 
captured at 4 second intervals using a Hamamatsu Orca-ER digital camera 
(Hamamatsu City, Japan) and processed offline using ImageJ 1.43 software (NIH, 
USA). Regions of interest of identical size were placed over nerve terminals and the 
total fluorescence intensity was monitored over time. All statistical analyses were 
performed using Microsoft Excel and GraphPad Prism (La Jolla, CA) software. The 
pHluorin fluorescence change was calculated as FΔ/F0, normalised to either the peak 
stimulus-evoked fluorescence (to calculate endocytic time constant - τ) or to total 
sypHy fluorescence revealed with alkali buffer (to calculate peak evoked sypHy 
response). n refers to the number of independent experiments performed.  
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2.9 Sciatic nerve ligation surgery 
Sugery was performed by Derek Thomson. Mice were anesthetised by inhalation 
with a mixed cocktail of dormitor and vetlar. Once anesthetised a small incision was 
made on the right leg just below the sciatic notch and the sciatic nerve exposed. The 
nerve was then tied off with a single tight surgical suture and the incision closed with 
a surgical suture. Mice were recovered from anesthesia with antisedan and observed 
for full recovery before returning to standard cages and conditions. 
2.10 Microscopy 
2.10.1 Fluorescence microscopy 
Fluoresence microscopy was performed using a Zeiss Axioplan 2 fluorescence 
microscope with Plan-neofluar objectives (Carl Zeiss), with filter sets for DAPI, 
FITC and Texas Red. Images were captured with a Coolsnap HQ CCD camera 
(Photometrics Ltd.) using scripts written for IPLab/iVision scanalytics software. 
2.10.2 Brightfield microscopy 
Brightfield microscopy was performed using a Zeiss Axioplan II fluorescence 
microscope with Plan-neofluar objectives (Carl Zeiss). Images were captured with a 
QImaging camera (IndigoScientific) using scripts written for IPLab/iVision 
scanalytics software. 
2.10.3 Macroscopic imaging 
Macroscopic imaging was performed using a Nikon AZ100 macroscope. Images 
were captured with a Qimaging Micropublished 5 cooled camera using scripts 
written for IPLab/iVision scanalytics software. 
2.10.4 Confocal microscopy on fixed samples 
Confocal microscopy was performed using a Nikon A1R confocal set up, composed 
of a Nikon Eclipse TiE microscope with resonant scanner and spectral detector. The 
Nikon A1R setup utilises four lasers (two diode, multiline Argon and DPSS solid 
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state laser) for excitation at 405, 457, 488, 514, 561 and 638nm and images were 
captured using NIS elements software (Nikon). 
2.10.5 Confocal microscopy-live cell imaging 
Confocal microscopy on live cells was perfomed as above using the perfect focus 
system. Cell viability was maintained using a large incubation chamber regulating 
temperature at 37°C and 5% CO2.  
2.10.6 Transmission electron microscopy 
Sciatic nerves were dissected from mid/late symptomatic Rab18-/- mice and 
littermate controls in PBS. Nerves were then pinned on dental wax and immersion 
fixed in 4% PFA/2.5% glutaraldehyde in PBS for two nights at 4°C. Following 
fixation, nerves were washed in PBS and immersed in 1% osmium tetroxide (sigma) 
overnight. Nerves were then dehydrated through 50%-70%-90%-100% ethanol and 
propylene oxide and embedded in Durcupan resin overnight. Ultrathin sections 
(approximately 60nm) were cut and collected on formvar-coated grids (Agar 
Scientific, UK). Grids were then stained with uranyl acetate and lead citrate and 
microscopy performed with a Philips CM12 transmission electron microscope 
equipped with Gatan camera. 
2.11 Statistical analysis 
All data was collected and analysed using ImageJ and GraphPad Prism 5 software 
where mean ± SEM, N= number of mice and n= number of muscles quantified. 





Chapter 3 Generation and phenotypic 
characterisation of a novel Rab18-/- mouse 
3.1 Introduction  
Causative loss-of-function mutations for Warburg Micro syndrome have previously 
been identified in RAB3GAP1 (Aligianis et al., 2005), RAB3GAP2 (Borck et al., 
2010), RAB18 (Bem et al., 2011) and TBC1D20 (Liegel et al., 2013, paper in press). 
However mice lacking Rab3gap1 do not recapitulate the disease phenotype (Sakane 
et al., 2006) and studies characterising the blind sterile mouse despite reporting 
ocular and endocrine abnormalities have not described any neurological deterioration 
(Liegel et al., 2013, paper in press). A mammalian model recapitulating both the 
ocular and neurological aspects of Warburg Micro syndrome was therefore critical to 
provide insights into disease pathogenesis. Previous studies using morpholino 
knockdown of rab18a and rab18b in zebrafish suggested a role for RAB18 in normal 
eye and brain development (Bem et al., 2011). To investigate the role of RAB18 in 
disease, Rab18 genetrap mice were generated by MRC Harwell as part of the 
EUMODIC (The European Mouse Disease Clinic) screen; a large consortium of 18 
research clinics undertaking primary mouse phenotyping assessment 
(www.eumodic.org). Rab18 genetrap mice were created using the FlipRosaβGeo 
cassette inserted into 129P2/OlaHsd (E14TG2a) embryonic stem (ES) cells (Figure 
3.1). Details of the genetrap and targeting can be found at 
http://www.informatics.jax.org/javawi2/servlet/WIFetch?page=alleleDetail&key=57
4626. Positive ES cell clones were injected into blastocysts and transferred to 
pseudopregnant foster mothers to generate chimeras. Mice were bred to 129P2/Ola to 
retain the ES cell background, in keeping with the EUMODIC programme for 
phenotypic assessment. 
The FlipRosaβGeo cassette is composed of a splice acceptor site (SA), a 
promoterless reporter gene and a premature polyadenylation and termination 
sequence (pA). The gene trap is inserted into an intron of a protein coding gene. The 
transcript is expressed from the endogenous promoter in frame to the β-geo reporter 
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gene and prematurely terminated at the polyadenylation sequence, resulting in a 
truncated version of the protein which is likely to be non-functional. The cassette is 
flanked by frt and F3 sites, targets for FLPe recombinase and loxP and lox5171 sites, 
targets for Cre recombinase, enabling directional recombination under the action of 
FLPe and Cre to generate a site-specific or temporal specific conditional allele 
(Schnutgen et al., 2005). 
 
Figure 3.1- The FlipRosaβGeo cassette 
Schematic of the FlipRosaβGeo cassette adapted from Schnutgen 2005. Transcripts 
are transcribed from the endogenous promoter to the splice acceptor site in the 
genetrap cassette and terminated prematurely at the polyadenylation sequence. When 
crossed with FLPe the cassette is inverted onto the antisense, non-coding strand at 
either FRT or F3 sites and excises paired heterotypic repeats, locking the cassette in 
its inverse orientation. When crossed with Cre the cassette is reinverted onto the 
sense, coding strand at either loxP or lox5171 sites, repairing splicing and 
reintroducing the mutation. LTR, long terminal repeat; frt and F3 target for FLPe 
recombinase, loxP and lox511 targets for Cre recombinase; SA, splice acceptor; 
βgeo, β-galactosidase/neomycin phosphotransferase fusion gene; pA, 




The Rab18 genetrap mouse was created using the Rab18Gt(EUCE0233a03)Hmgu allele 
(hereafter referred to as Rab18-), inserting the genetrap cassette into intron 2 of 
Rab18. This allele was chosen as the homozygous L24Q (c.71T>A, p.Leu24Gln) 
RAB18 patient mutation in exon 2 has previously been shown to be pathogenic 
resulting in a functionally null protein that is incapable of binding guanine (Bem et 
al., 2011). Additionally, RAB protein structure is highly conserved. All RAB 
proteins have a C-terminal hypervariable domain with one or two cysteine residues 
that are prenylated by RAB GGTase (Rab geranylgeranyltransferase) (Pereira-Leal et 
al., 2001). This prenylation is essential for membrane localisation (Kinsella and 
Maltese, 1992) and as a result a small unprenylated polypeptide without this 
geranygeranylation target site is unlikely to be functional.  
 
Figure 3.2- Generation of Rab18-/- mice 
Rab18-/- mice, allele Rab18Gt(EUCE0233a03)Hmgu were generated from ES cells with 
insertion of the FlipRosaβGeo cassette into intron 2 of Rab18. Black boxes represent 
Rab18 exons. 
 
In this chapter I describe the genotyping and phenotypic characterisation of a novel 
Rab18-/- mouse model that recapitulates many of the characteristic features of 
Warburg Micro syndrome including congenital cataracts, atonic pupils and 






129P2/OlaHsd Rab18+/- heterozygotes were obtained from MRC Harwell and 
intercrossed with littermates to generate a pure 129P2/OlaHsd strain. However, as 
129P2/Ola females are poor breeders with small litter sizes, 129P2/OlaHsd 
heterozygotes were also backcrossed onto C57BL/6J. No phenotypic differences 
were observed between the two strains. The majority of experiments described in this 
thesis were undertaken on Rab18-/- mice backcrossed to C57BL/6J for one or two 
generations however, gross phenotypic analysis of Rab18-/- backcrossed for nine 
generations revealed no overt differences.  
3.2.1 Genotyping of Rab18-/- mice 
PCR primers were designed to distinguish between wild type, heterozygote and 
Rab18-/- mice (Figure 3.3). Primers F1 and R1 were designed in intron 2 upstream 
and downstream of the cassette insertion site respectively. Primer R2 was designed 
within the loxP site of the genetrap cassette. DNA was extracted from tail clip 
(embryos) or ear clip (weaned pups) from each mouse and amplified by PCR. 
Multiplex PCR often gave variable results with the wild type allele dominating over 
the mutant allele, and heterozygote mice often mistyped as wild type. As a result two 
PCRs were routinely set up for each mouse. Primer F1 and primer R1 (Figure 3.3A) 
produced a band of 467 bp for the wild type allele and primer F1 and primer R2 
(Figure 3.3C) produced a band of 825 bp for the mutant allele. Upon insertion of the 
genetrap cassette the region between primers F1 and R1 was too large to amplify by 
the PCR protocol used and no band appeared in the wild type reaction. Heterozygote 
Rab18+/- mice showed bands in both PCR reactions. All genotyping results were 
confirmed by phenotyping blind to genotyping (see below). Figure 3.3D shows an 




Figure 3.3 PCR genotyping of Rab18-/- mice 
Rab18-/- mice are genotyped by PCR and gel electrophoresis for presence or absence 
of the genetrap cassette. (A-C) Schematic of the wild type (WT), heterozygote (HET) 
and Rab18-/- alleles, arrows F1, R1 and R2 represent primer locations used for 
genotyping. (D) PCR genotyping of WT, HET and Rab18-/- mice. Primers F1 
upstream and primer R1 downstream of the cassette shows a band of 467 bp for the 
WT allele. Primer F1 and Primer R2 in the loxP site of the cassette shows a band of 
825 bp for the mutant allele. Heterozygote mice show both bands. 
3.2.2 Preliminary data suggests Rab18 is ubiquitously 
expressed at E11.5 
The FlipRosaβGeo genetrap cassette contains a βGeo reporter gene. As the cassette 
is transcribed from the endogenous Rab18 promoter this can be used to provide a 
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visual readout of Rab18 gene expression. Analysis of β-galactosidase expression by 
X-gal staining in embryonic day 11.5 (E11.5) embryos showed Rab18 to be 
ubiquitously expressed in developing embryos (Figure 3.4).  
 
Figure 3.4 Rab18 appears ubiquitously expressed in E11.5 embryos 
The FlipRosaβGeo cassette inserts a βGeo reporter gene under the control of the 
endogenous Rab18 promoter, marking Rab18 gene expression. In E11.5 embryos 
Rab18 is ubiquitously expressed in heterozygote (B, HET) and Rab18-/- (C) embryos 
compared to wild type (A, WT).  
 
3.2.3 Rab18Gt(EUCE0233a03)Hmgu allele represents the null 
phenotype of RAB18 
The genetrap cassette is designed to initiate transcription from the endogenous 
promoter and terminate it prematurely at the polyadenylation sequence resulting in a 
severely truncated protein which should be non-functional. To examine the 
consequence of the genetrap insertion on Rab18 expression, RNA was isolated from 
E11.5 embryos and from which cDNA was synthesised for RT-PCR and qRT-PCR 
analysis. Reverse transcriptase PCR (RT-PCR) using primers flanking the genetrap 
insertion site (exons 1-5, red arrows in Figure 3.5A) showed very weak Rab18 
expression in Rab18-/- embryos (Figure 3.5B upper panel). Reduced expression levels 
were also apparent in the heterozygote compared to wild type control, however only 
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one sample was examined in the analysis. Analysis using primers 3’ to the cassette 
insertion site (exons 3-7, blue arrows in Figure 3.5A) detected Rab18 expression in 
all genotypes examined, albeit at a slightly lower intensity in Rab18-/- mice. This 
suggested the possibility of an alternative transcription start site, however, 
quantitative RT-PCR (qRT-PCR) using primers amplifying exons 4-5 showed no 
residual Rab18 mRNA expression compared to the control gene TBP (TATA binding 
protein) in Rab18-/- mouse embryonic fibroblasts. Additionally, Western blot analysis 
on wild type, heterozygote and Rab18-/- sciatic nerve using an antibody raised against 
the C-terminal of RAB18 showed a doublet band of the correct size (23 kDa) in 
control samples which was absent in Rab18-/-littermates. I can therefore conclude 
that the Rab18-/-mice represent the null phenotype of Rab18. 
 
Figure 3.5 Rab18-/- mice represent the null phenotype of RAB18 
Rab18-/- mice were generated by insertion of the FlipRosaβGeo genetrap cassette into 
intron 2 of Rab18. (A) Red and blue arrows represent primers used in RT-PCR. (B) 
RT-PCR analysis for Rab18 mRNA expression in E11.5 wild type (WT), 
heterozygote (HET) and Rab18-/- embryos. Primers flanking the genetrap cassette 
(exons 1-5, red arrows in A) showing residual mRNA expression in Rab18-/- 
embryos. Primers C-terminal to the cassette insertion site (exons 3-7, blue arrows in 
A) show bands in all genotypes examined albeit at a slightly lower intensity in 
Rab18-/- suggesting an alternative transcription start site, β-actin was used as a 
loading control. (C) quantitative RT-PCR analysis (graph shows mean and standard 
deviation for 3 technical replicates) shows no residual transcript in Rab18-/- mouse 
embryonic fibroblasts normalised to control gene TBP. (D) Western blot analysis in 
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Rab18-/- sciatic nerves with an antibody targeting the C-terminal hypervariable 
domain of RAB18, shows no RAB18 protein expression, β3 tubulin was used as a 
loading control. Numbers to the left of the blots represent molecular weight in kDa. 
3.2.4 Lack of gross organ pathology in Rab18-/- mice 
To determine the consequence of loss of Rab18-/- on gross organ development and 
viability a comprehensive necropsy analysis was undertaken by pathologist Dr David 
Brownstein on two 15 week old mid/late symptomatic Rab18-/- mice and 
heterozygote and wild type littermate controls. Mice were examined for 
histopathology including but not limited to the following (Appendix 2); internal 
organs (for example heart, liver and lungs), head, long bones, thigh muscle and 
spinal cord. No significant differences were found between any of the three 
genotypes examined (Figure 3.9, representative pictures). This suggests that loss of 
Rab18, despite being ubiquitously expressed, does not affect gross organ 




Figure 3.6 Loss of Rab18 does not affect gross organ histology 
15 week old mid/late symptomatic Rab18-/- mice and littermate controls (N=2) 
underwent detailed necropsy analysis performed by David Brownstein. (A-H) 
Representative micrographs of cerebellum (A-B), spinal cord (C-D), heart (E-F) and 
liver (G-H) from control and Rab18-/- littermates stained with H&E showing no gross 
organ pathology. Panels A-D and G-H scale bar represents 50μm, E-F scale bar 
represents 100μm.  
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3.2.5 General phenotyping of Rab18-/- mice 
Warburg Micro syndrome patients present with abnormalities affecting the ocular, 
neurological and endocrine systems (Aligianis et al., 2005, Borck et al., 2010, Bem et 
al., 2011, Warburg et al., 1993, Handley et al., 2013). I therefore performed gross 
phenotypic analysis of Rab18-/- mice taking into consideration the Warburg Micro 
syndrome patient phenotype. Rab18-/- mice were viable and fertile. At eye opening 
(approximately postnatal day 12, P12) Rab18-/- mice presented with dense nuclear 
congenital cataracts (Figure 3.6A). Examination of the pupillary response with the 
mydriatic agent tropicamide was undertaken by Lisa McKie and identified 
permanently constricted pupils that do not respond to dark or mydriatic agents (data 
not shown). Rab18-/- mice therefore recapitulated characteristic Warburg Micro 
syndrome ocular phenotypes with complete penetrance. This allowed me to 
distinguish Rab18-/- mice from wild type and heterozygote littermates blind to 
genotyping.  
From three weeks of age, when elevated by the tail, Rab18-/- mice displayed 
abnormal hind limb clasping compared to littermate controls (Figure 3.6B, left wild 
type, right Rab18-/-). This abnormal clasping reflex is observed in many mouse 
models for neurodegenerative disease and is seen as an indicator of neuronal 
dysfunction (Lalonde and Strazielle, 2011). As the mice age, the phenotype 
progressively deteriorated with variation in age of onset; the hind limb clasping 
became more prominent, the gait splayed and a noticeable decline in movement was 
observed. Due to home office regulations all mice were culled at this stage (Figure. 
3.6C) and are referred to as mid/late symptomatic throughout the remainder of this 
thesis. Taken together, Rab18-/- mice recapitulated many of the characteristic ocular 
and neurological features of Warburg Micro syndrome. Heterozygote mice were 
indistinguishable from wild type littermates and unless distinguished were used 




Figure 3.7 Rab18-/- mice show congenital nuclear cataracts, 
progressive hindlimb spasticity and reduced survival, recapitulating 
the Warburg Micro syndrome disease phenotype  
Gross phenotypic analysis of Rab18-/- mice. At eye opening (approximately P12) 
Rab18-/- mice are identifiable from littermates by the presence of congenital nuclear 
cataracts. (A) Slit lamp picture of cataracts in Rab18-/- adult lens. From three weeks 
of age Rab18-/- mice show abnormal hind limb clasping when elevated by the tail (B, 
69 
 
Rab18-/-) compared to littermate controls (B, WT) who spread their hind limbs. The 
hind limb phenotype progresses to splayed/weak limbs and the mice are culled at 
mid/late symptomatic time points. (C) Kaplan-Meirer Survival curve of all mice 
irrespective of background, log-rank (Mantel-Cox) test, Chi-squared 412.2, 2df, 
p<0.0001. (D) Kaplan-Meier Survival curve of all mice first generation backcross to 
C57BL/6J, log-rank (Mantel-Cox) test, Chi-squared 254.5, 2df, p<0.0001. 
Rab18-/- mice were viable and fertile, however both heterozygote and Rab18-/- mice 
were found at non-Mendelian ratios at weaning (Table 3.1, Chi-squared p<0.0001). 
Rab18-/- mice have been backcrossed to C57BL/6J for nine generations to generate a 
more congenic line, and studies are currently underway to determine whether this 
reduction in numbers is still observed. While carrying out the backcross, I also 
analysed the numbers of wild type and heterozygote mice born from a male 
heterozygote x female C57BL/6J cross and identified a reduction in the number of 
heterozygotes born (Table 3.1, Chi-squared p<0.0001). However, no significant 
differences were observed when male C57BL/6J mice were crossed to female 
heterozygotes. It must be noted that the number of litters examined when a female 
heterozygote was used in the cross was far fewer than male (11 litters compared to 
44). This reduction in heterozygotes could potentially be attributed to a sperm 
abnormality, with wild type sperm dominating over mutant and hence more wild type 
mice born. However, it must be noted that loss of a functional allele does not 
necessarily mean that the protein would be absent from the sperm, indeed HET bs 
mice can still pass on the null Tbc1d20 allele while the homozygotes are sterile 
(Leigel et al., 2013, paper in press). I therefore performed histological analysis of 
wax-embedded testis from control and Rab18-/-adult littermates and identified normal 
testis morphology with sperm heads and tails clearly visible (Figure 3.7). To further 
examine the fertility of Rab18-/- mice, crosses were set up between female Rab18-/- 
mice and heterozygote males and male Rab18-/- with heterozygote females. Only one 
attempt was taken to breed with a female Rab18-/- as she died very shortly after 
giving birth. Attempts at breeding female heterozygotes to Rab18-/- males proved 
successful. Together our results suggest that Rab18-/- mice are fertile. 
Despite the reduction in number of Rab18-/- and heterozygote mice observed at 
weaning, analysis of different embryonic stages (E11.5-E17.5, Table 3.1) showed no 
significant difference in numbers. This suggested that heterozygote and Rab18-/- 
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mice may die at or immediately following birth. However, no noticeable reduction in 
litter size was observed at weaning (average of 7.7 pups for HET x HET crosses 
compared to an average of 6.6 for male HET x female C57BL/6J and 7.125 for male 
C57BL6/J and female HET). It must also be noted that the number of embryonic 
litters examined was far smaller than those weaned. 
Table 3.1 Rab18-/- mice are found at non-Mendelian ratios at weaning  
Genotype WT HET Rab18-/- No. litters 
Chi-
squared 
All HET x HET litters weaned 336 388 164 118 p<0.0001 
Female HET x male C57BL/6J 188 104   44 p<0.0001 
Male HET x female C57BL/6J 38 34   11 Ns 
E11.5 HET x HET 6 16 11 4 Ns 
E12.5 HET x HET 12 20 10 5 Ns 
E13.5 HET x HET 6 13 9 3 Ns 
E15.5 HET x HET 18 38 13 9 Ns 
E16.5 HET x HET 1 7 3 1 Ns 






Figure 3.8 Loss of Rab18 does not result in gross testis histopathology  
Haematoxylin and eosin histological analysis of wax embedded testes from 17 week 
old control (A and C) and Rab18-/- (B and D) littermates showing no gross testes 
pathology with sperm heads and tails clearly visible. N=1, A-B scale bar represents 
100µm, C-D scale bar represents 50µm. 
 
Initial analysis of Rab18-/- mice crossed for one generation to C57BL/6J showed no 
obvious noticeable differences in size or weight. However, after backcrossing for 9 
generations, preliminary weight measurements on a defined background have shown 
a reduction in weight of Rab18-/- mice at weaning (Table 3.2 and Figure 3.8, N=2). 
However, one mutant went on to gain weight comparable to littermate controls at 6 
weeks of age whereas the other remained runted. Further studies are underway to 




Table 3.2 9th generation to C57BL/6J Rab18-/- mice weigh less than 
littermate controls at weaning  
  3wk 4wk 5wk 6wk 
WT 6.9g 10.9g 16g 19.0g 
WT 6.1g 10.6g 14.8g 17.0g 
HET 7.2g 10.8g 13.3g 15.0g 
Rab18-/- 5.1g 4.5g 5.6g 7.0g 
Rab18-/- 4.9g 6.4g 10.0g 14.0g 
 
Rab18-/- mice crossed for nine generations to C57BL/6J were weighed every week 
from weaning (3 weeks of age). Preliminary data shows Rab18-/- mice (N=2) to be 





In this chapter I describe the genotyping and phenotypic characterisation of a novel 
Rab18-/- mouse model. I have shown that Rab18 is ubiquitously expressed in the 
developing embryo. To examine the role of RAB18 in disease pathogenesis, Rab18-/- 
genetrap mice were generated using the FlipRosaβGeo cassette and are null for 
Rab18. Rab18-/- mice were viable and fertile. I have shown that loss of Rab18 does 
not cause gross developmental defects but specific abnormalities in the lens and hind 
limbs, recapitulating many of the characteristic ocular and neurological features of 
Warburg Micro syndrome. 
3.3.1 RAB18 appears ubiquitously expressed in the 
developing embryo and Rab18-/- mice represent the null 
phenotype of Rab18 
Rab18-/- mice were created using the FlipRosaβGeo cassette inserted into intron 2 of 
Rab18. Analysis of β-galactosidase expression by X-gal staining showed that Rab18 
is ubiquitously expressed in E11.5 developing embryos (Figure 3.4). However, this is 
preliminary analysis; in detailed expression analysis would require 
immunohistochemistry and RNA in situ hybridisation experiments to be performed 
at various ages of embryogenesis and in different organ types of the adult. RAB18 
ubiquitous expression has previously been demonstrated in adult rat and mouse 
tissues and 24hpf zebrafish morphants (Lutcke et al., 1994, Yu et al., 1993, Bem et 
al., 2011).  However, all three studies reported various levels of enrichment, with the 
greatest expression found in the brain. It would therefore be of interest to examine 
Rab18 expression in more detail in neuronal and non-neuronal tissues by in situ 
hybridisation to determine whether expression is enriched in organs showing 
pathological phenotypes. Additionally, how loss of a ubiquitous protein results in 
abnormalities in a specific subset of organs/tissues remains to be determined. 
However, this is a common attribute of many additional neurodegenerative diseases 
including spinal muscular atrophy (mutations in SMN) specifically causing neuronal 
phenotypes despite ubiquitous expression (Monani, 2005). The neuronal and ocular 
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phenotype observed in our Rab18-/- model could be attributed to loss of RAB18 
having a greater functional consequence in neuronal and ocular systems than other 
tissues.  
The genetrap cassette was predicted to terminate expression of Rab18 in intron 2 and 
result in a truncated and non-functional version of the protein. I have demonstrated 
that Rab18-/- mice represent the null phenotype of Rab18. RT-PCR analysis using 
primers 3’ of the gene trap cassette insertion site (Figure 3.5A) did suggest the 
possibility of a potential alternative transcription start site. However, through qRT-
PCR and Western blot analysis targeting C-terminal to the cassette, I have shown 
that the genetrap results in no residual Rab18 expression. The Rab18-/- genetrap 
mouse presented in this study shows phenotypes that occur upon the earliest possible 
loss of Rab18. The FlipRosaβGeo cassette provides the added benefit of being an 
inducible system and enabling the generation of a site- or temporal-specific 
conditional allele (Schnutgen et al., 2005). Experiments are currently ongoing where 
Rab18-/- mice have initially been crossed to FLPe to repair the mutation and then to 
tamoxifen inducible Cre-ER to generate temporal specific knockouts and examine 
Rab18 loss at different ages and/or stages of development and delineate the role of 
Rab18 in degeneration compared to development. This will be of particular interest 
in the lens to question whether loss of Rab18 in adulthood causes age-related 
cataracts or whether the underlying abnormality is in fact developmental in origin. 
 
3.3.2 Rab18-/- mice recapitulate characteristic ocular and 
neurological phenotypes of Warburg Micro syndrome 
Rab18-/- mice were viable and fertile. At eye opening Rab18-/- mice presented with 
dense nuclear congenital cataracts and atonic pupils. From three weeks of age they 
showed abnormal hind limb clasping upon tail suspension which progressed to a 
splayed gait and a noticeable decline in movement. Rab18-/- mice therefore 
recapitulated characteristic ocular and neurological phenotypes of Warburg Micro 
syndrome with complete penetrance. However, more detailed analyses in the future 
may show additional features as either recapitulated or absent, for example, 
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micropthalmia and microcornea are characteristic presenting features of Warburg 
Micro syndrome but as of yet have not been observed in our mouse model. Further 
analyses and eye measurements would need to be undertaken to examine this in 
greater detail. Warburg Micro syndrome patients additionally show many 
neurological abnormalities including progressive spastic paraplegia and 
polymicrogyria. Although no gross brain pathology was observed in the necropsy 
analysis presented here, it remains possible that neuronal migration abnormalities 
may still be apparent. However, as mice have very few gyri or sulci, polymicrogyria 
is much more difficult to identify than in humans and studies looking for subtle 
abnormalities in neuronal migration would have to be undertaken.  
Warburg Micro syndrome patients additionally show postnatal growth retardation. 
The preliminary observation that after backcrossing for 9 generations to C57BL/6J 
Rab18-/- mice were smaller than littermate controls at weaning suggested that this 
feature of the disease may also be recapitulated. However, further analyses will need 
to be undertaken to confirm this. Additionally, it would be of interest to examine the 
weight of Rab18-/- embryos and neonates to determine whether this observed 
reduction is post-natal or pre-natal in origin. 
As Rab18-/- mice were generated by MRC Harwell, primary phenotypic assessment 
is currently being undertaken as part of the EUMODIC programme, examining 
dysmorphology, weight, clinical chemistry and behaviour. When available, data will 
be published at www.europhenome.org. 
3.3.3 Other mammalian models for Warburg Micro syndrome 
Despite the fact that loss-of-function mutations in any of the four causative genes 
causes a clinically indistinguishable patient phenotype (Aligianis et al., 2005, Bem et 
al., 2011, Borck et al., 2010)(Leigel et al., 2013, in press), other mammalian models 
for Warburg Micro syndrome have failed to report any neurological phenotypes 
(Sakane et al., 2006)(Leigel et al., 2013, in press). RAB3GAP1 is encoded by a major 
transcript of 24 exons and a minor transcript that lacks the first 50 aa (exons 1-3) and 
has a small additional exon of 3 aa. The only reported causative mutation in exon 1 
of RAB3GAP1 to date is a C.9delC, p.Asp4Thrffs*51 frameshift mutation in one 
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Martsolf family. RT-PCR analysis performed by Handley et al. (Handley et al., 
2013) reported a reduction in expression of the full-length transcript and an 
upregulation of the shorter transcript in patient cDNA. This suggested that the 
alternative transcript may partially fulfil the function of full length RAB3GAP1 and 
ameliorate the more severe Warburg Micro syndrome phenotype observed when the 
full length transcript is lost. Rab3gap1 deficient mice targeting exons 1 and 2 and 
flies targeting exon 1 have been generated (Sakane et al., 2006, Muller et al., 2011). 
Both models displayed subtle alterations in synaptic plasticity but failed to 
recapitulate any of the characteristic ocular or neurological phenotypes of the human 
disease. To date only one protein-coding transcript has been identified in the mouse 
(Ensembl GRCm38), however, a previous fly assembly (Ensembl BDGP5.4) has 
reported an alternative shorter transcript (rab3-GAP-RB). Additionally, a recent 
paper analysing RAB3GAP1 levels in rat epidermal keratinocytes identified a short 
80kDa isoform and an alternative transcription start site at the start of exon 3 
(Youssef et al., 2013). These models may therefore represent incomplete disruption 
of the gene.  
Causative mutations for Warburg Micro syndrome have recently been identified in 
TBC1D20 and the blind sterile (bs) mouse model (Leigel et al., 2013, in press). bs 
mice presented with lenticular cataracts and male sterility with abnormalities in the 
sperm head (Sotomayor and Handel, 1986, Varnum, 1983) however, gross 
phenotypic analysis did not identify any hind limb clasping and future work would 
need to be undertaken to examine whether any neurological phenotypes are 
recapitulated. Additionally, the Tbc1d20 mutation in bs mice is an in-frame 
p.Arg232_Val235del deletion that results in a dramatic reduction in GAP activity but 
not complete loss. Furthermore, protein stability in the mouse mutant was not 
assessed. 
As Rab18-/- recapitulate many of the characteristic ocular and neurological 
phenotypes of Warburg Micro syndrome, we believe the phenotype to be centralised 
around loss of Rab18. Studies are currently being undertaken in the laboratory to 




In summary, I have described a novel Rab18-/- mouse model that presents with 
congenital cataracts, atonic pupils and progressive hind limb weakness. Chapters 5 
and 6 will further examine the observed ocular and neurological phenotypes. 
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Chapter 4 RAB18 localisation 
4.1 Introduction  
RAB18’s role in trafficking is still emerging and its cellular effectors are yet to be 
identified. RAB18 is ubiquitously expressed but found at varying intensities in 
different cell types and tissues (Figure 3.4 and (Lutcke et al., 1994)). Over the past 
20 years several conflicting publications examining RAB18’s cellular localisation 
and function in different cell types have been reported. Initial studies localised 
RAB18 to mouse kidney tubule and intestinal epithelial cells and proposed a role in 
endocytosis (Lutcke et al., 1994). Additional studies have localised RAB18 to lipid 
droplets in adipocytes, fibroblasts and epithelial cells (Vero, 3T3-L1 fibroblasts and 
differentiated adipocytes and HepG2 cells) and reported a role in both lipolysis and 
lipogenesis (Martin et al., 2005, Ozeki et al., 2005, Pulido et al., 2011). In vero cells, 
RAB18 has also been shown to localise to the endoplasmic reticulum and in variable 
degrees to the Golgi apparatus (Martin et al., 2005, Dejgaard et al., 2008). RAB18 
has also been reported to have a role in Golgi to ER trafficking through the COPI-
independent pathway (Dejgaard et al., 2008), however systematic screens of multiple 
RAB proteins have failed to identify RAB18 in this pathway (Fuchs et al., 2007, 
Haas et al., 2007). Studies in neuroendocrine cells and pituitary melanotropes have 
also identified an interaction of RAB18 with secretory granules where it seemingly 
functions to inhibit their exocytosis (Vazquez-Martinez et al., 2007).  
As part of my detailed characterisation of the Rab18-/- genetrap mouse I examined the 
localisation of RAB18 in mouse embryonic fibroblasts (MEFs) and primary 
hippocampal neurons. I set out to determine whether RAB18 localisation may be 
relevant to a cellular phenotype that is common to all cells and results in pathology. 
Or alternatively, does RAB18 serve to distinguish a cell-specific/specialised 




Many commercially available and custom-made RAB18 antibodies have been 
generated targeting the C-terminus. Despite the high structural conservation amongst 
the RAB protein family, the C-terminus is hyper-variable and as such an ideal target 
for the design of antibodies that should in theory not cross react with other RABs. 
Immunofluorescence experiments testing RAB18 antibody specificity have 
previously been undertaken in our laboratory (including many of the antibodies used 
in published studies) on wild type and Rab18-/- MEFs. However, in our hands no 
differences in staining intensity or pattern were observed between the two genotypes 
(Mark Handley, personal communication). Consequently, I have examined the 
localisation of overexpressed RAB18 using GFP or mCherry tagged constructs. GFP 
tagged proteins are routinely used in the study of RAB protein localisation (Dejgaard 
et al., 2008, Handley et al., 2007) and have previously been reported to show 
comparable localisation of exogenous GFP tagged and endogenous proteins as 
demonstrated directly in the case for RAB18 by Ozeki et al., (Ozeki et al., 2005). 
RAB proteins are always tagged with fluorescent proteins at the N-terminus. N-
terminal modification should not disrupt RAB protein function (Tolmachova et al., 
2004), whereas the C-terminal hypervariable domain contains the target site for 
geranylgeranylation and hence is essential for membrane insertion and localisation 
(Pereira-Leal and Seabra, 2001, Kinsella and Maltese, 1992). 
4.2.1 GFP-RAB18 localisation and dynamics in control and 
Rab18-/- mouse embryonic fibroblasts 
To study the cellular phenotypes of control and Rab18-/- mice, MEFs were isolated 
from E11.5 embryos and transfected with GFP or mCherry tagged RAB18 
constructs. GFP and mCherry tagged RAB18 constructs showed the same staining 
pattern and as a result were used interchangeably. All transfected MEFs for co-
localisation experiments were imaged live 24 hours post-transfection in order to 
exclude the potential for artefacts following PFA fixation and cell permeabilisation.  
Wild type MEFs transfected with mCherry-RAB18 showed a reticular pattern of 
labelling, reminiscent of the ER (Figure 4.1A). This is consistent with previous 
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reports in Vero, COS7 and NRK cells (Martin et al., 2005, Dejgaard et al., 2008). 
Co-transfection experiments were therefore undertaken with mCherry-RAB18 and 
GFP-TBC1D20-RA to confirm this localisation. TBC1D20 is a reported RAB1 and 
RAB2 GAP that has a well characterised localisation to the ER (Haas et al., 2007). 
The RA (p.R150A) mutation is catalytically inactive, thus overexpression should 
have limited consequences for localisation but can be used as a cellular marker for 
the ER. Immunofluorescence experiments on live cells identified co-localisation of 
RAB18 with TBC1D20, suggesting RAB18 localises to the ER in MEFs (Figure 
4.1A-C). To examine for any abnormalities in ER morphology upon loss of RAB18, 
MEFs derived from control and Rab18-/- littermates were transfected with GFP-
TBC1D20-RA and again imaged live. No obvious discernible differences were noted 
between the two genotypes suggesting RAB18 localised to the ER, but upon loss of 




Figure 4.1 mCherry-RAB18 localises to the ER protein in mouse 
embryonic fibroblasts  
(A-C) Wild type mouse embryonic fibroblasts co-transfected with mCherry-RAB18 
(red) and the catalytically inactive ER protein, GFP-TBC1D20-RA (green) showing 
localisation of RAB18 to the endoplasmic reticulum. Merged image (C) is a 
composite of mCherry-RAB18 (A) and GFP-TBC1D20-RA (B). (D-E) Control (D) 
and Rab18-/- (E) mouse embryonic fibroblasts transfected with the ER protein GFP-
TBC1D20-RA (green) and the nuclear stain Hoescht (blue) showing no gross 




When wild type MEFs were transfected with mCherry-RAB18 to examine ER 
morphology, an enrichment of RAB18 in the perinuclear region was also observed 
(Figure 4.1A). This is consistent with localisation to the Golgi apparatus. RAB18 
localisation primarily to the cis-Golgi has previously been described in COS7, Vero 
and NRK cell lines (Dejgaard et al., 2008). Multiple attempts to clone cis-Golgi 
markers GRASP65 or GM130 into GFP or mCherry tagged vectors were 
unsuccessful, so the trans-Golgi was targeted for localisation experiments. To 
confirm the co-localisation of RAB18 to the Golgi, MEFs from wild type embryos 
were co-transfected with GFP-RAB18 and CFP-GalT (Figure 4.2A-C). GalT 
(trans/TGN enzyme β1,4-galactosyltransferase) is mainly located in the trans-
cisternae and TGN (trans Golgi network) and was used as a marker for the trans-
Golgi (Storrie et al., 1998). MEFs co-transfected with GFP-RAB18 and CFP-GalT 
confirmed localisation of RAB18 to the Golgi apparatus (Figure 4.2C). The Dejgaard 
study additionally noted that upon overexpression of GFP-RAB18 the Golgi 
apparatus fragmented and appeared dispersed in different cell lines (Dejgaard et al., 
2008). I did not observe any obvious fragmentation of the Golgi upon overexpression 
of GFP-RAB18 in MEF lines. To examine for any abnormalities in Golgi 
morphology upon loss of RAB18, PFA fixed wild type (Figure 4.2D) and Rab18-/- 
(Figure 4.2E) MEFs were stained with the cis-Golgi antibody GM130 (green) and the 
nuclear counterstain DAPI (blue) and imaged by confocal microscopy. Five 
randomly selected images from each sample (N=3 wild type and N=3 Rab18-/-) were 
imported into Volocity 3D image analysis software and mean Golgi area per cell 
(µm2) calculated. No differences were observed in mean Golgi area between wild 
type or Rab18-/- MEFs, suggesting that loss of RAB18 had no effect on Golgi size 






Figure 4.2 GFP-RAB18 colocalises with the Golgi marker GalT in mouse 
embryonic fibroblasts but has no effect on Golgi area upon loss of 
RAB18 
(A-C) Mouse embryonic fibroblasts co-transfected with GFP-RAB18 (green) and the 
trans-Golgi marker CFP-GalT (blue) showing enrichment of GFP-RAB18 at the 
Golgi apparatus. Merged image (C) is a composite of GFP-RAB18 (A) and CFP-
GalT (B). (D-F) Fixed control (D) and Rab18-/- (E) mouse embryonic fibroblasts co-
stained with the cis-Golgi marker GM130 (green) and the nuclear stain DAPI (blue). 
(F) Quantification of Golgi area using Volocity software shows that loss of RAB18 
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has no major effect on Golgi size. N=3, mean ± SEM, ns= unpaired t-test not 
significant. Scale bar represents 10µm. 
 
RAB18 has been identified as a major component of lipid droplets in an in-depth 
proteomics screen (Ozeki et al., 2005) and subsequent studies have confirmed its 
localisation to lipid droplets in adipocytes, fibroblasts and epithelial cell lines (Ozeki 
et al., 2005, Martin et al., 2005, Pulido et al., 2011). To examine the localisation of 
RAB18 to lipid droplets in MEFs, wild type cells were transfected with GFP-RAB18 
and incubated overnight in parallel with oleic acid conjugated to bovine serum 
albumin (BSA) to induce lipid droplet formation, and the neutral lipid stain BODIPY 
558/568 C12 to label these lipid droplets. GFP-RAB18 staining was again observed in 
the ER but appeared enriched in rings immediately surrounding lipid droplets (Figure 
4.3 A-C). This is in agreement with previous reports (Pulido et al., 2011, Martin et 
al., 2005, Ozeki et al., 2005). To quantify for any abnormalities in lipid droplet 
morphology upon loss of Rab18, control and Rab18-/- MEFs were treated with oleic 
acid for 24 hours, fixed in PFA and labelled with the neutral lipid stain BODIPY 
493/503 (green) and DAPI (blue) (Figure 4.3 D-E). Five images from each cell line 
(N=3 wild type, N=3 Rab18-/-) were imported into ImageJ and the size of each lipid 
droplet measured (particle size plugin). The mean lipid droplet size (in pixels) for 
each sample was quantified rather than fluorescence intensity as variations in 
staining intensity were frequently observed between wells. Our analysis identified an 
enlargement of lipid droplets in Rab18-/- MEFs compared to controls (mean lipid 
droplet size, 8.89 ± 0.24 pixels in control and 12.82 ± 1.23pixels in Rab18-/-).  
Taken together our data suggests that loss of RAB18 in MEFs does not result in 
gross abnormal morphology of the ER or Golgi. However, enlarged lipid droplets in 





Figure 4.3 Localisation of GFP-RAB18 to lipid droplets in mouse 
embryonic fibroblasts  
(A-C) Mouse embryonic fibroblasts transfected with GFP-RAB18 (green) and loaded 
with oleic acid and the neutral lipid stain BODIPY 558/568 C12 (red) and the nuclei 
stain Hoescht (blue) showing localisation of RAB18 in rings surrounding lipid 
droplets. Merged image (C) is a composite of GFP-RAB18 (A) and Bodipy C12 (B) 
and. (D-F) Control (D) and Rab18-/- (E) mouse embryonic fibroblasts treated with 
oleic acid for 24 hours then fixed and stained with the neutral lipid stain BODIPY 
493/503 (green) and DAPI (blue). (F) Quantification of lipid droplet size showing 
enlarged lipid droplets in Rab18-/-MEFs. N=3, mean ± SEM, (mean lipid droplet size, 
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8.9 pixels in control and 12.8 pixels in Rab18-/-), *p<0.05 unpaired t-test. Scale bar 
represents 10µm.  
 
4.2.2 GFP-RAB18 localisation and dynamics in primary 
hippocampal neurons 
Abnormalities affecting the peripheral and central nervous systems are hallmark 
features of Warburg Micro syndrome; patients exhibit severe developmental delay 
and polymicrogyria, indicative of possible neuronal migration abnormalities and 
axonal peripheral neuropathy. To examine if the reported localisations of RAB18 
were also present in a specific cell type that may be relevant to disease, localisation 
experiments were performed in primary hippocampal neurons. Hippocampal neurons 
were isolated from E17.5 wild type embryos and cultured for 12-14 days in vitro 
(DIV) to reach developmental maturity. Attempts to co-transfect neurons with GFP-
RAB18 and the trans-Golgi marker GalT proved unsuccessful, so to confirm the 
localisation of RAB18 to the Golgi, GFP-RAB18 transfected primary hippocampal 
neurons were PFA fixed and immunofluorescence performed with the cis-Golgi 
antibody GM130 (Figure 4.4). We observed that, as in MEFs, GFP-RAB18 co-






Figure 4.4 GFP-RAB18 colocalises with the cis-Golgi marker GM130 in 
primary hippocampal neurons 
(A-C) Primary hippocampal neurons transfected with GFP-RAB18 (green) and 
immunostained with the cis-Golgi marker GM130 (red) showing co-localisation of 
RAB18 and the cis-Golgi in hippocampal neuron soma. Merged image (C) is a 
composite of GFP-RAB18 (A) and GM130 (B). Scale bar represents 10µm.  
To further examine the localisation of GFP-RAB18 and to counteract any effects of 
fixation, wild type primary hippocampal neurons were transfected with GFP-RAB18 
and imaged live by confocal microscopy. When microscope intensity levels were 
increased (until staining in the soma became saturated), GFP-RAB18 staining was 
observed throughout the neuronal processes (Figure 4.5A). However, frequently, we 
observed variable accumulations of signal along processes. Time lapse recording 
over multiple hours (2 minute intervals for 16 hours) revealed that GFP-RAB18 
occassionally slowly accumulated in puncta within neurite processes that were then 
retrogradely transported back up the neuronal process towards the cell soma. This 
novel observation of the localisation and behaviour of RAB18 in hippocampal 
neurons suggests that RAB18 may play distinct roles in neuronal processes from that 





Figure 4.5 GFP-RAB18 localises to neuronal processes in primary 
hippocampal neurons and is mobile 
(A) Primary hippocampal neurons transfected with GFP-RAB18 (green) and live 
imaged with a confocal microscope. GFP-RAB18 localises throughout neurons 
including in dense puncta in neuronal processes. GFP-RAB18 transfected neurons 
were imaged in real time and panels B-D show boxed region in A at 346 (B), 352 (C) 
and 358 minutes (D) indicating that RAB18 positive puncta are dynamically 






In this chapter I report the localisation of RAB18 to the ER and Golgi, a broad 
consensus localisation previously reported in multiple different cell types (Dejgaard 
et al., 2008, Martin et al., 2005). Although this is not the first study examining 
RAB18 localisation in fibroblasts, I report for the first time the localisation of 
RAB18 and the cellular consequences of its loss in MEFs. My studies have shown 
that loss of Rab18 does not result in gross morphological abnormalities in the ER or 
Golgi, but an enlargement of lipid droplets. Although I have been unable to rule out 
the hypothesis that Warburg Micro syndrome pathology originates from some 
ubiquitous cellular function, I have provided evidence for GFP-RAB18 localising 
throughout the neuron and in accumulations along neurite processes which are 
mobile. This may underlie a cell-type specific function of RAB18 and future work 
has been directed towards investigation of pathological events in the nervous system 
of Rab18-/- mice (chapter 6). 
4.3.1 Confirmation of previously reported localisations of 
GFP-RAB18 
The majority of the work described in this chapter was carried out on live cells 
transfected with GFP or mCherry tagged proteins to examine the localisation of 
RAB18. Overexpression of a fluorescently tagged protein can disrupt normal 
endogenous function and localisation (Spector and Goldman, 2010). It is therefore of 
great importance to determine whether the localisations reported here are in 
agreement with normal RAB18 function prior to further analysis. The easiest way to 
determine if a fusion protein is correctly localised is to perform 
immunocytochemistry with a specific antibody. There are multiple cases in the 
literature whereby the localisation of RAB18 has been examined by 
immunofluorescence and showed consistent results with GFP transfection. However, 
during the course of this project the specificity of many commercially available and 
custom-made RAB18 antibodies was examined and could not distinguish differences 
between control and Rab18-/- MEFs (undertaken by Dr Mark Handley). This could be 
attributed to differences in antibody specificity in human and mouse cells or 
90 
 
potentially differences in fixation and permeabilisation protocols. As a result, care 
must be taken when drawing conclusions from the novel protein localisation I have 
identified. However, several of the results presented here suggest that GFP-RAB18 
recapitulates normal endogenous RAB18 localisation. Primarily, I along with others 
(Martin et al., 2005, Ozeki et al., 2005, Pulido et al., 2011) have identified GFP-
RAB18 to localise to the surface of lipid droplets. RAB18 was also independently 
identified in an in-depth proteomics screen for molecules involved in lipid droplet 
function (Ozeki et al., 2005). Additionally, I and others have also reported the 
localisation of RAB18 to the ER and Golgi complex, using independently generated 
GFP and mCherry-tagged RAB18 constructs and the localisation of RAB18 to the 
ER has also been confirmed by electron microscopy (Martin et al., 2005).  
Experiments to confirm the localisation of RAB18 to polarised epithelial cells, as 
shown in Lutcke et al., 1994 were not performed as other studies have failed to 
recapitulate the co-localisation of RAB18 with endosomal markers (Ozeki et al., 
2005).  
4.3.2 RAB18 and lipid droplets 
Lipid droplets are dynamic organelles composed of a phospholipid monolayer 
surrounding a dense core of neutral lipids (Martin and Parton, 2006). In this study I 
have reported the localisation of RAB18 to the surface of lipid droplets in agreement 
with previous studies (Martin et al., 2005, Ozeki et al., 2005, Pulido et al., 2011) and 
an enlargement of lipid droplet area in Rab18-/- MEFs.  
Recent proteomic analysis has identified many additional RAB proteins on lipid 
droplets including RAB1, 2, 5, 6, 7, 8, 10, 14, 18 and 32 (Ozeki et al., 2005) 
suggesting a link between lipid droplets and membrane trafficking. Furthermore, 
many of these identified RAB proteins link lipid droplets to specific membranes, 
providing further evidence for their dynamic nature. For example, RAB5 is found on 
the surface of lipid droplets where specifically in its GTP bound state it recruits early 
endosome markers, including EEA1 (Liu et al., 2007). Additionally, overexpression 
of RAB18 resulted in translocation of lipid droplets within close contact to and 
occasional encroachment by the rough ER membrane (Ozeki et al., 2005). 
91 
 
RAB18 has been reported to function in both triacylglycerol accumulation and 
hydrolysis with RAB18 labelling at the surface of lipid droplets enhanced upon 
induction of lipolysis with isoproterenol or forskolin (Martin et al., 2005) and also 
upon lipogenesis induction with insulin treatment (Pulido et al., 2011). It is 
interesting how RAB18 may be implicated in two isolated processes. One possibility 
is that RAB18 may be involved in lipid droplet trafficking and thus mediating the 
exchange of materials between the lipid droplet and ER membranes. Furthermore, 
Martin et al., 2005 have shown that RAB18 labelled lipid droplets are highly mobile 
and undergo rapid oscillatory movements to the cell periphery and also reported 
movement of GFP-RAB18 positive ER structures to the periphery and lipid droplet 
surface (Martin et al., 2005). As I and others have localised RAB18 to the ER 
(Dejgaard et al., 2008) it is therefore tempting to speculate that RAB18 may be 
specifically involved in the lipid droplet to ER point of contact, however, it cannot be 
ruled out that RAB18 may potentially have a more generalised role in linking the ER 
to other organelles. Detailed analysis of RAB function on early endosomes identified 
that RAB5 and RAB11 undergo cyclical activity on and off lipid droplet membranes 
in a GTP dependent manner. However, the same analyses showed that RAB GDI did 
not extract RAB18 from lipid droplets (Liu et al., 2007). This may potentially point 
to RAB18 having a more stable association with lipid droplets as compared to the 
transient association observed with other RABs. This could suggest that RAB18 may 
directly regulate lipid droplets, consistent with our findings. Enlarged lipid droplets 
have also been observed in RAB3GAP1, RAB3GAP2 and TBC1D20 patient cell lines 
and bs MEFS (Liegel et al., 2013, in press), suggesting that the lipid droplet 
phenotype may be related to Warburg Micro syndrome pathogenesis. It would be of 
interest to determine whether enlarged lipid droplets are recapitulated in cells 
relevant to the Warburg Micro syndrome phenotype.  
4.3.3 Insights into RAB18 function in primary hippocampal 
neurons 
Many of the patient phenotypes associated with Warburg Micro syndrome are 
neuronal in origin and hence point towards a role for the causative genes in neuronal 
homeostasis. As a result, the localisation of GFP-RAB18 was examined in a more 
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relevant cell type for pathogenesis, primary hippocampal neurons. Wild type primary 
hippocampal neurons transfected with GFP-RAB18 co-localised with the cis-Golgi 
marker GM130 in the cell soma. Additionally, when laser intensity was increased 
GFP-RAB18 localisation was observed throughout the neuron with puncta 
accumulations observed along some neuronal processes. Time lapse imaging 
revealed that frequently these accumulations were mobile and trafficked along the 
axon in what appears to be a retrograde manner. This novel localisation and 
behaviour of RAB18 suggests it may fulfil distinct functions in neuronal processes 
and points towards a potential role in axonal transport. Neurological phenotypes 
associated with Warburg Micro syndrome may therefore result from perturbations of 
specialised, RAB18-dependent pathways in neurons. Experiments were also 
performed transfecting neurons with GFP only constructs and this puncta localisation 
and mobility was not observed (data not shown). 
RAB protein localisation and expression has previously been examined in 
Drosophila brains and identified 10 neuronal specific RABs (RABX1, RAB3, 
RABX4, RAB9, RAB19, RAB21, RAB23, RAB26, RAB27 and RAB32) with 
enriched or exclusive localisation to neuronal synapses (Chan et al., 2011). RAB18 
however, was found to be ubiquitously expressed, but analysis of the posterior 
portion of the ventral ganglion showed preferential localisation to the cell body. We 
also observed GFP-RAB18 to preferentially localise to the cell body in neurons but 
additionally localise along neuronal processes. Additionally, in the fly model, 
overexpressed RAB18 co-localised with the early endosomal marker RAB5 and 
altered RAB5 localisation. As both RAB18 and RAB5 localise to the surface of lipid 
droplets (Liu et al., 2007, Ozeki et al., 2005) it would be of interest to examine 
whether the punctae observed in our GFP-RAB18 transfected neurons overlap with 
the endosomal compartment. Furthermore, the majority of the neuronal specific 
RABs were also found to co-localise with synaptic vesicle markers (Chan et al., 
2011). Given the well established roles of the RAB3 family of proteins in synaptic 
vesicle exocytosis (Schluter et al., 2002) and the identification of RAB18 being 
implicated in the negative regulation of exocytosis (Vazquez-Martinez et al., 2007) it 
is of great importance to determine whether the puncta localisation of GFP-RAB18 




In this chapter I have examined the localisation of RAB18 in MEFs and compared 
wild type and Rab18-/-cellular phenotypes. I have shown that GFP-RAB18 localised 
to the ER, Golgi apparatus and lipid droplets in agreement with previous reports and 
that loss of Rab18 resulted in enlarged lipid droplets. I also examined the localisation 
of RAB18 in hippocampal neurons, and identified that its co-localisation with the 
cis-Golgi was mostly consistent with what was seen in MEFs, but an additional, 
possibly cell-type specific function in neuronal processes was observed. From this 
data, we have shown that the disease relevant function of RAB18 may be ubiquitous 
or potentially cell type specific. To further our analysis of neuronal specific 
phenotypes associated with Warburg Micro syndrome, I have undertaken detailed 
pathological analysis of neuronal phenotypes in Rab18-/- mice and this data will be 
presented in chapter 6.  
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Chapter 5 Characterisation of the Rab18-/- 
ocular phenotype 
5.1 Introduction 
In this chapter I will focus on characterisation of the ocular phenotypes observed in 
Warburg Micro syndrome patients and Rab18-/- mice. 
5.1.1 Anatomy of the eye 
The eye is surrounded by a thick outer protective sclera and thin inner pigmented 
choroid. At the anterior of the eye, the sclera develops into the thin, transparent 
cornea, and the choroid forms the iris which gives the eye its coloured appearance 
and regulates the amount of light that enters the eye through the pupil, a hole in the 
iris. The cornea together with the lens functions to refract incoming light rays and 
focus the observed object on the retina. The ciliary body, a complex set of smooth 
muscles, functions to hold the lens in place and alter its biconvex shape to focus on 
objects near and far. The lens and ciliary body divide the eye into two chambers, the 
foremost filled with aqueous humour secreted by the ciliary epithelium and posterior 
with vitreous humour, which accounts for 80% of the volume of the eye. The retina 
is located interior to the choroid and is where the light sensitive photoreceptors (rods 
and cones) can be found.  
5.1.2 Warburg Micro syndrome ocular abnormalities 
Warburg Micro syndrome patients present with eye abnormalities including 
congenital bilateral cataracts, microphthalmia, microcornea (<10mm diameter) and 
small atonic pupils (Warburg et al., 1993). During general phenotyping of our Rab18-
/- mouse model we observed no obvious abnormalities in eye size (although studies 
are currently underway to quantify this) but atonic pupils and congenital cataracts 
with complete penetrance. The majority of our analyses have focused on identifying 
the histological abnormalities underlying ocular development and congenital 
cataracts in Rab18-/- mice.  
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5.1.3 Mouse lens development  
Several reviews which have described the development and morphology of the 
murine lens in detail are summarised below (Graw, 2009, Graw, 2004, Graw, 1999, 
Graw, 2003, Francis et al., 1999, Cvekl and Piatigorsky, 1996, Michael and Bron, 
2011, Fitzpatrick and van Heyningen, 2005). 
Figure 5.1 shows the major morphological events in mammalian lens development. 
At approximately late gastrulation, the eye field, a population of cells in the anterior 
neural plate of the primitive ectoderm, laterally splits into two optic vesicles that 
extend towards the surface ectoderm. As the optic vesicle comes into close proximity 
with the surface ectoderm the ectoderm thickens to form the lens placode, and the 
optic vesicle invaginates to form the early optic cup (Figure 5.1A). At approximately 
E10.5, the lens placode invaginates into the optic cup forming the lens pit (Figure 
5.1B). At E11.5 the two edges of the lens pit approach and fuse to form the lens 
vesicle (Figure 5.1C). The lens vesicle then detaches from the surface ectoderm 
which recovers and goes on to differentiate into the prospective cornea. Epithelial 
cells lining the posterior of the lens vesicle then differentiate and elongate upwards to 
form the primary lens nucleus that fills the internal cavity and this process is 
complete by E13.5. A subpopulation of epithelial cells at the anterior pole of the lens 
retain their epithelial characteristics and form a monolayer of ‘stem-like’ cells 
(Figure 5.1D). These epithelial cells travel to the dorsal and ventral equators where 
they elongate and differentiate into secondary lens fibre cells throughout life forming 




Figure 5.1: Mouse lens development  
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Lens development commences at approximately E9.5-E10 with thickening of the 
surface ectoderm to form the lens placode (the future lens) (A). (B) At E10.5, the 
lens placode invaginates into the optic cup forming the lens pit. (C) By E11.5, the 
two edges of the lens pit come together to form the lens vesicle and detach from the 
surface ectoderm. (D) By E13.5, epithelial cells lining the posterior of the vesicle 
have elongated and differentiated into primary fibre cells, closing the lens vesicle. A 
monolayer of epithelial cells surrounds the anterior of the lens. (Adpated from Cveki 
& Piatigorsky 1996). 
 
Figure 5.2: Adult lens morphology and organisation  
The lens is surrounded by a thick protective lens capsule. At the anterior of the lens 
is a mono layer of epithelial cells. As the lens forms from the lens vesicle the primary 
fibre cells differentiate from the posterior epithelial cells and elongate to the anterior 
forming the lens nucleus. A second wave of fibre formation then commences with 
the differentiation of epithelial cells at the dorsal and ventral equators meeting at the 
lens suture (A). As fibre cells differentiate they lose their nuclei and organelles to 




As lens fibre cells differentiate they lose their organelles, nuclei and mitochondria 
and accumulate large quantities of crystallin proteins (Figure 5.2B). For primary 
fibre cells this process takes place approximately E17/E18 in the mouse, whereas 
secondary fibre cells which grow throughout life lose their organelles as they migrate 
from the periphery to the cortex. The centre of the mature lens is thus composed of a 
highly ordered network of metabolically inactive hexagonal lens fibre cells with 
minimal intracellular spaces. Fibre cells are therefore avasculature and are dependent 
upon ion pumps between cells to enable cell-cell communication and maintain 
homeostasis. Greater than 90% of soluble protein in the mature lens is made up of 
the crystallin family (α, β and γ subfamilies). Crystallin proteins are present in very 
large quantities in the lens and all three families are essential to preserve normal lens 
transparency by increasing the refractive index of the lens. α-crystallin however, has 
an additional role functioning as a chaperone to aid the retention of proteins in their 
normal natured state (Horwitz, 1992). Other proteins in the lens include cytoskeletal 
proteins such as vimentin, CP49 (phakinin) and CP115/CP95 (filensin) who function 
to maintain the strict arrangement of hexagonal lens fibre cells. Abnormalities in 
denucleation, retention of organelles or mutations in crystallin, cytoskeletal or 
connexin proteins result in loss of normal lens transparency and cataract 
development.  
5.1.4 Congenital cataracts 
Unlike age related cataracts, congenital cataracts are in fact rare, with an incidence of 
30 in every 100,000 births in the developed world (Graw et al., 2004). The majority 
of our understanding into isolated nonsyndromic cases of congenital cataracts has 
arisen from the use of mouse models with many spontaneously arisen and induced 
mutations after ENU, X-ray or γ-ray irradiation characterised to identify the 
morphological abnormalities underlying cataract development. For example, 
mutations in the β and γ-crystallin gene family (Cryg) result in a spectrum of 
opacities in both heterozygote and homozygote mice (Graw et al., 2004). Crygdenu910 
and Crygeenu449mutations result in a mild phenotype with a subtle mass in the centre 
of the lens and abnormal nuclei degradation suggestive of a defect in lens fibre 
differentiation. Crygcenu369 and Crygdk10 mutations cause a more severe phenotype 
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with a shift of the lens nucleus to the anterior and many large vacuoles (Graw et al., 
2004). Additionally, the CrygbNop mouse shows swollen anterior and posterior lens 
fibres, abnormalities in organisation of the nuclear bow and polar cataracts (Graw et 
al., 1990). However, most incidences of congenital cataract are syndromic and 
associated with other abnormalities, for example cataracts are observed in Smith-
Lemli-Opitz syndrome (Cotlier and Rice, 1971) and 1.4% of Down’s syndrome cases 
in a Danish cohort (Haargaard and Fledelius, 2006).  
As stated above normal lens development is dependent upon processes involving cell 
migration and cellular differentiation, with abnormalities in either process resulting 
in loss of normal lens transparency and cataract development. In this chapter I 
therefore describe histological examination for migration and cellular differentiation 
abnormalities in Rab18-/-mice. To examine the role of RAB18 in cell migration I 
analysed lenses at different stages of embryogenesis to examine for any 
abnormalities in lens formation and closure. Additionally, to investigate the process 
of fibre cell differentiation I examined the denucleation process and lens fibre 





5.2.1 Defective lens development in Rab18-/- mice 
Initial characterisation of the Rab18-/-phenotype (described in chapter 4) identified 
congenital nuclear cataracts and atonic pupils with complete penetrance. To further 
characterise the lens defects and examine for any underlying morphological 
abnormalities, eyes from control and Rab18-/- mice were histologically assessed at 
various stages of embryogenesis. Intact embryos (E12.5), heads (E15.5) or dissected 
eyes (E17.5 and P1.5) were wax-embedded and eye morphology investigated 
through haematoxylin and eosin staining. Analysis at E12.5 identified no 
abnormalities in the developing retina, the optic stalk or the vitreous body in control 
or Rab18-/- mice suggesting that eye development initiates normally in Rab18-/- 
mutants (Figure 5.3 A-B). However, by this stage of development in control lenses 
the epithelial cells lining the posterior of the lens vesicle had differentiated and 
elongated to the anterior, filling the lens vesicle with primary fibre cells and forming 
the lens nucleus (Figure 5.3A). In Rab18-/- littermates at the same stage the primary 
fibre cells were yet to elongate to the tip of the lens vesicle, suggestive of a delay in 
lens development (Figure 5.3B). To further analyse lens morphology subsequent 
histological analyses were undertaken at E15.5, E17.5 and P1.5. By E15.5 the lens 
vesicle in Rab18-/- mice had now filled but small vacuoles were apparent at the 
anterior of the lens (Figure 5.3D). Higher magnification images at E17.5 showed 
these vacuoles had become enlarged and the characteristic monolayer of epithelial 
cells surrounding the anterior of the lens is multicellular (Figure 5.3F). As fibre cells 
differentiate they lose their organelles and nuclei within the centre of the lens, 
resulting in an organelle free zone (OFZ) to prevent light scattering, as observed in 
the control lens at P1.5 (Figure 5.3G). However, analysis of Rab18-/-lenses at P1.5 
identified large nuclear aggregates and pyknotic nuclei within the centre of the lens 
(Figure 5.3H). Control lenses showed normal morphology at all stages examined 
(Figure 5.3A, C, E and G). Taken together this data suggests that loss of Rab18 
results in a delay in closure of the lens vesicle, vacuoles within the lens and 






Figure 5.3: Rab18-/- mice show defective lens development as early as 
E12.5 
Haematoxylin and eosin staining on control and Rab18-/-eyes at E12.5 (A-B), E15.5 
(C-D), E17.5 (E-F) and P1.5 (G-H). (A-B) Analysis at E12.5 showing a delay in 
closure of the lens vesicle in Rab18-/- lenses (B) compared to control (A). (C-D) 
Analysis at E15.5 showing the lens vesicle in Rab18-/- eyes has now closed but 
vacuoles have developed at the anterior of the lens (D). (E-F) Analysis at E17.5 
showing enlargement of the vacuoles in Rab18-/- mice and the epithelium 
surrounding the lens has become multilayered (F) as opposed to the monolayer of 
epithelial cells observed in control eyes (E). (G-H) Analysis at P1.5 showing the 
fibre cells in the centre of the control eye have lost their nuclei and organelles to 
prevent light scattering (G); however, pyknotic nuclei and large vacuoles are evidentt 
in the centre of the Rab18-/- lens (H). Panels A-D and G-H scale bar represents 
200µm, panels E-F scale bar represents 50µm. 
5.2.2 Rab18-/-eye abnormalities are restricted to the lens in 
adult mice 
To examine the consequences of loss of Rab18 on ocular structures in the mature 
adult eye, further histological (haematoxylin and eosin) staining was performed on 
eyes from 7 week old control and Rab18-/- littermates. No obvious pathological 
changes were identified in the retinal layers (Figure 5.4 A-B) in wild type or Rab18-/- 
eyes, suggesting the observed phenotype in Rab18-/- mice may be restricted to the 
lens. Note, that the Rab18-/- eye examined in figure 5.4B was unpigmented so no 
RPE (retinal pigment epithelium) is observed. As adult lenses are difficult to section 
with cracking and shattering regularly observed, in detailed histological analysis to 
examine cataract and eye morphology in adult mice was undertaken using optical 
projection tomography (OPT performed by Harris Morrison). OPT enables 
examination of biological tissues in 3D space. As with the histological analysis OPT 
identified large nuclear cataracts in the centre of the lens but no gross abnormalities 




Figure 5.4: Ocular defects in Rab18-/- mice are restricted to the lens 
Rab18-/- mice present at eye opening with dense nuclear congenital cataracts. (A-B) 
Histological analysis with haematoxylin and eosin on 7 week old wax-embedded 
eyes showing normal retinal morphology in control (A) and Rab18-/- (B) mice. Note 
that the eye in B is unpigmented and no retinal pigment epithelium is observed. (C-F) 
Optical projection tomography performed on 6 week old albino control (C and E) 
and Rab18-/- (D and F) eyes. Panels A-B scale bar represents 100µm, panels E-F 
scale bar represents 400µm. 
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5.2.3 Abnormalities in organisation and denucleation of lens 
fibre cells 
Normal lens transparency is dependent upon the tight organisation of lens fibre cells, 
narrow intercellular spaces and loss of nuclei and organelles. Abnormalities in any of 
these processes results in loss of lens transparency and cataract development. I 
therefore set out to examine for any abnormalities in the organisation or denucleation 
of the lens in Rab18-/-mice.  
During my initial histological analysis of embryonic cataract development in the 
Rab18-/- lens centralised pyknotic nuclei were evident in the lens from E17.5 (Figure 
5.3). To further examine nuclei distribution in the lens, eyes from P1.5 control and 
Rab18-/- littermates were stained with DAPI (Figure 5.5). At P1.5 fibre cells in the 
centre of the control lens have undergone denucleation resulting in an organelle free 
zone whereas newly differentiated fibres at the equatorial zone retain their nuclei 
(Figure 5.5A). In Rab18-/-lenses nuclei are present in the equatorial zone but also 
clearly retained in the centre of the lens suggestive of abnormalities in lens fibre 
denucleation (Figure 5.5B). 
Additionally, DAPI staining revealed that the epithelial cells in Rab18-/- mice were 
not a strict monolayer but multi-layering of cells was observed immediately anterior 




Figure 5.5: Abnormalities in fibre cell denucleation in Rab18-/- lenses 
As fibre cells differentiate those in the centre of the lens lose nuclei and organelles to 
maintain transparency. (A) Eyes from P1.5 control mice stained with DAPI to 
examine nuclei distribution shows nuclei to be restricted to the younger lens fibre 
cells added at the equatorial zone (Figure 5.2). (B) Eyes from Rab18-/- littermates 
show cell nuclei to be distributed throughout the lens, suggesting abnormalities in 




In order to examine the organisation of lens fibre cells in more detail preliminary 
studies were undertaken to label P1.5 control and Rab18-/- sagittally sectioned eyes 
with periaxin (Figure 5.6). Periaxin has previously been shown to localise to the lens 
fibre cell plasma membrane (Maddala et al., 2011). Analysis of lens fibre cells at the 
equatorial zone, where the newest fibres are laid down showed normal organisation 
in control and Rab18-/-lenses (Figure 5.6 D-E). However, staining of fibre cells at the 
tip of the anterior pole showed gross discrepancies between control and Rab18-/- 
samples. In the control eye the lens fibre cells were highly organised whereas in the 
Rab18-/-lens swellings in the fibres were often seen (Figure 5.6 F-G). However, to 
examine the organisation of fibre cells in more detail periaxin staining would need to 
be repeated on control and Rab18-/- eyes sectioned through the equatorial plane to 






Figure 5.6: Abnormalities in fibre cell organisation in Rab18-/- lenses 
(A-C) Analysis of lens fibre organisation in P1.5 eyes stained with periaxin (green). 
Cell nuclei were labelled with DAPI (blue) in control (A) and Rab18-/- eyes (B-C). 
(D-E) Periaxin staining at the equator where epithelial cells differentiate into primary 
fibre cells shows normal organisation in control (D) and Rab18-/- lenses. (F-G) 
Periaxin staining at the top of the lens, just below the lens epithelium shows swelling 
of fibre cells in Rab18-/- lenses (G) compared to control (F). Panels A-C scale bar 
represents 200µm, panels D-G scale bar represents 50µm. 
 
5.2.4 RAB18 is not expressed in the bulk of adult lens 
As loss of Rab18 results in lens abnormalities including congenital nuclear cataracts 
I set out to determine whether RAB18 is expressed in the adult lens. Lenses from 
control and Rab18-/-mice were dissected and immediately homogenised in RIPA 
buffer, separated by electrophoresis on an SDS-PAGE gel and immunoblotted for 
RAB18 (Figure 5.7). As the RAB18 antibody shows many bands on western blotting 
heterozygote sciatic nerve was also loaded as a positive control. The heterozygote 
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sciatic nerve sample showed two bands at approximately 23 kDa that I have 
previously shown to be missing in the Rab18-/- sciatic nerves (Figure 3.5D). Lens 
protein extracts from heterozygote and Rab18-/- mice showed one band run at slightly 
lower molecular weight, which failed to disappear in the Rab18-/- sample, indicating 
that RAB18 is not expressed in the bulk of the adult lens. The same membrane was 
also stained with ponceau S to determine protein expression in the lens and no 
differences observed (Figure 5.7B). As ponceau S is less sensitive than coomassie 
blue staining, supernatants from different lens extracts were run on an SDS-PAGE 
gel and stained with Coomassie blue to determine any differences in total protein 
content between control and Rab18-/- samples. No obvious differential bands were 
identified between genotypes (Figure 5.8). Furthermore, as cataractous lenses often 
show nuclear aggregates within the lens the resultant pellets following protein 
extraction were boiled in SDS-PAGE buffer and run on a coomassie gel to determine 
whether any aggregates may have been retained in the pellet that could be attributed 
to the lenticular cataract. Again, no differences between control and Rab18-/-samples 
were observed (Figure 5.8). However, despite the fact that we failed to observe 
RAB18 expression in the adult lens; this does not necessarily mean it is absent from 
the entire lens. The bulk of the lens is composed of fibre cells which are 
metabolically inactive, however, a small niche of ‘stem-like’ epithelial cells exist 
anterior to the lens, but in such small numbers that epithelial specific proteins would 
probably be undetectable. Our data therefore suggests that RAB18 does not appear to 




Figure 5.7: RAB18 is not expressed in the bulk of the adult lens 
Analysis of RAB18 expression in the adult mouse lens. (A) Western blot analysis of 
lens and sciatic nerve extracts from heterozygote (HET) and Rab18-/- adult mice. 
RAB18 is expressed as a doublet in sciatic nerves samples, however, lens extracts 
show a band of lower molecular weight which does not disappear in the Rab18-/- 
sample and is not believed to be RAB18; α-tubulin was used as a loading control, 





Figure 5.8: No obvious protein differences in supernatant or pellet 
lens extracts in control and Rab18-/- mice 
Coomassie stained SDS-PAGE analysis of control and Rab18-/-lens extracts showing 
no obvious differences in protein expression in either supernatant or pelleted samples 








In this chapter I describe detailed characterisation of the congenital cataracts 
identified in Rab18-/- mice. Through histological examination I have identified a 
delay in closure of the lens vesicle at E12.5. Examination of adult eyes by histology 
and OPT identified no other ocular abnormalities suggesting the phenotype is 
restricted to the lens. Additionally, preliminary studies identified abnormalities in 
denucleation and organisation of lens fibre cells in Rab18-/- neonates suggestive of a 
defect in lens fibre differentiation.  
5.3.1 Warburg Micro syndrome ocular phenotypes 
During initial phenotypic characterisation of Rab18-/- mice, I identified congenital 
cataracts and atonic pupils recapitulating ocular phenotypes associated with Warburg 
Micro syndrome. However, Warburg Micro syndrome patients also characteristically 
present with other ocular abnormalities including micropthalmia, microcornea, 
cortical blindness and optic atrophy. Our analyses to date have focused on the 
congenital cataracts but further investigation into the other ocular features would be 
essential to definitively confirm or deny their presence.  
5.3.2 Ocular defects in Rab18-/- mice include delayed lens 
closure and cataract development 
Histological analysis at E12.5 in Rab18-/- mice identified a delay in closure of the 
lens vesicle suggestive of a timed delay in ocular development. This retardment 
could potentially be attributed to retarded growth of the eye and it would therefore be 
of interest to examine eye sizes compared to body weight at all stages examined. 
This would also aid clarification of whether Rab18-/- mice recapitulate the 
micropthalmia observed in Warburg Micro syndrome patients. Furthermore, it must 
be noted that in our analyses small lenses were observed in some Rab18-/- neonates 
but not all. Further characterisation of eye and lens size should now be undertaken. 
By E15.5 the lens vesicle in Rab18-/- mice appeared to have closed but vacuoles were 
apparent at the anterior below the lens epithelium. Intermediate embryonic stages 
would need to be examined to determine whether the vesicle closes in its entirety 
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prior to vacuole formation or are the vacuoles a result of specific areas of the lens 
vesicle that do not close. By E17.5 the vacuoles had become enlarged and the 
metabolically active epithelial cells that should be in a monolayer on the anterior of 
the lens were now multi-layered in Rab18-/- mice. As lens fibre cells differentiate 
they lose organelles and nuclei, become metabolically inactive and are dependent 
upon the metabolic activity of the epithelial cells and superficial fibre cells to pass 
small ions and nutrients through gap junctions to the centre of the lens. It would be of 
interest to determine whether this increase in epithelial cell number could be linked 
to an increased need of epithelial precursors for lens fibre differentation. At P1.5 
control mice show a mature lens with differentiated fibre cells lacking organelles and 
nuclei resulting in an OFZ in the centre of the lens. However, Rab18-/- mice at the 
same stage show large nuclear aggregates and evidence of centralised pyknotic 
nuclei suggestive of abnormalities in lens fibre differentiation.  
5.3.3 Rab18-/- mice show abnormalities in lens fibre cell 
differentiation and organisation 
Lens transparency is retained via denucleation and loss of organelles in the centre of 
the lens and the tightly ordered packaging of lens fibre cells. To further examine for 
defects in lens fibre differentiation P1.5 control and Rab18-/- eyes were stained with 
DAPI to label the cell nuclei. Our analyses showed that P1.5 control eyes have an 
OFZ in the centre of the lens whereas Rab18-/-lenses retain nuclei in the centralised 
fibre cells, suggestive of abnormalities in fibre cell denucleation. It would be of 
interest to also stain the lens with apoptosis markers such as TUNEL to determine 
whether the nuclei are slowly degenerating and undergoing apoptosis but in a 
delayed manner or whether the process in its entirety is blocked. Lenses from control 
and Rab18-/-mice should also be labelled with differentiation makers such as the α, β 
and γ-crystallins, whose expression increases dramatically upon fibre cell 
differentiation to further confirm for any gross defects in differentiation.  
Analysis of lenticular organisation was undertaken in P1.5 Rab18-/-lenses labelled 
with periaxin (PRX), a lens fibre membrane marker (Maddala et al., 2011). 
Preliminary analysis of sagittal lens sections hinted at a disorganisation of lens fibre 
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cells, however, to further characterise their morphology sectioning at the equatorial 
plane of the eye would need to be undertaken to examine the characteristic 
honeycomb architecture and quantifications of fibre cell length to width ratio 
calculated, as shown to be altered upon loss of ephrin-A5 (Cooper et al., 2008). The 
morphology and microarchitecture of individual fibre cells could also be analysed by 
scanning electron microscopy. 
5.3.4 Suggested abnormalities in lens epithelial cells 
In addition to abnormalities in denucleation of lens fibre cells, histological analysis 
of the epithelial cell monolayer in P1.5 Rab18-/- eyes stained with DAPI identified 
overgrowth of the monolayer and potential infringement of epithelial cells into the 
lens fibre cells. This is also observed in a TGFβ-induced mouse model.  However, 
these mice displayed anterior subcapsular cataracts suggesting that the infringement 
of epithelial cells into the lens fibres disrupts the organisation and causes cataracts 
(Lovicu et al., 2004). In our Rab18-/-mouse model this was not observed. I have 
identified nuclear congenital cataracts, suggesting that the epithelial cell phenotype 
maybe a secondary or unrelated consequence and not a primary phenotype, however 
further studies would need to be undertaken to examine this further. 
5.3.5 RAB18 is not expressed in the bulk of the adult lens 
Interestingly, I have shown that RAB18 was not present in the bulk of the adult lens. 
The developmental expression of RAB18 has not been evaluated as yet but studies 
such as Western blot anlaysis on embryonic or neonatal lenses or sectioning of LacZ 
stained embryonic or neonatal eyes could examine the location and timecourse of 
RAB18 expression in the developing lens. The early lens phenotype observed upon 
loss of Rab18 points towards a role for RAB18 in early eye development. However, 
loss of very early expressed genes for example Pax6 and Sox2 by contrast result in 
much more severe phenotypes such as anophthalmia (Graw, 2004), suggesting that 
RAB18’s expression could in fact be slightly later in eye development and would 




5.3.6 The role of RAB proteins in lens and cataract 
development 
Studies performed by Rao et al., have identified several small GTPases in the 
monkey and human lens (Rao et al., 1997b) that redistributed from the membrane to 
the cytosol and induced cataract formation upon lovastatin treatment (Rao et al., 
1997a). Lovastatin and other HMG-COA reductase inhibitors block the first step of 
the cholesterol biosynthesis pathway and as a result inhibit isoprenoid production. 
RAB proteins like other small GTPases are dependent upon isoprenylation for 
attachment into membranes and hence normal function (Rao et al., 1997a, Kinsella 
and Maltese, 1992). This supports my results of the involvement of small GTPases in 
cataract development. However, to my knowledge further characterisation of the role 
of RAB GTPases in the lens has yet to be undertaken. 
Previous studies have reported RAB18 to localise to lipid droplets and play a role in 
lipolysis and lipogenesis (Martin et al., 2005, Ozeki et al., 2005, Pulido et al., 2011), 
and Rab18-/- MEFS show enlarged lipid droplets (Figure 4.3). Lipid droplets are the 
storage sites of neutral lipids the major lipid being cholesterol. Cholesterol is an 
essential component of lens fibre cell membranes and as a result the lens contains the 
highest levels of cholesterol observed in the human body where it is observed in 
patches in the lipid bilayer (Borchman and Yappert, 2010). It is interesting that many 
of the features of Warburg Micro syndrome including cataracts are recapitulated in 
another genetic disorder with mutations in cholesterol metabolism, such as Smith-
Lemli-Opitz syndrome (Cotlier and Rice, 1971). This suggests a link between 
RAB18, lipids and cataract development, and hopefully analyses of lipid and 
cholesterol levels in the Rab18-/- lens may provide the basis of future studies. 
5.3.7 Summary 
In summary, I have described here detailed histological characterisation of the 
congenital cataracts observed during initial phenotyping of Rab18-/- mice. I have 
identified a delay in closure of the lens vesicle at E12.5 and abnormalities in lens 
fibre organisation and differentiation in neonates. Histological and OPT analysis of 
adult eyes restricted the phenotypic abnormalities to the lens. 
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The Rab18-/-mouse has made it possible to examine the aetiology of the Warburg 
Micro syndrome ocular phenotypes in a manner that is not possible in human 
patients. The data reported here has also enabled us to draw conclusions about the 
human disease, for example we have examined not only the role of RAB18 in disease 
but also in eye development and have identified a deficit in fibre cell differentiation 
which may be specific to these cells or relate to a more general role. As such fibre 
cell differentiation could potentially provide a model system in which to study the 
molecular functions of RAB18 and/or RAB18 dysfunction which may or may not 




Chapter 6 Characterisation of neurological 
pathology in Rab18-/- mice 
6.1 Introduction 
Children with Warburg Micro syndrome are severely handicapped and 
characteristically show truncal hypotonia. From approximately 8-12 months, they 
develop progressive lower limb spasticity, eventually leading to spastic quadriplegia 
by the teenage years. Progressive axonal neuropathy has also been noted (Bem et al., 
2011, Handley et al., 2013, Abdel-Salam et al., 2007, Derbent et al., 2004). In 
chapter 3 of this thesis I reported neurological deterioration of the hind limbs in 
Rab18-/- mice progressing from abnormal hind limb clasping, to splayed limbs, 
extended gait and a noticeable decline in movement. Additionally, we have observed 
the novel localisation of GFP-RAB18 to distinct mobile puncta along neuronal 
processes, pointing towards a previously unreported role for RAB18 within neurons.  
Given that notable advances in our understanding of pathological mechanisms 
underlying human neurological conditions have come from the characterisation of 
mouse models lacking or overexpressing a particular gene of interest, we set out to 
further characterise the hind limb weakness observed in Rab18-/- mice with the aim 
of providing insights into neuropathological changes underlying the Warburg Micro 
syndrome phenotype.  
Given the progressive lower limb spasticity in Warburg Micro syndrome patients and 
observed hind limb weakness in Rab18-/- mice we focused the majority of our 
analyses on the morphology and function of lower motor neurons. Motor neurons can 
be divided into two main sub-types. Upper motor neurons project into the spinal cord 
from higher centres in the brain and brainstem, where they synapse (either directly or 
indirectly) with lower motor neurons. Lower motor neuron cell bodies are located in 
cranial nerve nuclei or the ventral grey horn of the spinal cord, with their axons 
projecting into peripheral nerves and their synaptic terminals synapsing with skeletal 
muscle fibres at the neuromuscular junction (NMJ). Thus, motor neurons are the 
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longest cells in the human body, with some cells (for example those innervating the 
extremities of the lower limb) over 1 meter in length. As a result, they are highly 
sensitive to perturbations in protein transport or cytoskeletal organisation and are the 
site of pathological deterioration in many neurodegenerative diseases, including 
spinal muscular atrophy, hereditary spastic paraplegia and amyotrophic lateral 
sclerosis (Kasher et al., 2009, El-Kadi et al., 2007, Ikenaka et al., 2012, Dale et al., 
2011). 
6.1.1 The neuronal cytoskeleton 
Motor neurons, like many other cell types, contain a highly organised cytoskeleton; 
providing structure, support and the tracks on which axonal transport takes place. 
The neuronal cytoskeleton is comprised of three classes of proteins; actin 
microfilaments, microtubules and intermediate filaments. For in detailed reviews 
please see (El-Kadi et al., 2007, Perrot and Eyer, 2009, Ikenaka et al., 2012, Yuan et 
al., 2012). 
Both microtubules and microfilaments play critical roles in axonal transport, forming 
the tracks on which proteins are transported (El-Kadi et al., 2007). Microtubule 
filaments are formed from 13 tracks of alternating α and β tubulin heterodimers, 
producing a final filament of 24 nm. Microtubules thus form long but discontinuous 
tracks throughout the axon. They are highly polarised structures with slow growing 
(minus) ends pointing towards the cell body and fast growing (plus) ends growing 
towards the axon termini. Microtubule filaments form the tracks for long range 
transport, and their organisation is critical for efficient transport and hence neuronal 
survival (Conde and Caceres, 2009). Actin microfilaments are shorter (6-8nm) 
microfilaments formed from two twisted strands of β and γ actin monomers. Like 
microtubules, actin filaments are also polarised with plus and minus ends and are 
thought to provide the tracks for short range axonal transport.  
Six classes of intermediate filaments exist; neurofilament triplet proteins, α-
internexin, peripherin, vimentin, nestin and synemin, varying in temporal and spatial 
expression patterns (Perrot and Eyer, 2009). Neurofilament proteins comprise the 
largest cytoskeletal component of myelinated axons, where they function to establish 
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and maintain axonal calibre (Yuan et al., 2012, Perrot and Eyer, 2009). Three 
different classes of neurofilament exist; 68kDa NEFL (neurofilament light chain), 
165kDa NEFM (neurofilament medium chain) and 200kDa NEFH (neurofilament 
heavy chain). The three neurofilament isoforms share a common tripartite structure 
composed of; an approximately 310 amino acid highly conserved α-helical coiled 
coil rod domain, an N-terminal head domain and a C-terminal tail domain that varies 
in length between isoforms (Geisler et al., 1983). Two α-helical coiled coil domains 
(one from NEFL and the other from NEFM or NEFH) come together to form a 
parallel dimer (Szaro and Strong, 2009). Two of these resultant dimers join in an 
antiparallel fashion to form tetramers. Unlike microtubules and microfilaments, 
neurofilaments thus lack polarity. Eight tetramers can then form an approximately 
60nm length filament that join end to end producing the final intermediate filament. 
The tail domains of NEFM and NEFH radiate externally from the filament where 
they interact with organelles and other neurofilaments and thus primarily function as 
‘spacers’ defining the axonal calibre and hence axonal conduction velocity (Szaro 
and Strong, 2009). 
Neurofilament function and expression is regulated through vast post-translational 
modifications. For example neurofilament proteins are phosphorylated at head and 
tail domains and this is thought to play a key role in the regulation of neurofilament 
assembly (Hisanaga et al., 1990). Neurofilament proteins are synthesised in the cell 
body and transported bidirectionally along microtubules via kinesin and 
dynein/dynactin motor proteins (Wagner et al., 2004, Brown et al., 2005, Yabe et al., 
1999). Additionally, phosphorylation at KSP (KSXXP) motifs within NEFM and 
NEFH tail domains has previously been shown to regulate neurofilament transport 
(Ackerley et al., 2003). 
Accumulations of neurofilament proteins and aberrant phosphorylation of different 
neurofilament isoforms are hallmark features observed in many human disorders 
characterised by both central nervous system and motor neuron dysfunction. Genetic 
mapping and the generation and characterisation of mouse models have helped 
delineate the functional role of neurofilament proteins and their involvement in 
neurodegeneration (Table 6.1). These studies have identified that neurofilament 
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accumulations can result from mutations in neurofilament proteins themselves, for 
example, mutations in NEFL cause Charcot-Marie-Tooth type II with characteristic 
peripheral neuropathy and reduced nerve conduction velocities (Jordanova et al., 
2003), and transfection of CMT mutant neurofilaments into SW13 cells and neurons 
disrupts both the assembly and transport of neurofilaments (Brownlees et al., 2002). 
Additionally, accumulations may result from mutations in the molecular machinery 
responsible for their transport. For example, postnatal deletion of KIF5A in neurons 
with a Cre- recombinase transgene resulted in accumulations of all three 
neurofilament isoforms in neuronal cell bodies (Xia et al., 2003). Furthermore, 
correct stochiometry of different neurofilament isoforms is required for their function 
as generation of transgenic mice overexpressing human NEFH (a model for ALS) 
displayed perikaryal neurofilament accumulations and abnormalities in 
neurofilament transport (Julien et al., 1995). 
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Table 6.1: Mouse models of neurodegenerative disease with accumulations of neurofilament  
NMJ-Neuromuscular junction, SMA- Spinal Muscular atrophy, HSP-Hereditary Spastic Paraplegia, NF- neurofilament. Please note that this 
is not an exhaustive list due to the large number of mouse models now generated but shows evidence of neurofilament accumulation in 
many distinct neurodegenerative diseases. 
Mouse model Human disease Phenotype Reference 
SmnF7/SmnΔ7, NSE-
Cre+ 
SMA Accumulations of NEFM and phosphorylated NEFH at the NMJ, but no 
change in total levels. 
(Cifuentes-Diaz et al., 
2002) 
Smn-/-;SMN2 SMA Accumulation of neurofilaments, deneverated endplates and muscular 
atrophy  
(Murray et al., 2008) 
Smn-/-;SMN2;Δ7 SMA Accumulation of neurofilaments, deneverated endplates and muscular 
atrophy 
(Murray et al., 2008) 
Spg7-/- (paraplegin 
knockout) 
HSP Accumulation of NF and organelles in the spinal cord and peripheral 
axons accompanied by axonal swellings and morphologically abnormal 
mitochondria 
(Ferreirinha et al., 2004) 
Wobbler mouse Motor neuron 
disease 
Accumulation of NF and motor neuron degeneration in the ventral horn 
of the cervical spinal cord 




HSP (SPG10) Accumulations of NEFL, NEFM and NEFH within cell bodies of 
peripheral sensory neurons, also loss of large calibre axons was 
observed 
(Xia et al., 2003) 
G1H (human SOD1 
G93A overexpression) 
ALS Spheroids rich in neuronal isoforms including NF and phosphorylated 
NF isoforms in spinal cord and prominent astrocytosis 
(Tu et al., 1996) 
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6.1.2 Axonal transport 
The majority of axonal proteins are synthesised in the neuronal cell body and 
transported to their sites of function via axonal transport. Efficient protein transport 
is therefore critical for the development and survival of axons and the correct 
function of nerve terminals. For detailed reviews please see (De Vos et al., 2008, 
Millecamps and Julien, 2013, El-Kadi et al., 2007).  
The majority of axonal transport occurs on microtubule tracks driven by two distinct 
classes of molecular motors driving transport with structural polarity. Kinesin motor 
proteins drive anterograde transport from the cell body to the synaptic termini. 
Dyenin motor proteins together with its adaptor protein dynactin drive retrograde 
transport from the termini back towards the soma. A third class of motor proteins, the 
myosin motors also exist and are responsible for short distance axonal trafficking in a 
bidirectional manner along actin microfilaments.  
Proteins or protein subunits (that are then assembled at the synapse) can be trafficked 
along microtubules by either fast or slow axonal transport. Fast axonal transport 
moves organelles such as lysosomes, endosomes and mitochondria, at a rate of 1µm 
per second. Slow axonal transport transports cytoskeletal and cytosolic proteins at a 
rate of 1mm per day (De Vos et al., 2008). Recent studies have identified that the 
transport velocity of axonal components is not dependent upon the rate of transport 
but rather the amount of time spent in a paused state. For example previous studies 
have identified that neurofilaments are trafficked along microtubules in a 
bidirectional manner, alternating between rapid movements and prolonged pauses 
(Brown et al., 2005). 
Accumulations of proteins such as neurofilament at either the axon termini and/or the 
cell body are hallmark features of many neurodegenerative diseases. This suggests 
that disruption to axonal transport and hence abnormalities in axonal homeostasis 
may underlie or be a consequence of many neurodegenerative diseases (Table 6.2). It 
is therefore of interest to definitively determine whether protein accumulations 
themselves are pathogenic or present an epiphenomenom resulting from an 
underlying defect in transport or trafficking. 
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Table 6.2: Mouse models of neurodegenerative disease with axonal transport defects  
NMJ-Neuromuscular junction, SMA- Spinal Muscular atrophy, HSP-Hereditary Spastic Paraplegia, NF- neurofilament. Again please note 
that this is not an exhaustive list but represents the growing body of evidence identifying axonal transport defects implicated in the 
underlying pathology of many neurodegenerative diseases. 




ALS Reduction in transport of NF, tubulin and actin. Degenerating axons 
lacking neurofilaments, mitochondria and small ER. 





ALS Abnormal retrograde transport of adenovirus containing E.coli lacZ 
injected into gastrocnemius muscles 
(Murakami et al., 
2001) 
SMAΔ7 SMA Normal global distribution of NF. Reduction in fast anterograde 
transport of SV-2 and synaptotagmin. Reduction in dynein levels in 
agreement with NF accumulations at NMJ. 
(Dale et al., 2011) 
Spg7-/- (paraplegin 
knockout) 
HSP Disorganisation of cytoskeleton in spinal cord and sciatic nerve and 
retardation in retrograde transport. 
(Ferreirinha et al., 
2004) 
KIF5A-/- HSP Primary motor neuron cultures from KIF5A-/- mice reduction in 
anterograde and retrograde transport of mitochondria. 
(Karle et al., 2012) 
EMRC/36.5c 
(c.1092+2T>G in 
Spastin exon 7) 
HSP Primary cortical neurons axonal swellings of tubulin and 
mitochondria, tau , NF and APP, anterograde transport defects of APP 
and mitochondria. 
(Kasher et al., 
2009) 
Gjb1-/- null CMT1X Impairment of anterograde and retrograde axonal transport of synaptic 
vesicle proteins and abnormal accumulation of kinesin and dynein 
following sciatic nerve ligation 




6.1.3 The neuromuscular junction  
Many studies examining nerve-muscle connectivity and hence synaptic pathology 
have focused upon examination of the neuromuscular junction (NMJ) (Ribchester, 
2009, Cifuentes-Diaz et al., 2002, Ribchester et al., 2004). Importantly, NMJ 
disruption is also a common early event in lower motor neuron pathology, so 
assessments of NMJ integrity are often used as a sensitive assay for motor neuron 
viability (Fischer et al., 2004, Cifuentes-Diaz et al., 2002); as a result NMJ 
morphology was examined in this study.  
As the axon of a lower motor neuron nears its target of skeletal muscle fibres it loses 
its myelin sheath and splits into multiple branches, with each branch forming a 
synapse with an individual muscle fibre: the neuromuscular junction (NMJ). The 
NMJ functions to transmit chemical signals from nerve to muscle, principally via 
release of acetylcholine (ACh) (Sanes and Lichtman, 1999, Hughes et al., 2006). 
The NMJ is comprised of four distinct cell types; the presynaptic motor nerve 
terminal, the post synaptic endplate of the muscle fibre, terminal Schwann cells and 
the recently identified Kranocyte (Sanes and Lichtman, 1999, Court et al., 2008). As 
branches of the motor neuron meet skeletal muscle fibres they lose their myelin 
sheath and form the presynaptic motor nerve terminal. The motor nerve terminal is 
highly polarised with mitochondria directed away from the terminal and large 
amounts of synaptic vesicles clustered at active zones, sites of release of the 
neurotransmitter acetylcholine (ACh). As an action potential reaches the presynaptic 
nerve terminal, calcium channels open resulting in a large calcium influx. Increases 
in internal calcium concentration depolarise the nerve terminal and drive synaptic 
vesicles to fuse with the plasma membrane and release their contents of ACh into the 
synaptic cleft. The synaptic cleft is approximately 50nm thick and largely composed 
of basal lamina as a support matrix and the enzyme acetylcholinesterase (AChE), 
which rapidly hydrolyses ACh and prevents prolonged activation. The postsynaptic 
membrane is designed for rapid response to ACh release. Its membrane invaginates 
to form multiple secondary synaptic folds placed immediately opposite active zones; 
the tips of such folds hold the acetylcholine receptor (AChR). AChR receive the 
released ACh and produce a post synaptic potential, the EPP (endplate potential), 
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which propagates through the muscle fibre leading to muscle contraction (Sanes and 
Lichtman, 1999, Hughes et al., 2006).  
  
Figure 6.1: The neuromuscular junction 
As motor axons meet muscle fibres, they lose their myelin sheath and split into 
multiple branches that each innervate an individual muscle fibre at the 
neuromuscular junction. The motor nerve terminal forms a presynaptic bouton filled 
with acetylcholine filled synaptic vesicles. Upon induction of an action potential, 
vesicles release acetylcholine into the synaptic cleft where they are taken up by the 
acetylcholine receptors on the post-synaptic muscle fibre. Additionally, the motor 
nerve terminal is encapsulated with a terminal Schwann cell and kranocyte to 
‘insulate’ the NMJ. 
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In this chapter I have directed my focus towards characterisation of neuropathology 




6.2 Results:  
Warburg Micro syndrome patients develop lower limb spasticity from 8-12 months 
of age that is progressive, leading to spastic quadriplegia and axonal peripheral 
neuropathy later in life. Interestingly, the Rab18-/- mouse also presents with 
progressive hind limb weakness from weaning (3 weeks of age). No 
histopathological data is available from patients as most families decline post-
mortem examination, so I set out to use the Rab18-/- mouse model to investigate the 
underlying causes of neuromuscular defects in Rab18-/- mice that could hopefully be 
extrapolated to Warburg Micro syndrome patients.  
6.2.1 Normal synaptic vesicle recycling in Rab18-/- mice 
At the start of this study loss-of-function mutations in RAB3GAP1, RAB3GAP2 or 
RAB18 only were reported to result in clinically indistinguishable Warburg Micro 
syndrome phenotypes (Aligianis et al., 2005, Borck et al., 2010, Bem et al., 2011). I 
therefore initially set out to examine the expression levels of RAB3GAP1, 
RAB3GAP2 and RAB3A, a specific target of RAB3GAP1 and RAB3GAP2, to 
determine whether loss of Rab18-/- results in their aberrant expression. The RAB3 
family of proteins are specifically localised to synaptic vesicles and function in 
synaptic neurotransmitter release (Fischer von Mollard et al., 1990, Fischer von 
Mollard et al., 1991, Schluter et al., 2002). To analyse the levels of RAB3GAP1, 
RAB3GAP2 and RAB3A at the synapse of Rab18-/- mice, synapse enriched fractions 
(crude synaptosomal protein extracts) were isolated from 4 wild type (WT), 6 
heterozygote (HET) and 5 Rab18-/-brains in ice cold isotonic sucrose solution and 
analysed by Western blotting (Figure 6.2). As the RAB3GAP1 and RAB3GAP2 
antibodies used in this study resulted in many additional non specific bands upon 
Western blotting, myc tagged RAB3GAP1 and RAB3GAP2 transfected HEK293 
cell extracts (generated by Dr Mark Handley) were also run as positive controls to 
definitively confirm the correct band. The addition of a molecular tag should have no 
major impact on protein function but run at a slightly higher molecular weight. 
Western blot analysis identified no differences in expression levels of RAB3GAP1, 
RAB3GAP2 and RAB3A in crude synaptosomes isolated from wild type, 
heterozygote and Rab18-/- mice. Thus, loss of Rab18 had no gross impact on protein 
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levels of RAB3GAP1 and RAB3GAP2, suggesting that the neurological 
deterioration observed is not due to downstream consequences of altered 
RAB3GAP1 and/or RAB3GAP2 expression. 
 
Figure 6.2 Loss of RAB18 has no effect levels of RAB3GAP1, RAB3GAP2 
and RAB3A in synaptosomes 
Western blot analysis of crude synaptosomes isolated from wild type, heterozygote 
and Rab18-/- mouse brains were blotted for RAB3GAP1 (A), RAB3GAP2 (B) and 
RAB3A (C) and showed no differences in overall protein levels. In (A) and (B) 
MYC tagged RAB3GAP1 and RAB3GAP2 were used as a positive control. β3 
tubulin was used as a loading control for all westerns, note that the β3 tubulin 
antibody used specifically targets the neuronal specific isoform and as a result no 
loading band is shown in the HEK293 transfected cell extracts. Marker sizes are 
shown in kDa to the left of each blot. 
RAB3GAP1 and RAB3GAP2 have well established roles in regulation of the RAB3 
family in synaptic vesicle recycling (Nagano et al., 1998, Fukui et al., 1997, Fischer 
von Mollard et al., 1991, Schluter et al., 2002). I therefore set out to determine 
whether the neurological deterioration observed in Rab18-/- mice could be attributed 
to gross abnormalities in synaptic vesicle recycling at peripheral nervous system 
(PNS) or central nervous system (CNS) synapses.  
To evaluate synaptic vesicle recycling in the PNS, synaptic vesicles at 
neuromuscular synapses were labelled with the styryl dye FM1-43fx. Styryl dyes are 
composed of a positively charged head attached to a lipophilic tail by a double or 
multiple double-bond bridge and routinely used in in vitro studies of the synaptic 
vesicle cycle (Cochilla et al., 1999). In brief, the styryl dye is added to the external 
media and binds to the outer leaflet of the plasma membrane. Upon stimulation of 
exocytosis, synaptic vesicles fuse with the plasma membrane, undergo exocytosis 
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and reciprocal endocytosis taking up the styryl dye (Cochilla et al., 1999). Any non-
internalised dye was removed by multiple washes in oxygenated Ringer solution, so 
only that endocytosed by synaptic vesicles was examined in our analyses. To analyse 
synaptic vesicle recycling in the PNS I examined recycling synaptic vesicles at active 
neuromuscular junctions (NMJs) in lumbrical muscles (hind paw) of control and 
mid/late symptomatic Rab18-/- mice. Post synaptic acetylcholine receptors of the 
motor endplate were labelled with TRITC-α-BTX (red) and recycling synaptic 
vesicles with FM1-43fx (green). I utilised a fixable analogue of FM1-43 (FM1-43fx), 
this enabled retention of the fluorescent signal whilst I dissected individual muscles 
from their attached tendons prior to microscopy analysis. Upon stimulation of 
synaptic vesicle recycling with a high potassium solution, both control and Rab18-/- 
synapses efficiently endocytosed the FM dye (Figure 6.3 A-F). To quantify for any 
abnormalities in the number of active NMJs with recycling synaptic vesicles, the 
percentage of endplates (stained with TRITC-α-BTX, red) positive for FM1-43 
staining (green) was calculated. No significant differences were observed between 
genotypes (Figure 6.3 G). Additionally, the fluorescence intensity of the FM dye 
normalised to TRITC-α-BTX staining was calculated to quantify for any 
abnormalities in the number of synaptic vesicles or the rate of recycling, and again 
no significant differences were observed (Figure 6.3 H). Taken together, this 
suggests that loss of Rab18 has no major effect on gross parameters of synaptic 




Figure 6.3 Loss of Rab18 has no major effect on synaptic vesicle 
recycling in the PNS 
(A-F) Fluorescence micrographs of synaptic vesicle recycling at the neuromuscular 
junctions of control (A-C) and mid/late symptomatic Rab18-/- (D-F) mice. Post-
synaptic acetylcholine receptors of the motor endplate were labelled with TRITC-
conjugated α-bungarotoxin (A and D, red) and recycling synaptic vesicles labelled 
with FM1-43fx following a high potassium solution to induce synaptic vesicle 
recycling (B and E, green). Merged images (C and F) are composites of TRITC-
conjugated α-bungarotoxin (A and D) and FM1-43fx (B and E). (G) Bar chart (mean 
± SEM) showing the majority of endplates examined effectively took up the FM1-
43fx styryl dye irrespective of genotype (Mann-Whitney test, two tailed, p 
value=0.3786, n=12 muscles). (H) Bar chart (mean ± SEM) showing no difference 
in FM1-43fx fluorescence intensity normalised to TRITC-conjugated α-bungarotoxin 
in control and Rab18-/- littermates (unpaired two tailed t-test, p value=0.8624, n=10 





To examine synaptic vesicle recycling specifically at CNS synapses, isolated primary 
cortical neurons from wild type and Rab18-/- embryos were transfected with the 
genetic reporter synaptophysin-pHluorin (sypHy) (Granseth et al., 2006) in 
collaboration with Dr Sarah Gordon (Centre for Integrative Physiology). pHluorins 
are pH sensitive variations on GFP, and are routinely used in the study of 
neurotransmitter release as molecular markers of the pH of their surrounding 
environment. The pHluorin fluorescence is quenched in acidic environments, and 
increases at neutral pH (Fig 6.4 A). In the case of sypHy, the pHluorin is fused to the 
second intralumenal domain of synaptophysin, such that its fluorescence is quenched 
by the acidic pH inside synaptic vesicles (approximately pH 5.5). Upon exocytosis, 
sypHy is exposed to the neutral pH of extracellular medium (approximately pH 7.4) 
resulting in an increase in fluorescence. The pHluorin is then endocytosed, and 
following vesicle reacidification its fluorescence is again quenched. Vesicle 
reacidification is very fast, so the decrease in fluorescence acts as a reporter of the 
rate of endocytosis (Atluri and Ryan, 2006). To examine the consequences of loss of 
Rab18 on the synaptic vesicle cycle, sypHy transfected cortical neurons from wild 
type (WT) and Rab18-/- (KO) embryos were stimulated at 10 Hz with a train of 300 
action potentials to induce synaptic vesicle recycling and examine the kinetics of 
endocytosis. Cells were then additionally pulsed with ammonia buffer (NH4Cl) to 
deacidify the synaptic vesicles and report the total pHluorin fluorescence (Figure 6.4 
B). pHluorin traces were normalised to NH4Cl to reveal the total amount of synaptic 
vesicles exocytosed upon electrical stimulus and revealed no significant differences 
in the amount of vesicles released by the evoked stimulus (Figure 6.4 C). 
Normalisation of the sypHy trace to the peak of the evoked stimulus is used to report 
differences in the kinetics of endocytosis (Fig 6.4 D). One-phase exponential decay 
curves were fit to the endocytosis component of the sypHy traces (from 50-200s) and 
the endocytic time constant (tau,τ) was calculated. There was no difference in τ 
between WT and Rab18-/- neurons. Thus, loss of Rab18 has no major impact on gross 




Figure 6.4 Loss of Rab18 has no major effect on synaptic vesicle 
recycling in the CNS 
Experiments performed in collaboration with Dr Sarah Gordon. (A) pHluorin 
mechanism of action. (B-E) Analysis of synaptic vesicle recycling in cortical neurons 
isolated from wild type (WT) and Rab18-/- (KO) E17.5 embryos. (B and D) Cortical 
neurons transfected with sypHy were stimulated with a train of 300 action potentials 
(10 Hz) and subsequently perfused with NH4Cl to induce synaptic vesicle 
deacidification and reveal total pHluorin fluorescence. Traces illustrate the average 
fluorescence response over time (wild-type (WT, blue circles, n = 9) and Rab18-/- 
(KO, red circles, n = 7) ± SEM). (B) Traces were normalised to NH4Cl to reveal the 
total vesicle pool and identified (C) the lack of effect of RAB18 deletion on size of 
total vesicle pool (t-test p=0.74). (D) Traces were normalised to the stimulation peak 
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(10Hz) and (E) identified no differences in the average speed of endocytosis, 
endocytic time contast τ (t-test p=0.55).  
6.2.2   Anatomical characteristics of FDB, lumbrical and TVA 
muscles used for investigation of PNS pathology 
Rab18-/- mice present at weaning with abnormal hind limb clasping, deteriorating to 
progressive, hind limb weakness, abnormal gait and decline in movement. In order to 
determine whether motor neuron pathology was contributing to this phenotype, 
neuromuscular junctions were initially examined across a range of different muscle 
groups from control and Rab18-/- mice at both early symptomatic (3 weeks of age, 
onset of abnormal grasping phenotype) and mid/late symptomatic (splayed hind 
limbs, often dragged behind the body) time points. The following muscles were used 
for analyses; the transverse abdominus (TVA) a slow-twitch, postural muscle from 
the abdominal wall, the lumbrical muscles, a group of four fast-twitch muscles from 
the hind paw innervated by the medial and plantar branches of the tibial nerve and 
the flexor digitorum brevis (FDB), a fast-twitch muscle from the hind paw innervated 
by the medial plantar nerve.  
6.2.3 Hind limb weakness in Rab18-/- mice is not due to gross 
abnormalities in skeletal muscles 
To determine whether the observed hind limb weakness in Rab18-/- mice could be 
partly attributed to atrophy of skeletal muscle fibres as has been noted in other mouse 
models of neurodegenerative disease (Murray et al., 2008) I quantified for any 
abnormalities in skeletal muscle fibre morphology. During lumbrical muscle 
dissections skeletal muscle fibres were teased apart to visualise individual fibres and 
brightfield pictures taken. Images were imported into ImageJ and three 
measurements of muscle fibre diameter were taken along the length of each fibre (as 
shown in Figure 6.5A) and the average calculated. No significant difference in 
muscle fibre diameter was noted in lumbrical muscle preparations from Rab18-/- mice 
and littermate controls (Figure 6.5B).  
Additionally, to quantify for atrophy of motor endplates at the NMJ, post synaptic 
acetylcholine receptors from control, early and mid/late symptomatic Rab18-/- FDB, 
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lumbrical and TVA muscle preparations were labelled with TRITC-conjugated-α-
BTX (TRITC-α-BTX). Fluorescence micrographs encompassing a minimum of 30 
endplates from each individual muscle were imaged. Images were imported into 
ImageJ and endplate area manually outlined as in Figure 6.5C. Quantification 
revealed no significant differences in endplate area in any muscle types examined in 
either early or mid/late symptomatic Rab18-/- mice (Figure 6.5 D-F). Taken together 
the data shows that the hind limb weakness observed in Rab18-/- mice cannot be 
attributed to gross perturbations in muscle fibre size or endplate area suggesting that 





Figure 6.5 No differences in muscle fibre diameter or endplate area in 
control and Rab18-/- mice 
(A-B) Muscle fibre diameter. Three diameter measurements along each muscle fibre 
were taken as in (A) and the average calculated. (B) Bar chart of muscle fibre 
diameter measurements showing no significant differences between control and 
Rab18-/- mice (unpaired two tailed t-test, early symptomatic p value=0.8484, n=10 
muscles, mid/late symptomatic p value=0.2091, n=10 muscles). (C-F) Endplate area.  
Motor endplates were manually outlined as shown in (C). (D-F) Bar charts showing 
no differences in endplate area measurements from FDB (D), lumbrical (E) and TVA 
(F) muscle preparations from control, early (3 week old) and mid/late symptomatic 
Rab18-/- mice. Unpaired two-tailed t-test. Early symptomatic: FDB p value=0.8661, 
n=7 muscles, lumbrical p value= 0.6966, n=10 muscles, TVA n=1 muscle. Mid/late 
symptomatic: FDB p value=0.4038, n=9 muscles control and n=8 muscles Rab18-/-, 
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lumbrical p value p value=0.2887, n=10 muscles, TVA p value=0.7290, n=3 
muscles. ns= not significant. 
6.2.4 Normal NMJ innervations but pathological 
accumulations in motor nerve terminals of Rab18-/- mice 
As I had determined that loss of Rab18 does not result in gross perturbation of 
synaptic vesicle recycling or atrophy of skeletal muscle fibres I next set out to look 
for any pathological abnormalities in nerve-muscle connectivity at the NMJ, as a 
readout for the health-status of the lower motor neuron. NMJs from whole-mount 
FDB, lumbrical and TVA muscle preparations were examined in Rab18-/- mice and 
littermate controls at both early symptomatic and mid/late symptomatic timepoints. 
Post synaptic acetylcholine receptors of the motor endplate were labelled with 
TRITC-α-BTX (Figure 6.6, red), innervating axons with antibodies against 165kDa 
neurofilament protein (NEFM) (Figure 6.6, green) and presynaptic synaptic terminals 
with antibodies against the synaptic vesicle protein, SV2 (Figure 6.6, green). 
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Figure 6.6 Immunohistochemistry of the neuromuscular junction in 
control and Rab18-/- mice 
Representative confocal micrographs of neuromuscular junctions in FDB (A, D and 
G), lumbrical (B, E and H) and TVA (C, F and I) muscle preparations from control 
(A-C), early (D-F) and mid/late symptomatic Rab18-/- mice. Post synaptic 
acetylcholine receptors of motor endplates were immunohistochemically labelled 
with TRITC-conjugated α-bungarotoxin (red), neurofilaments with 165kDa NEFM 




During early postnatal development of the NMJ, the majority of skeletal muscle 
fibres are initially innervated by multiple motor axons. Over a period of several days 
following birth motor endplates undergo a highly competitive process of synapse 
elimination, losing many of their innervated branches, leaving only one input per 
endplate (Sanes and Lichtman, 1999). To quantify for any perturbations in the 
formation of appropriate neuromuscular connectivity, or any abnormalities in 
development, NMJs from control and mid/late symptomatic Rab18-/- mice were 
quantified for the number of synaptic inputs. All NMJs analysed had established 
innervations from a lower motor neuron. Additionally, at mid/late symptomatic 
timepoints no differences in the number of innverating axons per NMJ were 
identified in FDB and TVA muscles, however, a small increased in lumbrical 
muscles was observed (Figure 6.7). Furthermore, many mouse models of 
neurodegenerative disease show abnormalities in synaptic innervations with vacant 
endplates observed during late stages of disease (Cifuentes-Diaz et al., 2002, Achilli 
et al., 2009). To determine whether nerve muscle connectivity at the NMJ was 
maintained in the presence of the observed hind limb phenotype, NMJs from control, 
early and mid/late symptomatic Rab18-/- mice were quantified as being fully 
occupied (post synaptic SV2 staining completely overlies the endplate), partially 
occupied (less than 70% of the endplate is overlaid by SV2 staining) or vacant (no 
SV2 staining). The majority of motor endplates examined in Rab18-/- mice were fully 
occupied at both early and mid/late symptomatic time points (Figure 6.8). Taken 
together this suggests that Rab18-/- NMJs retain normal synaptic innervation despite 







6.2.5 Abnormal accumulation of neurofilament proteins at 
the NMJ in Rab18-/- mice 
Whilst conducting endplate occupancy and innervation counts we routinely observed 
large accumulations in the presynaptic motor nerve terminal at NMJs from Rab18-/- 
mice at both early and mid/late symptomatic time points (Figure 6.6). During our 
initial experiments innervating axons were stained with antibodies against 165kDa 
NEFM and presynaptic terminals with the synaptic vesicle protein SV2, both 
visualised with the same secondary antibodies. To determine the nature of the 
accumulations separate immunohistochemical experiments were undertaken labelling 
the NMJ of whole-mount lumbrical muscles from mid/late symptomatic Rab18-/- 
mice with TRITC-α-BTX and one of either NEFM (Figure 6.9 A-C) or SV2 (Figure 
6.9 D-F). Separate immunostaining showed the accumulations were composed of 
neurofilament proteins, and normal levels of synaptic vesicles were observed (Figure 
6.9).
 
Figure 6.9 Neurofilament accumulations but normal synaptic vesicle 
levels at the NMJ of Rab18-/-mice 
(A-F) Confocal micrographs of neuromuscular junctions in lumbrical muscle 
preparations from mid/late symptomatic Rab18-/- mice. Post synaptic acetylcholine 
receptors of motor endplates were immunohistochemically labelled with TRITC-
conjugated α-bungarotoxin (red), and co-stained with either 165kDa NEFM (green, 
A) and synaptic vesicles with SV2 (green, D). (C and F) are merged composites of 
(A and B) and (D and E) respectively. Note the accumulations of NEFM at the NMJ 
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of Rab18-/- mice (C) but normal levels of synaptic vesicle proteins (F). Scale bar 
represents 10µm. 
To determine whether the neurofilament accumulations increased with disease 
progression the number of endplates positive for accumulations of neurofilament in 
FDB, lumbrical and TVA muscle preparations from control, early and mid/late 
symptomatic Rab18-/- mice were quantified. NMJs were identified as containing 
neurofilament accumulations if they contained 1 or more large aggregates of staining 
at the motor nerve terminal not matching the underlying motor endplate labelling 
with TRITC-α-BTX. 20% of endplates in FDB and lumbrical muscles from early 
symptomatic Rab18-/- mice had accumulations of neurofilament increasing to 
approximately 60% by mid/late symptomatic time points (Figure 6.10 A-B and D-E). 
The postural transverse abdominus muscle also contained accumulations of 
neurofilament in approximately 20% of NMJs at early symptomatic time points but 
this stayed at a steady state level despite disease progression (Figure 6.10 C and F). 
Taken together this suggests that loss of Rab18 results in neurofilament 
accumulations at the NMJ, which increased with disease progression in hind limb 
muscles where I had previously observed an overt neurological phenotype.  
Figure 6.10 Neurofilament accumulations at the neuromuscular 
junction in Rab18-/- mice 
Quantification of percentage of motor endplates with neurofilament (nf) 
accumulations in FDB (A and D), lumbrical (B and E) and TVA (C and F) muscle 
preparations from control, early (A-C, 3 week old) and mid/late symptomatic Rab18-
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/- (D-F) mice. Mann Whitney test. Early symptomatic: FDB p value=0.0026, n=8 
muscles control and n=7 muscles Rab18-/-, lumbrical p value= 0.0096, n=10 muscles 
control and n=8 muscles Rab18-/-, TVA n=1 muscle. Mid/late symptomatic: FDB p 
value=0.0005, n=9 muscles control and n=8 muscles Rab18-/-, lumbrical p 
value=0.0002, n=10 muscles, TVA p value=0.0765, n=3 muscles. Ns= not 
significant, ** p<0.005, ***p<0.001. 
 
As we observed large accumulations of neurofilament medium protein (NEFM) at 
the neuromuscular junctions; I therefore set out to determine whether these 
accumulations contained other isoforms of neurofilament or differentially 
phosphorylated neurofilaments as observed in many other neurodegenerative 
diseases (Table 6.1). NMJs from whole-mount lumbrical muscle preparations were 
stained with Alexa647-α-BTX labelling the post synaptic acetylcholine receptors of 
the motor endplate (Figure 6.11 A and B, magenta), and innervating axons with a 
combination of 165kDa neurofilament (NEFM) (Figure 6.11, green) and 200kDa 
neurofilament (NEFH) (Figure 6.11, green) or hypophosphorylated NEFH (Figure 
6.13, red) and 68kDa neurofilament (NEFL) (Figure 6.12, green). Confocal 
micrographs imaged at the same intensity levels identified that accumulations at the 
neuromuscular junction of Rab18-/- mice are composed of all three isoforms of 
neurofilament; NEFL, NEFM and NEFH. Taken together this suggests that loss of 
Rab18 results in a gross disorganisation of neurofilaments rather than targeting one 
specific isoform. We additionally observed accumulations of hypophosphorylated 
NEFH at the NMJ (Figure 6.12, red). Hypophosphorylation of neurofilament 
isoforms has been reported to increase neurofilament transport (Jung et al., 2000, 
Ackerley et al., 2003) and could potentially serve as a possible explanation for the 






Figure 6.11 Accumulation of NEFM and NEFH at the neuromuscular 
junction in Rab18-/- mice 
Confocal micrographs of neuromuscular junctions in lumbrical muscle preparations 
from control (A, C, E and G) and mid/late symptomatic Rab18-/- (B, D, F and H) 
mice. Post synaptic acetylcholine receptors of motor endplates were 
immunohistochemically labelled with Alexa647-conjugated α-bungarotoxin 
(magenta), 165kDa NEFM (red) and 200kDa NEFH (green). Note the accumulations 




Figure 6.12 Accumulation of hypophosphorylated NEFH and NEFL at 
the neuromuscular junction in Rab18-/- mice 
Confocal micrographs of neuromuscular junctions in lumbrical muscle preparations 
from control (A, C, E and G) and mid/late symptomatic Rab18-/- (B, D, F and H) 
mice. Post synaptic acetylcholine receptors of motor endplates were 
immunohistochemically labelled with Alexa647-conjugated α-bungarotoxin 
(magenta), hypophosphorylated 200kDa NEFH (red) and 68kDa NEFL (green). Note 
the accumulations of hypophosphorylated NEFH and NEFL in Rab18-/- mice. Scale 
bar represents 50µm. 
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6.2.6 Widespread neuronal cytoskeletal disorganisation in 
Rab18-/- mice 
To determine whether the observed neurofilament accumulations could be attributed 
to abnormalities in organisation of the cytoskeleton in general and/or disruption to 
axonal transport processes as observed in other mouse models of neurodegenerative 
disease (Table 6.2), I next focused my attention on examination of axonal structure in 
the sciatic nerve of Rab18-/- mice. To identify any abnormalities in the structure of 
axons from Rab18-/- mice I examined the ultrastructure of the sciatic nerve from 
control (Figure 6.13 A) and mid/late symptomatic Rab18-/- mice (Figure 6.13B) by 
transmission electron microscopy. In all cases the nerve was dissected from the 
sciatic notch and along the tibial branch to the knee joint.  Initial ultrastructural 
analyses identified that both genotypes failed to show any characteristic markers of 
degeneration (such as myelin thinning/unwrapping and breakdown), in agreement 
with our observations at the NMJ. Similarly, the gross morphology of axonal 
mitochondria was unchanged in Rab18-/- mice.  
At higher magnification, normal organisation of the cytoskeleton (incorporating both 
neurofilament and microtubule networks) was seen in sciatic nerves from control 
mice, with vertically orientated filaments observed (Figure 6.13 C). In contrast, gross 
disorganisation of the axonal cytoskeleton was observed in Rab18-/- mice (Figure 
6.13 D) with randomly orientated filaments, suggestive of gross abnormalities in 
cytoskeletal organisation. To confirm the observation of normal myelination in 
Rab18-/- mice G-ratio calculations were undertaken (G-ratio=diameter of 
axon/diameter of axon plus myelin), and identified no gross differences in G-ratio 
(Figure 6.13 E) or relationship of axon diameter to G-ratio (Figure 6.13 F and G). 
Thus, loss of Rab18 resulted in disorganisation of the axonal cytoskeleton in 









Figure 6.13 Cytoskeletal disorganisation of the sciatic nerve in Rab18-/- 
mice  
 (A-B) Ultrastructural analysis of the sciatic nerve in control (A) and Rab18-/- (B) 
mice by transmission electron microscopy. No evidence of myelin sheath breakdown 
or axonal degeneration observed was observed in either genotype. (C-D) Higher 
magnification images of the axonal cytoskeleton from a single axon in A and B 
respectively. (C) In control mice both microtubule and neurofilaments are orientated 
vertically and shown as dense puncta. (D) Gross disorganisation of the cytoskeleton 
(microtubules and neurofilaments) in Rab18-/- littermates, with random orientated 
filaments. (E-G) Quantification of myelination identified no abnormalities in G-ratio 
(G-ratio=diameter of axon/diameter of axon plus myelin) Unpaired two-tailed t-test. 
G-ratio p value=0.7610, N=3 mice (E) or spread of axon diameter compared to G-
ratio in control (F) and Rab18-/- mice (G). Panels A-D scale bar represents 1µm.  
 
The neurological symptoms of the Warburg Micro syndrome phenotype are not 
restricted to the PNS, with patients presenting with central nervous system and ocular 
abnormalities. Therefore, I examined whether the cytoskeletal disorganisation 
observed in the PNS also extended to axons in the CNS of Rab18-/- mice. Eyes were 
removed from culled mice and the intact optic nerve dissected from immediate 
connection to the eye, with care taken during dissection to avoid damage to the 
nerve. Transmission electron microscopy on sections of the optic nerve in control 
(Figure 6.14 A) and mid/late symptomatic Rab18-/- (Figure 6.14 B) mice again 
identified no markers of degeneration, with both myelination and axonal morphology 
appearing normal. However, upon closer examination of the axon, disorganisation of 
the cytoskeleton (microtubules and neurofilaments) was also observed in some axon 
profiles of the optic nerve of Rab18-/- mice (Figure 6.14C). Taken together these data 
suggest that loss of Rab18 results in disorganisation of the cytoskeleton throughout 
the nervous system. 
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Figure 6.14 Ultrastructural examination of the optic nerve by electron 
microscopy showing gross cytoskeletal disorganisation in Rab18-/- mice 
Transmission electron micrographs of the optic nerve from control (A) and mid/late 
symptomatic Rab18-/- mice (B and C). (A-B) Note the myelin sheaths remain intact. 
(C) High magnification images showing disorganisation of the cytoskeleton in some 
but not all axon profiles in Rab18-/-optic nerves. N=1, panels A-B scale bar 




6.2.7 Accumulations of microtubules at the NMJ in Rab18-/- 
mice 
My observations of neurofilament accumulations at the NMJ and disorganisation of 
the axonal cytoskeleton (incorporating both neurofilament and microtubule 
networks) pointed towards the possibility that other cytoskeletal proteins may 
additionally be accumulating in motor neurons. I therefore returned to the whole-
mount muscle/NMJ preparations to establish whether Rab18-/- mice also exhibit 
accumulations of microtubules at the NMJ. NMJs in whole-mount FDB muscle 
preparations from control (Figure 6.15 A) and mid/late symptomatic Rab18-/- (Figure 
6.15 B) mice were labelled with TRITC-α-BTX staining the post synaptic 
acetylcholine receptors and neuronal specific βIII tubulin, as a marker of 
microtubules. Again, as expected, normal innervation and endplate morphology were 
observed in both genotypes. However, gross accumulations of microtubule proteins 
were observed at the NMJ of Rab18-/- animals, phenocopying the morphologies 
observed in previous labelling with neurofilament antibodies. 
 
Figure 6.15 Microtubule accumulation at the neuromuscular junction 
in Rab18-/- mice 
Confocal micrographs of neuromuscular junctions in FDB muscle preparations from 
control (A) and mid/late symptomatic Rab18-/- (B) mice. Post synaptic acetylcholine 
receptors of motor endplates were immunohistochemically labelled with TRITC-
conjugated α-bungarotoxin (red) and neuronal specific βIII tubulin (green). Note the 
accumulations of microtubules in Rab18-/- mice. Scale bar represents 10µm. 
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6.2.8 Examination of axonal transport by sciatic nerve ligation 
experiments 
My results so far have identified grossly abnormal accumulations of neurofilament 
and microtubule proteins at the NMJ alongisde cytoskeletal disorganisation of axons 
in the sciatic nerve. I therefore wanted to establish whether the observed 
accumulations could be attributed, at least in part, to perturbations in axonal 
transport.  
The study of neurofilament transport is well-established and many studies have now 
identified that, under normal circumstances, neurofilaments are trafficked along 
microtubules in a bidirectional manner, by slow axonal transport alternating between 
short rapid movements and prolonged pauses (Brown et al., 2005). Furthermore, 
studies have identified that the molecular motor KIF5A is critical for efficient 
neurofilament transport (Xia et al., 2003, Wang and Brown, 2010). Mutations that 
are predicted to result in a dominant negative or loss-of-function of KIF5A kinesin 
activity cause a form of hereditary spastic paraplegia (SPG10) (Reid et al., 2002). 
Additionally, KIF5A null mouse models are embryonic lethal with accumulations of 
neurofilament protein observed in cell bodies, indicative of an abnormality in 
neurofilament axonal transport (Xia et al., 2003). I therefore analysed levels of 
KIF5A protein in the sciatic nerve of Rab18-/- mice.  
Sciatic nerves were dissected from control and mid symptomatic Rab18-/- mice and 
cut into two segments proximal and distal to the tibial branchpoint. No significant 
differences were observed in the amount of total KIF5A in proximal and distal 
portions of control or mid symptomatic Rab18-/- nerves (Figure 6.16 A). We 
therefore utilised unilateral sciatic nerve ligation experiments with the aim of 
identifying any potential deficits in trafficking, such as you might hypothesise to 
occur when the organisation of the axonal cytoskeleton is disrupted. Tight ligature of 
the sciatic nerve prevents the transport of proteins between proximal and distal 
segments. As a result, any accumulations observed proximal to the ligature are 
indicative of anterograde transport abnormalities and any abnormalities distal 
representing retrograde transport abnormalities. Mid symptomatic Rab18-/- mice at 6 
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weeks of age were selected for sciatic nerve ligation experiments after the onset of 
abnormal hind limb grasping but before the mice became too sick to ensure a healthy 
recovery following surgery. The sciatic nerve from one leg was ligated with a 
surgical suture knot to tie off the nerve just below the sciatic notch. After 24 hours 
mice were sacrificed and segments proximal and distal to the ligature site taken. The 
unligated nerve from the other leg was taken as control.  As kinesin proteins function 
as anterograde motors, sciatic ligation would be expected to cause an accumulation 
of KIF5a proximal to the ligature and a reduction distal to the ligature in a healthy 
nerve.  In three independent experiments this expected pattern was observed in 
nerves from both control and Rab18-/- mice (Figure 6.16 B).  However, upon closer 
comparison of KIF5A levels, a reduction of KIF5a was observed distal to the ligature 
in Rab18-/- nerve (Figure 6.16 C). Ratio comparisons of KIF5a levels in proximal 
compared to distal nerve stumps identified a significant increase in the 
proximal:distal ratio in Rab18-/- nerves as compared to wild-type nerves (Figure 6.16 
D). Together this points towards an abnormality in the retrograde transport of 





Figure 6.16 Abnormalities in axonal transport of KIF5A 
Western blot analysis of levels of KIF5a in unligated wild-type and Rab18-/- sciatic 
nerves, showing no gross differences in KIF5A levels (A). β3 tubulin was used as a 
loading control. (B) Representative western blot of levels of KIF5a following sciatic 
nerve ligation in wild-type and Rab18-/- sciatic nerves, β3 tubulin was used as a 
loading control, representative blot was not used for densitometry. (C) Quantification 
of KIF5a levels in ligated sciatic nerves from control and Rab18-/- mice. (D) The 
ratio between proximal and distal samples calculated, showing an increased ratio of 
proximal:distal in Rab18-/- nerves. Values were normalised to tubulin loading in each 
lane. N=3,  ***=p>0.001, unpaired two-tailed t-test. 
 
To investigate whether this finding represented a global defect in axon trafficking, 
we examined trafficking of a known molecular cargo of fast axonal transport, 
amyloid precursor protein (APP), following sciatic nerve ligation (Figure 6.17A). 
These experiments identified a decrease of APP proximal to the ligature and an 
increase in the distal portion of the Rab18-/- nerve (Figure 6.17 B). Ratiometric 
analysis of proximal:distal in Rab18-/- mice did show a trend with a slight reduction 
in the distal Rab18-/- samples, however, variations between samples were observed 
and as a result did not reach significant levels (Figure 6.17 C). These results indicate 
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that KIF5a-dependent retrograde axonal transport may be specifically affected in 
Rab18-/- nerves and may potentially point towards the possibility that RAB18 
influences trafficking of neurofilaments in neurons by regulating this specific aspect 
of axonal transport. APP pathways showed no significant changes, however, more 
studies would need to be performed to examine this further. 
 
Figure 6.17 Normal trafficking of amyloid precursor protein (APP) in 
Rab18-/- mice following sciatic nerve ligation 
(A)Representative western blot of levels of amyloid precursor protein (APP) 
following sciatic nerve ligation in wild-type and mid-symptomatic (6 week old) 
Rab18-/ mice, showing no significant differences in levels of APP. β3 tubulin was 
used as a loading control. (B) Quantification of APP levels in unligated and ligated 
sciatic nerves from control and Rab18-/- mice. (C) The ratio between proximal and 
distal samples calculated, showing no significant differences in APP levels between 
control and Rab18-/- nerves. Values were normalised to tubulin loading in each lane. 






In our aforementioned sciatic nerve ligation experiments βIII tubulin was used as a 
control for loading. Due to their high abundance and usually constant levels, 
antibodies targeting various tubulin isoforms are routinely used as loading controls 
for Western blotting experiments. However, there are several potential problems with 
this approach. Principally, in my data reported here I have identified accumulations 
in filament proteins (neurofilament and microtubule) in studies of the NMJ. To 
confirm its validity as a loading control in our experiments, βIII tubulin levels in 
sciatic nerve extracts were compared to those of Myelin protein zero (MP0) and 
observed no significant differences (Figure 6.18). MP0 was selected as previous 
ultrastructural analysis of the sciatic nerve and G-ratio quantifications identified no 
abnormalities in myelination. Additionally, in the above sciatic nerve ligation 
experiments densitometry was performed with and without normalisation to tubulin 
and identified no significant alterations in expression pattern. Taken together, I 






Figure 6.18 Rationale behind using β3 tubulin as a loading control for 
sciatic nerve ligation experiments 
Western blot analysis of βIII tubulin levels in intact unligated sciatic nerves. In this 
case myelin protein zero (MP0) was used as a loading control and identified no 
significant differences between wild type (WT) and Rab18-/- nerves. 
 
6.2.9 iTRAQ proteomics screening of the peripheral nerve 
proteome in Rab18-/- mice 
In order to undertake a large-scale, unbiased analysis of the consequences of RAB18 
depletion on the molecular composition of the PNS, iTRAQ proteomics analyses 
were performed on sciatic nerves isolated from 6 week old heterozygote control and 
Rab18-/- mice. All samples used in this analysis were taken from male mice from the 
same breeding pair, backcrossed for 9 generations to C57BL/6J, in order to eliminate 
any variation in background effects. Six nerves from each of three heterozygote and 
three homozygote mice were pooled and homogenised in 1/40 weight/volume 0.5M 
triethylammonium bicarbonate, 1% SDS and 1mM PMSF. To quantify protein levels 
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in these samples, 2µl of each was run on a SDS-PAGE gel alongside 5µg, 10µg and 
14µg of wild type sciatic nerve and stained with Coomassie blue (Figure 6.19). The 
nerve sample used for comparison was previously homogenised in 1x RIPA buffer 
and so it was possible to determine protein concentration with a Pierce BCA protein 
assay kit.  
 
Figure 6.19 Coomassie stain of sciatic nerve samples sent for 
proteomic analysis 
5µg, 10µg and 14µg of wild type sciatic nerve previously homogenised in 1x RIPA 
buffer and protein concentration calculated with Pierce BCA protein assay kit was 
run as a positive control alongside 2µl of the resultant homogenate for iTRAQ 
proteomics. The aforementioned samples were run on an SDS-PAGE gel and stained 
with Coomassie blue. 
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Samples were then sent to Dundee Cell products for isobaric tag for relative and 
absolute quantitation (iTRAQ) proteomic analysis and the resultant mass 
spectrometry data searched against the Mascot Search Engine using the following 
parameters; enzyme specificity trypsin, false discovery rate 1%, database 
IPImouse_20130120, max peptide length 6 and max missed cleavages 2. Their 
analysis identified 1337 proteins for which expression levels could be compared 
between the two genotypes. In order to identify proteins differentially expressed in 
Rab18-/- compared to heterozygote nerves, we set a stringent filtering criteria of 20% 
difference in levels and identified by two or more unique peptides. From this criteria, 
202 proteins were significantly altered, 112 upregulated (Appendix 3) and 90 
downregulated (Appendix 4) upon loss of Rab18. Interestingly, both neurofilament 
and tubulin isoforms were downregulated in Rab18-/- nerves (Appendix 4), further 
supporting our identification of cytoskeletal abnormalities in Rab18-/- nerves. It 
should also be noted that Rab18 was the second highest protein downregulated in our 
study at a ratio of 0.315 compared to heterozygote controls but was only found by 
one unique peptide and so was removed from the filtered tables. This is in agreement 
with our Western blotting analysis showing no observable RAB18 in sciatic nerves 
of Rab18-/- mice compared to controls.  
To examine whether the altered proteins are specific and the effects on protein levels 
are present in all mice without Rab18, I examined the levels of one upregulated 
protein Apolipoprotein D (ApoD) and one downregulated protein peripheral myelin 
protein 2 (PMP2) in isolated sciatic nerve samples from wild type (WT), 
heterozygote (HET) and Rab18-/- mid symptomatic mice. I carried out western 
blotting for levels of APOD in heterozygote and Rab18-/- sciatic nerves and showed 
APOD to be very dramatically upregulated in Rab18-/- nerves (Figure 6.20 A).  It was 
surprising that PMP2 showed a decrease in proteomic analysis of Rab18-/- sciatic 
nerves given that we did not observe any myelination defects upon EM. I therefore 
carried out western blotting on levels of PMP2 in wild type, heterozygote and Rab18-
/- sciatic nerves and did not confirm the proteomics finding, suggesting that some hits 
are artefacts (Figure 6.20 C). In both cases, a parallel blot of the same protein 
samples was run and stained with Coomassie blue for analysis of protein loading 




Figure 6.20 Proteomic validation 
(A) Representative western blot analysis of heterozygote (HET) and Rab18-/- mice, 
not used for iTRAQ analysis showing increased levels of Apolipoprotein D (ApoD) 
in Rab18-/- mice compared to controls, thus validating the proteomics screen. (B) 
Coomassie stained gel of samples run in (A) showing no gross discrepancies in 
protein loading that could account for the observed effect. (C) Representative 
western blot analysis of wild type (WT), heterozygote (HET) and Rab18-/- mice, 
(samples were not used for iTRAQ analysis) showing equal levels of PMP2 in all 
lanes. (D) Coomassie stained gel of parallel samples to those run in (C) confirming 
equal protein loading in all lanes.  
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To identify functional molecular pathways altered upon loss of Rab18 in the sciatic 
nerve, we performed Ingenuity Pathway Analysis (IPA) (in collaboration with Tom 
Wishart). IPA software utilises published information of direct and indirect protein 
interactions to identify clustering of proteins in particular core pathways or linked to 
biological function and/or disease. Ontology analysis identified 44 proteins clustered 
around movement disorders and 35 around neuromuscular disorders (Table 6.3). Of 
particular interest to us was clustering of proteins and pathways relating to cellular 
assembly and organisation; including 28 proteins with known roles and/or links to 
organisation of the cytoskeleton and 25 in microtubule dynamics (Table 6.4). This 
suggests that loss of Rab18 results in many cellular downstream consequences in 
pathways regulating organisation of the cytoskeleton. 
 
Table 6.3: Ingenuity pathway analysis highlights clustering of proteins 




Table 6.4: Ingenuity pathway analysis of functional clustering 
highlights alterations in cellular assembly and organisation. 
 
In summary, our data reported here supports a critical role for RAB18 in 





In this chapter I describe characterisation of the neuropathological hind limb 
phenotype observed in Rab18-/- mice, resulting in 6 major findings. First, I identified 
normal levels of RAB3GAP1, RAB3GAP2 and RAB3A in Rab18-/- mice, suggesting 
that the phenotype of Warburg Micro syndrome is not a result of gross dysregulation 
of the RAB3 cycle. Additionally, analysis of synaptic vesicle recycling at PNS and 
CNS synapses identified no gross discrepancies in synaptic vesicle exocytosis or 
endocytosis. Second, I showed that the hind limb weakness observed in Rab18-/- 
mice occurred in the absence of any characteristic hallmark features of degeneration 
at either PNS synapses or axon profiles of the sciatic nerve, with normal myelination, 
endplate occupancy and muscle fibre morphology all observed. Third, I identified 
gross accumulation of neurofilament and microtubule proteins at the NMJ, directly 
correlating with disease progression. Fourth, I identified gross disorganisation of 
axonal cytoskeletal architecture in Rab18-/- mice. Fifth, preliminary analysis of 
axonal transport identified potential selective abnormalities in KIF5A specific 
pathways, although studies of APP transport showed no significant alterations. 
Further studies are needed to examine this in more detail. Finally, I have 
demonstrated through in depth proteomic and ontology analysis that loss of Rab18 
results in perturbations in cellular pathways regulating cytoskeletal organisation and 
maintenance in sciatic nerves. 
6.3.1 Neurofilament and microtubule accumulations at the 
NMJ and cytoskeletal disorganisation in peripheral nerves 
One of the most striking observations in Rab18-/- mice was the abnormal 
accumulation of cytoskeletal proteins at the NMJ and gross disorganisation of the 
cytoskeleton without accompanying loss of innervation or skeletal muscle. However, 
studies examining motor neuron dysfunction are now bringing to light isolation of 
pre and post synaptic and axonal and synaptic pathology in a range of different 
muscle types. For example Shen et al., reported muscular pathology in hNF-LE397K 
mice modelling Charcot-Marie-Tooth type 2E without significant nerve and NMJ 
pathology (Shen et al., 2011). Additionally, Murray et al., reported dissociation of 
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pre and post synaptic pathology in SMN mice, with some vacant endplates showing 
normal morphology (Murray et al., 2008). Furthermore, studies examining ALS 
mouse models have definitively isolated axonal transport deficits and 
neurodegeneration (Marinkovic et al., 2012). Our study could therefore possibly 
point towards a specific involvement of axonal transport deficits and cytoskeletal 
disruption distinct from neurodegeneration and muscular pathology. Furthermore, 
our observations of accumulations at the NMJ and cytoskeletal disorganisation of 
axons in the sciatic nerve implies that the accumulations may be associated with a 
deficit that affects nerve function without instigating cell death pathways. For 
example, it would be of interest to examine whether the progressive hind limb 
phenotype could potentially be due to deterioration of nerve conduction velocities as 
could be explored with specialist electrophysiological techniques. 
Accumulations of cytoskeletal proteins and aberrant post-translational modifications 
are hallmark features of many neurodegenerative diseases (Table 6.1). Interestingly, 
we observed accumulations of all three isoforms of neurofilament protein (NEFL, 
NEFM and NEFH) at the NMJ. Quantification of the number of endplates positive 
for NEFM accumulations in early and mid/late symptomatic Rab18-/- mice revealed 
that these accumulations increased with disease severity. Furthermore, axons 
innervating the hind limb muscles, where we previously observed deterioration, 
contained more endplates with accumulations than in axons innervating truncal 
muscles. This suggests that neurofilament accumulations may be a correlate of 
disease progression in Rab18-/- mice and potentially Warburg Micro syndrome 
patients. However, it would be of interest to examine neurofilament levels in pre-
symptomatic Rab18-/- mice to determine whether the observed neurofilament 
accumulations in approximately 20% of endplates in all early symptomatic muscles 
examined represents a baseline upon depletion of Rab18 or a marker of onset of 
disease progression. Preliminary studies also identified large accumulations of hypo-
phosphorylated NEFH. However, further experiments would need to be conducted 
comparing antibody levels specifically directed against hypo-, hyper- and normally 
phosphorylated NEFM and NEFH isoforms before we can definitively confirm or 
rule out the involvement of aberrant post-translational modifications of 
neurofilament in the phenotype of our Rab18-/- mouse model. At this stage it remains 
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unclear whether altered phosphorylation causes the observed neurofilament 
accumulations or is the result of them, our data reporting a defect in trafficking of 
KIF5A the molecular motor implicated in neurofilament transport appears to support 
the latter.  
Axonal transport is a fundamental process for axonal viability as the vast majority of 
axonal proteins are synthesized in the cell body and transported through the axon 
along cytoskeletal tracks to specific compartments for example synaptic proteins 
targeted to the axon terminal (De Vos et al., 2008). Interestingly, however, it appears 
that the cytoskeletal disorganization observed in Rab18-/- mice does not represent 
global deficiencies in axonal transport. This was unsurprising as we did not observe 
deterioration of axons and NMJs, pointing towards the fact that at least some axonal 
transport must be occurring normally for cell viability to be ensured. Furthermore, no 
significant differences were observed in the trafficking of APP, although variation 
was seen between samples, at this stage I cannot say whether APP pathways may be 
definitely altered or not. We did observe a reduction in KIF5A distal to the ligature 
site in Rab18-/- nerves indicative of a reduction in retrograde transport. KIF5A is the 
molecular motor attributed to driving the anterograde (and a small proportion of 
retrograde) transport of neurofilaments (Xia et al., 2003, Wang and Brown, 2010) 
and mutations cause SPG10 (Reid et al., 2002). Neurofilament transport in axons 
occurs via slow axonal transport; with rapid bursts interchanged with prolonged 
pauses (Brown et al., 2005). However, studies examining conditional deletion of 
NEFL in mice and EGFP-NEFL dynamics in primary cortical neurons have 
identified only a minority of neurofilaments undergo slow axonal transport, with the 
majority maintained in a fixed stationary lattice (Millecamps et al., 2007, Yuan et al., 
2009). Additionally, we also identified accumulations of the microtubule marker βIII 
tubulin at Rab18-/- nerve terminals. Microtubules form the cytoskeleton tracks on 
which axonal transport occurs. However, studies have brought to light that, like 
neurofilaments, the majority of microtubules are stationary forming discontinuous 
cytoskeletal tracks, but a subset of short microtubule polymers are transported 
rapidly along axons, with speeds similar to that of the molecular motors dynein and 
kinesin, interchanged with frequent prolonged pauses (Wang and Brown, 2002). Our 
analysis presented here has identified accumulations of microtubule and 
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neurofilament proteins at the NMJ. Furthermore, our proteomic and ontology 
analysis of proteins altered by greater than 20% in the sciatic nerves of Rab18-/- 
compared to heterozygote littermates identified alterations in core proteins 
implicated in cytoskeleton assembly and organisation, further supporting a role for 
RAB18 in cytoskeletal dynamics for example reductions in the levels of NEFL, 
NEFM and NEFH, and four tubulin isoforms (tubulin alpha-4a, tubulin alpha-1a, 
tubulin beta-5 chain, tubulin beta-3) were observed in Rab18-/- sciatic nerves. 
However, it remains unclear whether the observed reduction in levels of components 
of the cytoskeleton in axons (neurofilament and tubulin proteins) by iTRAQ and 
accumulations at the NMJ are the result of trafficking defects or the result of this 
disorganisation. Following this, it is also possible that the disorganisation could 
disrupt the microtubule tracks and result in trafficking abnormalities. It is therefore 
of particular interest that although the axonal cytoskeleton showed gross 
disorganisation, analysis of protein levels by iTRAQ and potentially trafficking of 
the anterograde cargo APP, identified that many abundant proteins are trafficked 
normally, it may be therefore that neurofilaments and microtubules are particularly 
sensitive to trafficking perturbations or loss of Rab18 may target specific trafficking 
pathways, as suggested by the KIF5A data. Interestingly, we also identified 
alterations to many proteins previously shown to be implicated in neurodegenerative 
disease. It would be of interest to examine sciatic nerve architecture in early 
symptomatic Rab18-/- mice to aid the isolation of disorganisation or accumulations as 
the primary pathological hallmark of Warburg Micro syndrome pathology in 
peripheral nerves. Through this we could hopefully decipher whether cytoskeletal 
disorganisation increases in severity concomitantly with neurofilament 
accumulations or whether Rab18-/- mice exhibit abnormalities in organisation from 
early axon development, and it is solely the neurofilament and microtubule polymers 
that accumulate with disease.   
Proteomic validation was undertaken examining the levels of apolipoprotein D 
(ApoD) in isolated Rab18-/- sciatic nerves, and confirmed significant enrichment 
upon loss of Rab18. Apolipoprotein D is a member of the apolipoprotein family 
functioning in lipid binding and transport and characterisation of the ApoD knockout 
mouse model has shown ApoD to be critical for maintenance of the myelin sheath 
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and its expression level elevated in response to injury (Ganfornina et al., 2010). As 
we observed normal myelination in Rab18-/- mice, as shown through EM and G-ratio 
calculations, it is therefore possible that the large increase observed in Rab18-/- 
sciatic nerves could point towards ApoD serving a neuroprotective role potentially 
against the cytoskeletal disorganisation. Therefore, this finding of a dramatic 
increase in the levels of ApoD upon loss of Rab18 is akin to injury of the motor 
neurons rather than death. Further studies examining cellular stress markers such as 
IL6 and Vegfa and apoptotic markers such as TUNEL staining are warranted to 
determine the level of stress in Rab18-/- mice.  
6.3.2 Normal synaptic vesicle endocytosis and exocytosis in 
Rab18-/- neurons 
Abnormalities in cytoskeletal organisation and axonal trafficking could both 
potentially result in abnormalities in the number and rate of synaptic vesicle 
recycling at Rab18-/- synapses. To characterise for gross abnormalities in synaptic 
vesicle recycling, we utilised two well-established techniques (FM1-43 and sypHy) 
to demonstrate no gross abnormalities in presynaptic function at the PNS or size of 
the total vesicle pool or endocytosis at CNS Rab18-/- synapses. This suggests that, 
perhaps surprisingly, loss of Rab18 has no major impact on synaptic vesicle 
recycling in PNS or CNS synapses, however, this is consistent with our observations 
of normal innervation at the NMJ. 
Causative loss-of-function mutations have previously been identified in RAB3GAP1, 
RAB3GAP2 or RAB18 resulting in a clinically indistinguishable patient phenotype. 
RAB3GAP1 and RAB3GAP2 specifically function in regulating the RAB3 family in 
calcium mediated exocytosis of hormones and neurotransmitters (Sudhof, 2004, 
Aligianis et al., 2005). Prior to generation of the Rab18-/- mouse, analysis of 
pathological mechanisms underlying Warburg Micro syndrome were focused around 
the role of RAB3 and synaptic vesicle recycling. It must be noted however, that none 
of the mouse or fly models published for Rab3 or Rab3 regulatory proteins have any 
reported neurological deteriorations in the CNS or PNS. For example; mice and flies 
deficient for the catalytic subunit, Rab3gap1 identified subtle alterations in synaptic 
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plasticity but failed to recapitulate any of the characteristic ocular or neurological 
phenotypes of the human disease (Sakane et al., 2006, Muller et al., 2011). 
Furthermore, examination of synaptic plasticity in Rab3 quadruple knockout mice 
(Rab3a, Rab3b, Rab3c and Rab3d) showed normal docking of synaptic vesicles at 
active zones in hippocampal neurons, normal axonal conductivity and a discrete 
reduction in synaptic vesicle exocytosis (Schluter et al., 2004). Rab3gep-/- mice 
(GEP- GDP/GTP exchange protein) die shortly after birth with no evoked responses 
in the diaphragm or gastrocnemius muscles. However, they showed normal axonal 
conductivity in the spinal cord and phrenic nerve but neuromuscular transmission 
abnormalities with few to no synaptic vesicles at Rab3gep-/- axon terminals (Tanaka 
et al., 2001).   
I propose that further studies should now be undertaken to examine for neurofilament 
and microtubule abnormalities and cytoskeletal disorganisation in animal models 
lacking Rab3 and Rab3 regulatory proteins. The Rab3gap1-/- mouse did not report 
any neurological deterioration but due to the identical phenotype observed upon 
RAB3GAP1, RAB3GAP2 or RAB18 loss it could potentially also exhibit slight 
increased levels of neurofilament. Additionally, if similar neuropathological 
abnormalities were observed in the Rab3gap1 mice but not Rab3 or Rab3GEF for 
example this may help to distinguish RAB3GAP function from that reported to 
regulate RAB3. Furthermore, quadruple Rab3 knockouts die very soon after birth 
due to respiratory failure, this could be due to neuronal dysfunction or a general 
defect of exocytosis, further studies would now be warranted to examine this. 
6.3.3 Summary 
In summary, I have described here detailed neuropathological characterisation of the 
hind limb weakness observed during initial phenotyping of Rab18-/- mice. I have 
demonstrated that loss of Rab18 does not result in gross abnormalities in synaptic 
vesicle recycling at PNS or CNS synapses but rather results in accumulations of 
microtubules and neurofilament proteins in motor neuron terminals. Furthermore, 
through electron microscopy of axons and proteomic analysis of Rab18-/- sciatic 
nerves I have identified RAB18-dependent disorganisation of microtubules and 
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neurofilaments and alterations in core molecular pathways implicated in assembly 
and confirmation of the cytoskeleton. 
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Chapter 7 Summary and general discussion 
7.1 Summary of findings in this study 
The principle aim of this study was to undertake a detailed characterisation of a 
novel Rab18-/- mouse model created by MRC Harwell as part of the EUMODIC 
screen.  
Rab18 genetrap mice were generated using the FlipRosaβGeo cassette. Initially, I 
carried out analysis of the genetrap and identified no residual mRNA or protein 
expression upon RT-PCR, qRT-PCR or Western blotting for RAB18. I therefore 
consider Rab18-/- mice to represent the null phenotype of Rab18. In humans, 
homozygous loss-of-function mutations in RAB18 cause Warburg Micro syndrome. I 
therefore utilised the Rab18-/- mouse model to examine for phenotypes relevant to 
Warburg Micro syndrome. Detailed phenotypic analysis identified specific 
abnormalities in the lens and the hind limbs, recapitulating many of the characteristic 
ocular and neurological features of Warburg Micro syndrome. 
Secondly, I set out to determine the localisation of RAB18 in mouse embryonic 
fibroblasts to determine whether loss of RAB18 resulted in a ubiquitous cellular 
phenotype. I have shown that RAB18 localises to the ER, Golgi apparatus and lipid 
droplet surface, in agreement with previous reports (Martin et al., 2005, Ozeki et al., 
2005, Pulido et al., 2011, Dejgaard et al., 2008). Interestingly, loss of RAB18 had no 
gross consequences on ER or Golgi apparatus morphology but resulted in enlarged 
lipid droplets. I was therefore unable to rule out the possibility that Warburg Micro 
syndrome pathology originates from a ubiquitous cellular function. However, my 
analyses of GFP-RAB18 localising to mobile accumulations along neurite processes 
of primary hippocampal neurons, potentially points towards a cell-type specific 
function for RAB18 in neurons. 
My subsequent work aimed to provide a more detailed characterisation of the ocular 
and neurological features observed during general phenotyping of the Rab18-/- mouse 
model. Rab18-/- mice presented at eye opening with dense nuclear congenital 
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cataracts and atonic pupils and went on to develop progressive hind limb weakness. 
Histological examination of embryonic and neonatal lens identified a delay in closure 
of the lens vesicle from E12.5, with large vacuoles, pyknotic nuclei and nuclear 
aggregates evident in the lens by birth. Additionally, preliminary analysis identified 
potential abnormalities in denucleation and organisation of lens fibre cells in Rab18-/- 
neonates suggestive of a defect in lens fibre cell differentiation.  
Detailed investigation of the neuronal pathology underlying the observed hind limb 
weakness suggested that, contrary to expectation, loss of RAB18 resulted in no major 
abnormalities in synaptic vesicle recycling at either PNS or CNS synapses. 
Additionally, normal levels of RAB3GAP1, RAB3GAP2 and RAB3A in crude 
synaptosomes isolated from Rab18-/- mice were observed. However, gross 
accumulations of microtubules and neurofilament proteins were observed at Rab18-/- 
NMJs and disorganisation of the axonal cytoskeletal architecture was seen in sciatic 
nerve profiles. Furthermore, in- depth proteomic and gene ontology analysis in 
sciatic nerves showed that loss of Rab18 resulted in modifications to several 
canonical pathways regulating cytoskeletal organisation and maintenance. 
Preliminary analysis of axonal transport by sciatic nerve ligation experiments, also 
pointed towards a potential abnormality in KIF5A dependent transport pathways.  
7.2 Link between the ocular and neurological 
phenotypes observed in Warburg Micro 
syndrome patients and Rab18-/- mice 
Rab18-/- mice exhibit dense nuclear congenital cataracts and progressive hind limb 
weakness. It is of interest how loss of a ubiquitously expressed protein can result in 
such specific abnormalities affecting both ocular and neurological systems whilst 
other cells and tissues remain essentially unaffected. As discussed in chapter 3, the 
phenomenon of restricted neuronal vulnerability upon loss of a ubiquitously 
expressed protein is observed in many models of neurodegenerative disease (Monani, 
2005). How loss of RAB18 specifically affects neurological and ocular systems must 
now be further examined. Many other disorders also exhibit neurodegeneration and 
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congenital cataracts including atypical familial lipodystrophy, hypomyelination and 
congenital cataract, and congenital cataract facial dysmorphism neuropathy 
syndrome (Berger et al., 2002, Biancheri et al., 2007, Shabo et al., 2005). Recent 
studies have therefore tried to establish a potential link between lens fibre cells and 
neurons and have identified a large degree of similarity; for example a number of 
gene products thought to be neuronal specific, have now also been shown to be 
expressed in the lens (Frederikse et al., 2012). Similarities in vesicular transport 
machinery have also been identified between neurons and lens fibre cells with RT-
PCR of 6 week old lens identifying the presence of molecular motors (including 
KIF5A), RAB proteins (including RAB3A), synapsin and synaptic vesicle proteins 
(including synaptotagmin I and synaptophysin I) (Frederikse et al., 2004). 
Additionally, Lo et al., 2003 have shown that lens fibre cells and neurons share a 
comparable morphology with an orientated microtubule system, with newly 
differentiated lens fibre cells containing polarised microtubules along their long axes 
and kinesin and dynein molecular motors. Furthermore, the Golgi apparatus and 
membranous vesicles reminiscent of vesicular transport mechanisms are evident in 
differentiating fibre cells of the outer cortex, but not found in either the inner cortex 
or the differentiated lens nucleus (Lo et al., 2003).  
It is therefore important to try and identify a link between the neuronal pathologies 
including neurofilament and microtubule accumulations and cytoskeletal 
disorganisation with the lenticular anomalies observed in Rab18-/- mice. A previous 
study characterising mice overexpressing neurofilament light chain reported the 
development of cataracts consistent with the possibility that cataract development 
may be linked to neurofilament abnormalities (Monteiro et al., 1990). This may in 
turn suggest a link between the cellular pathology observed in the lens fibre cells in 
Rab18-/- mice and those seen in the peripheral nervous system. Preliminary 
experiments have pointed towards abnormalities in lens fibre organisation properties 
in Rab18-/- mice.  Future work should therefore focus on examining the microtubule 
architecture in the developing lens by electron microscopy and identifying levels of 




7.3 Role of a RAB protein in cytoskeletal 
disorganisation  
RAB proteins primarily function in regulating vesicular trafficking so the 
identification of an unexpected role for RAB18 in cytoskeletal organisation is 
potentially interesting. One possible explanation for this finding has come from 
analysis of the smooth endoplasmic reticulum existing as a continuous network of 
tubules in axons. I, along with others, have shown RAB18 to be linked to the ER in 
multiple cell types (chapter 4) (Martin et al., 2005). It is now widely established that 
the smooth ER interacts with the neuronal cytoskeleton (Renvoise and Blackstone, 
2010). For example, previous studies have identified a link between the smooth ER 
and neurofilaments in transected squid giant axons and frog olfactory axons (Burton 
and Laveri, 1985, Metuzals et al., 1995). It is therefore not unfathomable that a 
deficit in RAB18 at the smooth ER may result in disorganisation to the axonal 
cytoskeleton. Other proteins are known to mediate associations between the ER and 
the cytoskeleton such as spastin and the REEP1-4 family of proteins and mutations in 
these genes cause peripheral neurological abnormalities similar to those observed in 
Warburg Micro syndrome (Renvoise and Blackstone, 2010, Montenegro et al., 
2012). Additionally, examination of the reticulon-like-1 fly orthologue of human 
reticulon 2 showed disorganisation of the smooth ER, microtubules and mitochondria 
in motor axons and at the NMJ (O'Sullivan et al., 2012). A role for atlastin (another 
hereditary spastic paraplegia gene) has also been reported in regulation of lipid 
droplet size, with knockdown causing a decreased diameter of lipid droplets (Klemm 
et al., 2013), and could potentially link the cytoskeleton disorganisation and lipid 
phenotype observed. Potentially, RAB18 may therefore function to maintain a link 
between the smooth ER and the cytoskeleton in peripheral nerves. 
Interestingly, I have also identified GFP-RAB18 to localise to dense puncta along 
processes of primary mouse hippocampal neurons that are trafficked rapidly in a 
retrograde manner. It has also been brought to light that a small component of the ER 
functions in large vesicular structures in dendrites that are rapidly trafficked in a 
bidirectional manner (Bannai et al., 2004). This trafficking is dependent on 
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microtubule organisation and the molecular motor, kinesin (Bannai et al., 2004). 
Analysis of ER vesicular trafficking in axons identified movement in a bidirectional 
manner and insensitive to nocodazole treatment (Aihara et al., 2001). It would now 
be of interest to identify whether these accumulations co-localise with markers of the 
smooth endoplasmic reticulum to determine if the punctae observed in GFP-RAB18 
transfected neurons represent the vesicular subcompartment of the ER showing rapid 
movement.  
Interestingly, there is a precedent for RAB proteins mediating a link between 
membrane trafficking and the cytoskeleton. One way they do this is via molecular 
motors. For example, GTP bound RAB6A directly interacts with KIF20A (Echard et 
al., 1998) whereas RAB3A interacts indirectly with KIF1Bβ/KIF1A via 
DENN/MADD (Niwa et al., 2008). I have shown in chapter 4 that GFP-RAB18 
positive puncta appear to be trafficked in a specifically retrograde manner. Future 
work should therefore determine whether RAB18 functions via a molecular motor. 
Preliminary studies in chapter 5 have suggested abnormalities in KIF5A dependent 
pathways; however, at this stage it is unclear whether this is the result of the 
cytoskeletal disorganisation or a cause of it. 
7.4 Future work 
In this thesis I have performed a detailed characterisation of pathological changes in 
Rab18-/- mice, a model for Warburg Micro syndrome. The majority of potential 
future work has been presented in the discussion section of each relevant chapter. 
Here, I will therefore focus on future work that could hopefully provide us with a 
link between not only the four causative genes but also pathological abnormalities 
observed in this study. Warburg Micro syndrome is a highly heterogeneous disorder, 
with mutations in one of RAB3GAP1, RAB3GAP2, RAB18 or TBC1D20 accounting 
for approximately 50% of cases. Further heterogeneity is therefore evident. Whole 
exome sequencing is currently being undertaken to identify other causative genes for 
Warburg Micro syndrome. It is hoped that the identification of further genes may aid 
the elucidation of the RAB protein network implicated in disease pathogenesis.  
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In this study I have primarily focused on the congenital cataracts and progressive 
hind limb weakness observed during general phenotyping of the Rab18-/- mouse 
model. Definitive analysis and characterisation of other phenotypes observed in 
Warburg Micro syndrome patients are now critical. For example, examination of any 
central nervous system or endocrine abnormalities should now be a focus of future 
work. 
7.4.1 Link between phenotypes observed  
A novel finding of this study was the identification of gross accumulations of 
neurofilament in motor neurons from Rab18-/- mice. Preliminary work also suggested 
that cytoskeletal disorganisation is a feature of the lens pathology. This raises the 
question of whether the pathology in the motor neurons and lenses result from 
deficiencies in the same, RAB18-regulated process. In order to further characterise 
the links between RAB18 and the cytoskeleton in each of these systems further 
studies should initially be focused on examination of levels of lens differentiation 
markers such as the α, β and γ-crystallins, in control and Rab18-/- mice. Also, 
sectioning of the equatorial plane of the lens and staining with PRX or scanning 
electron microscopy should be performed to definitively confirm or rule out 
abnormalities in the organisation of lens fibre cells in Rab18-/- mice. Additionally, 
the lens also expresses intermediate filament proteins, the principle of which being 
vimentin (FitzGerald, 2009), examination of intermediate filament levels in the lens 
by Western blotting should also be performed. Neurofilament accumulations are also 
observed in the CNS in many neurodegenerative diseases. For example, 
accumulations of neurofilament are observed in Lewy bodies in Parkinson disease 
brains (Goldman et al., 1983). Warburg Micro syndrome patients also display many 
central nervous system abnormalities including polymicrogyria and severe 
developmental delay; it would therefore be of interest to examine the levels of 
neurofilament proteins in the central nervous system of Rab18-/- mice.  
As discussed in section 7.3, RAB18 and its role in cytoskeletal disorganisation and 
transport may involve interactions with the smooth ER. To enable further 
characterisation of a link between RAB18 and the smooth ER, future studies should 
examine the morphology of the smooth ER in peripheral nerves by EM and examine 
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the NMJ to determine whether the smooth ER also accumulates with neurofilament 
and microtubules.  
I also observed accumulations of GFP-RAB18 along processes of primary mouse 
hippocampal neurons that are trafficked rapidly in a retrograde manner. Further 
characterisation of the nature of these accumulations to determine whether they 
represent synaptic vesicles (given the well-established roles of RAB3 proteins) or ER 
markers should now be undertaken. RAB18 is a member of the RAB family of small 
GTPases functioning as master regulators of vesicular trafficking. It would be of 
interest to examine the nucleotide binding properties of RAB18 in primary 
hippocampal neurons by transfection of GDP or GTP mutants and examine 
localisation. Co-transfection experiments with GFP-RAB18 and mCherry-
RAB3GAP1, RAB3GAP2 or TBC1D20 would be useful in determining the 
respective localisation of the four proteins.  
7.4.2 Link between Warburg Micro syndrome causative genes 
At this stage of our analysis it is now important to determine a link between the four 
causative genes that would result in an identical phenotype. As previously stated 
experiments are now being undertaken to determine if RAB3GAP2 has GEF activity 
towards RAB18 and TBC1D20 functions as a GAP for RAB18. However, it would 
also be of interest to examine for protein levels of TBC1D20 in Rab18-/- mice and 
RAB18 levels in Tbc1d20 bs mice. Furthermore, as studies undertaken by Leigel et 
al., have reported enlarged lipid droplets in RAB3GAP1, RAB3GAP2 and TBC1D20 
patient fibroblasts. A biochemical screen of lipid and cholesterol levels in Rab18-/- 
mice would be important to characterise any abnormalities. 
7.4.3 Generation of conditional knockouts 
The Rab18-/- mouse presented in the study was created using the FlipRosaβGeo 
cassette. This genetrap cassette utilises pairs of heterotypic lox and frt sites to allow 
the generation of temporal and tissue specific knockouts. I have crossed Rab18-/- 
mice to FLPe to flip the cassette into the reverse orientation on the antisense strand 
and thus repair the mutation. Litters from this mating have now been born and are 
positive for insertion of the cassette by primer specific PCR and gel electrophoresis 
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but negative for congenital cataracts or hind limb weakness. Crosses are now 
underway to breed Flipped Rab18-/- mice to CreER a tamoxifen inducible Cre, to 
reinvert the cassette onto the sense strand and reinsert the mutation. When these mice 
reach 6 weeks of age they will be injected with tamoxifen to knock out Rab18 and 
characterise any phenotypes in the adult nervous system, it is hoped that this will 
enable us to delineate the role of Rab18 in degeneration compared to development.  
7.5 Conclusion 
In summary, this study reports the first characterisation of a mouse model for Rab18, 
recapitulating both ocular and neurological features of Warburg Micro syndrome. 
Rab18-/-mice present with dense nuclear congenital cataracts, atonic pupils and 
progressive hind limb weakness, all phenotypes associated with Warburg Micro 
syndrome disease pathogenesis. I have shown that the abnormal ocular phenotypes in 
Rab18-/- mice begin from E12.5 with delay in closure of the lens vesicle. Analyses of 
the observed hind limb pathology have shown that loss of RAB18 does not result in 
abnormalities in synaptic vesicle recycling or RAB3 proteins, suggesting the 
pathology of Warburg Micro syndrome may not be centred on dysregulation of the 
RAB3 pathway as previously proposed. Furthermore, I have identified that loss of 
RAB18 results in accumulations of microtubule and neurofilament proteins at the 
NMJ and gross disorganisation of the neuronal cytoskeleton in sciatic nerve profiles. 
iTRAQ proteomic analysis of Rab18-/- peripheral nerve identified abnormalities in 
core molecular pathways implicated in organisation and maintenance of the axonal 
cytoskeleton. Rab18-/- mice model the major disease characteristics of Warburg 
Micro syndrome and I therefore propose a novel role for RAB18 in eye development 
and maintenance of cytoskeletal architecture in neurons, thus providing for the first 
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Appendix 1: Movie legends 
 
Movie 1: Optical projection tomography on adult wild-type albino eyes 
Optical projection tomography on adult wild-type albino eyes showing normal lens. 
 
Movie 2: Optical projection tomography on adult Rab18-/- albino eyes 
Optical projection tomography on adult Rab18-/- albino eyes showing dense nuclear 
cataracts in the centre of the lens. 
 
Movie 3: GFP-Rab18 undergoes dynamic movement in mouse primary 
hippocampal neurons.  
Time-lapse movie (2 minute intervals for 16 hours, 10fps) showing wild type mouse 
hippocampal neurons from E17.5 embryos transfected with GFP-RAB18 at 12-14 
DIV. GFP-RAB18 is localised throughout neurons and present in puncta in neuronal 

















Appendix 2: Necropsy report 
 
 
David Brownstein  
Room W3.16 
Queen's Medical Research Institute 
47 Little France Crescent 






Investigator: Ian Jackson 
Date of necropsy: 2/12/10 
Path#: DB55-58/10 
Subject: KO mouse model which is looking very interesting. Has  
cataracts and an apparent neuromuscular problem which results in  
hindlimb weakness progressing to paralysis. These are 106 day-old littermates, 
agouti, chinchilla?) and black. Two homozygotes are thin with barbered fur over 




































































Testis (mg): DB55 =118g , DB56 = 198, DB57=234, DB58=170  
Gross: homozygotes smaller than heterozygote or wt.  
 
Histopathology. The following tissues were examined and found  not to differ 
significantly between the two  homozygous and the heterozygous and wt  animals. 
A. heart-  
B. lung-  
C. thyroid, adrenals,  
D. testis or uterus-   
E. stomach, small intestine (3 levels)-  
F. caecum, colon, mesentery-  
G. liver, skin, abdominal mammary -  
H. brain (3 coronal levels)-  
I.  pituitary-.  
J.  lower urinary-  
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K. kidneys, interscapular brown fat -  
L.  spleen, pancreas, thymus, lymphosalivary -  
M. head (inc. eyes and mid/inner ears) -  
N. long bones with knee joint - 
O. lumbar spine/spinal cord/aorta- 
P. thoracic spine/spinal cord/aorta 
Q. cervical spine/spinal cord 





Appendix 3 iTRAQ identification of proteins >20% upregulated in Rab18-/- 
compared to heterozygote nerves with 2 or more unique peptides  







MYH4 myosin, heavy chain 4, skeletal muscle IPI00404837.3 32 4.278 
KRT1 keratin 1 IPI00625729.2 2 3.145 
KRT5 keratin 5 IPI00470126.4 4 2.842 
KRT10 keratin 10 IPI01008564.1 4 2.696 
COL1A2 collagen, type I, alpha 2 IPI00988109.1 12 2.556 
APOD apolipoprotein D IPI00314309.3 5 2.366 
KRT13 keratin 13 IPI00136056.1 2 2.355 
COL1A1 collagen, type I, alpha 1 IPI00329872.1 9 2.180 
KRT14 keratin 14 IPI00227140.1 5 1.928 
KRT2 keratin 2 IPI00622240.4 3 1.886 
LGALS3 lectin, galactoside-binding, soluble, 3 IPI00989544.2 2 1.871 
Ighg Immunoglobulin heavy chain (gamma polypeptide) IPI00109910.4 8 1.851 
Ighg2a immunoglobulin heavy constant gamma 2A IPI00954663.1 2 1.846 
ACTC1 actin, alpha, cardiac muscle 1 IPI00114593.1 8 1.731 
COL28A1 collagen, type XXVIII, alpha 1 IPI00357842.7 8 1.663 
HIST1H1C histone cluster 1, H1c IPI00223713.5 4 1.657 
IGHM immunoglobulin heavy constant mu IPI00468055.3 4 1.653 
RPL6 ribosomal protein L6 IPI00313222.5 11 1.645 
JUP junction plakoglobin IPI00229475.1 2 1.626 
HNRNPA2B
1 heterogeneous nuclear ribonucleoprotein A2/B1 IPI00405058.6 
4 
1.549 
IGKC immunoglobulin kappa constant IPI00850020.1 2 1.545 
Pzp pregnancy zone protein IPI00624663.3 12 1.543 
PCOLCE procollagen C-endopeptidase enhancer IPI00120176.1 2 1.533 
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HNRNPC heterogeneous nuclear ribonucleoprotein C (C1/C2) IPI00759870.1 2 1.508 
FGA fibrinogen alpha chain IPI00115522.3 8 1.493 
RPL18A ribosomal protein L18a IPI00162790.1 3 1.484 
COL6A3 collagen, type VI, alpha 3 IPI00988390.1 2 1.482 
COL4A1 collagen, type IV, alpha 1 IPI00109588.4 5 1.466 
FGG fibrinogen gamma chain IPI00990997.1 12 1.464 
RPL15 ribosomal protein L15 IPI00273803.4 2 1.459 
FGB fibrinogen beta chain IPI00279079.1 8 1.457 
RPL13A ribosomal protein L13a IPI00223217.6 3 1.414 
RPL24 ribosomal protein L24 IPI00880689.1 3 1.409 
RPL14 ribosomal protein L14 IPI00133185.3 3 1.408 
BCAP31 B-cell receptor-associated protein 31 IPI00230422.6 2 1.408 
COL4A2 collagen, type IV, alpha 2 IPI00338452.3 10 1.401 
THY1 Thy-1 cell surface antigen IPI00109727.1 4 1.399 
STEAP3 STEAP family member 3, metalloreductase IPI00830824.1 3 1.371 
RPS11 ribosomal protein S11 IPI00762542.2 5 1.362 
CAV1 caveolin 1, caveolae protein, 22kDa IPI00117829.1 3 1.348 
TM9SF2 transmembrane 9 superfamily member 2 IPI00988824.1 2 1.343 
Rpl10 ribosomal protein L10 IPI00775915.1 5 1.337 
LMNA lamin A/C IPI00400300.1 32 1.334 
NDUFB6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa IPI00648743.1 2 1.327 
Rrbp1 ribosome binding protein 1 IPI00755120.2 3 1.324 
LOC638399 60S ribosomal protein L31-like IPI00677102.1 2 1.323 
COPA coatomer protein complex, subunit alpha IPI00989407.1 4 1.322 
PABPC1 poly(A) binding protein, cytoplasmic 1 IPI00124287.2 2 1.322 
RPL7 ribosomal protein L7 IPI00311236.1 10 1.321 
MTCH1 mitochondrial carrier 1 IPI00742287.1 2 1.316 
Gm5453 predicted gene 5453 IPI00461641.2 3 1.306 
RPL18 ribosomal protein L18 IPI00555113.2 5 1.304 
HIST1H1B histone cluster 1, H1b IPI00230133.5 6 1.304 
SEC23A Sec23 homolog A (S. cerevisiae) IPI00985577.1 3 1.293 
ENTPD2 ectonucleoside triphosphate diphosphohydrolase 2 IPI00115089.2 9 1.293 
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POSTN periostin, osteoblast specific factor IPI00409326.1 10 1.290 
GNG12 guanine nucleotide binding protein (G protein), gamma 12 IPI00227838.4 3 1.290 
HNRNPL heterogeneous nuclear ribonucleoprotein L IPI00985815.1 4 1.289 
RPS4X ribosomal protein S4, X-linked IPI00990327.1 10 1.281 
PICALM phosphatidylinositol binding clathrin assembly protein IPI00404434.1 2 1.279 
GNB2L1 guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 IPI00317740.5 2 1.279 
APOA1 apolipoprotein A-I IPI00877236.1 13 1.276 
NDUFA9 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa IPI00120212.2 3 1.272 
NSDHL NAD(P) dependent steroid dehydrogenase-like IPI00128692.1 5 1.271 
CFH complement factor H IPI00856390.1 3 1.270 
RPS2 ribosomal protein S2 IPI00318492.11 10 1.267 
RPS3 ribosomal protein S3 IPI00134599.1 8 1.264 
KARS lysyl-tRNA synthetase IPI00620145.1 2 1.263 
Gm7429 predicted pseudogene 7429 IPI00463886.1 6 1.257 
DAD1 defender against cell death 1 IPI00109082.3 2 1.256 
MCAM melanoma cell adhesion molecule IPI00667748.1 4 1.252 
RPL10A ribosomal protein L10a IPI00849927.1 5 1.250 
DYNC1I1 dynein, cytoplasmic 1, intermediate chain 1 IPI00990353.1 2 1.250 
ANXA1 annexin A1 IPI00230395.5 9 1.249 
HNRNPU heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A) IPI00970121.1 10 1.247 
DDX5 DEAD (Asp-Glu-Ala-Asp) box helicase 5 IPI00420363.3 4 1.246 
MGLL monoglyceride lipase IPI00953761.1 3 1.245 
C3 complement component 3 IPI00323624.4 30 1.244 
SYNCRIP synaptotagmin binding, cytoplasmic RNA interacting protein IPI01027389.1 2 1.243 
LAMB2 laminin, beta 2 (laminin S) IPI00119065.2 47 1.242 
RPS15A ribosomal protein S15a IPI00857457.1 2 1.239 
KDELR3 




RPN1 ribophorin I IPI00309035.2 11 1.238 
MT-CO2 cytochrome c oxidase subunit II IPI00131176.1 3 1.237 
RPL8 ribosomal protein L8 IPI00137787.3 6 1.236 
TNXB tenascin XB IPI00130794.1 14 1.235 
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DHCR7 7-dehydrocholesterol reductase IPI00130988.1 3 1.232 
ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 IPI00556827.1 3 1.228 
P4HB prolyl 4-hydroxylase, beta polypeptide IPI00133522.2 8 1.225 
RTN1 reticulon 1 IPI00459442.1 3 1.222 
RPL9 ribosomal protein L9 IPI00881026.1 3 1.220 
CRIP2 cysteine-rich protein 2 IPI00121319.1 3 1.220 
EIF4H eukaryotic translation initiation factor 4H IPI00222560.7 2 1.219 
RPS9 ribosomal protein S9 IPI00420726.3 6 1.218 
COPG1 coatomer protein complex, subunit gamma 1 IPI00223437.5 2 1.217 
CYB5R3 cytochrome b5 reductase 3 IPI00759904.1 9 1.216 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 polypeptide IPI00762871.2 14 1.215 
MIF macrophage migration inhibitory factor (glycosylation-inhibiting factor) IPI00230427.5 2 1.213 
CTSD cathepsin D IPI00927957.1 5 1.211 
RPS16 ribosomal protein S16 IPI00469918.4 4 1.210 
PLP1 proteolipid protein 1 IPI00263013.4 8 1.208 
RPL29 ribosomal protein L29 IPI00874437.1 2 1.208 
MARC2 mitochondrial amidoxime reducing component 2 IPI00123276.1 3 1.207 
ITIH2 inter-alpha-trypsin inhibitor heavy chain 2 IPI00970608.1 2 1.202 






Appendix 4 iTRAQ identification of proteins >20% downregulated in 
Rab18-/- compared to heterozygote nerves with 2 or more unique 
peptides  
Symbol Protein name Accession # 
# 
Unique  Ratio  
peptides Rab18/het 
ALDH1A1 aldehyde dehydrogenase 1 family, member A1 IPI00626662.3 5 0.503 
SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 IPI00123927.1 5 0.539 
SDPR serum deprivation response IPI00135660.5 3 0.579 
VAT1L vesicle amine transport protein 1 homolog (T. californica)-like IPI00222759.3 16 0.594 
MYL6 myosin, light chain 6, alkali, smooth muscle and non-muscle IPI00354819.5 2 0.594 
AKR1B1 aldo-keto reductase family 1, member B1 (aldose reductase) IPI00223757.4 13 0.604 
PMP2 peripheral myelin protein 2 IPI00553439.2 13 0.605 
PRX periaxin IPI00762284.1 64 0.616 
OGN osteoglycin IPI00120848.1 13 0.625 
ASPA aspartoacylase IPI00881964.1 4 0.626 
NEFH neurofilament, heavy polypeptide IPI00675855.3 35 0.636 
SVIP small VCP/p97-interacting protein IPI00460224.3 2 0.639 
CNTF ciliary neurotrophic factor IPI00125017.1 6 0.641 
APOA4 apolipoprotein A-IV IPI00377351.3 2 0.654 
NEFM neurofilament, medium polypeptide IPI00323800.6 40 0.657 
TCEB2 transcription elongation factor B (SIII), polypeptide 2 (18kDa, elongin B) IPI00131224.1 2 0.664 
FBXO2 F-box protein 2 IPI00153176.2 2 0.664 
Serpina3k serine (or cysteine) peptidase inhibitor, clade A, member 3K IPI00131830.1 4 0.666 
SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 IPI00406302.2 4 0.671 
DYNC1LI1 dynein, cytoplasmic 1, light intermediate chain 1 IPI00153421.1 2 0.673 
NEFL neurofilament, light polypeptide IPI00554928.3 32 0.679 
TUBA4A tubulin, alpha 4a IPI00117350.1 6 0.680 
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ANXA5 annexin A5 IPI00317309.5 18 0.683 
TFG TRK-fused gene IPI00130013.4 7 0.683 
HDHD2 haloacid dehalogenase-like hydrolase domain containing 2 IPI00111166.7 2 0.684 
DDAH1 dimethylarginine dimethylaminohydrolase 1 IPI00109482.3 11 0.688 
PLEKHB1 pleckstrin homology domain containing, family B (evectins) member 1 IPI00858298.1 2 0.690 
ANXA6 annexin A6 IPI00554894.3 38 0.693 
UBE2K ubiquitin-conjugating enzyme E2K IPI00880781.1 2 0.693 
COL15A1 collagen, type XV, alpha 1 IPI00648224.1 15 0.702 
DCN decorin IPI00123196.1 15 0.707 
BCAS1 breast carcinoma amplified sequence 1 IPI00330860.3 13 0.708 
AARS alanyl-tRNA synthetase IPI00321308.4 3 0.708 
CKB creatine kinase, brain IPI00136703.1 13 0.708 
LUM lumican IPI00313900.1 13 0.709 
LDHB lactate dehydrogenase B IPI00229510.5 14 0.710 
EPB41L2 erythrocyte membrane protein band 4.1-like 2 IPI00330289.4 32 0.713 
TUBA1A tubulin, alpha 1a IPI00110753.1 6 0.716 
PRKCDBP protein kinase C, delta binding protein IPI00126939.1 8 0.716 
PTRF polymerase I and transcript release factor IPI00117689.1 15 0.721 
GLO1 glyoxalase I IPI00321734.7 6 0.724 
MDH1 malate dehydrogenase 1, NAD (soluble) IPI00336324.11 13 0.727 
HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 IPI00330804.4 15 0.728 
PRKCA protein kinase C, alpha IPI00321446.4 2 0.731 
NAPA N-ethylmaleimide-sensitive factor attachment protein, alpha IPI00118930.1 3 0.732 
PRDX6 peroxiredoxin 6 IPI00754071.1 5 0.735 
PRELP proline/arginine-rich end leucine-rich repeat protein IPI00122293.3 15 0.739 
NME1 NME/NM23 nucleoside diphosphate kinase 1 IPI00990246.1 9 0.740 
GMFB glia maturation factor, beta IPI00467495.4 3 0.741 
VSNL1 visinin-like 1 IPI00230418.5 3 0.743 
DYNLL1 dynein, light chain, LC8-type 1 IPI00121623.1 2 0.744 
STXBP6 syntaxin binding protein 6 (amisyn) IPI00720103.1 6 0.745 
CYB5A cytochrome b5 type A (microsomal) IPI00918942.1 3 0.746 
TUBB tubulin, beta class I IPI00117352.1 4 0.748 
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HSPA1A/HSPA1B heat shock 70kDa protein 1A IPI00798482.20 5 0.748 
Ube2n ubiquitin-conjugating enzyme E2N IPI00165854.3 4 0.750 
TUBB3 tubulin, beta 3 class III IPI00112251.1 6 0.751 
BGN biglycan IPI00123194.1 9 0.757 
GDI1 GDP dissociation inhibitor 1 IPI00323179.3 10 0.759 
MAPRE3 microtubule-associated protein, RP/EB family, member 3 IPI00830432.1 3 0.763 
Atp5h ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d IPI00881799.1 4 0.764 
CACYBP calcyclin binding protein IPI00115650.4 2 0.770 
USP5 ubiquitin specific peptidase 5 (isopeptidase T) IPI00881918.1 7 0.771 
CTNND1 catenin (cadherin-associated protein), delta 1 IPI00752631.1 3 0.772 
RUFY3 RUN and FYVE domain containing 3 IPI00622482.2 10 0.772 
YWHAH 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta 
polypeptide IPI00227392.5 5 0.773 
SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 IPI00129755.2 3 0.774 
Ckmt1 creatine kinase, mitochondrial 1, ubiquitous IPI00128296.1 7 0.777 
PGK1 phosphoglycerate kinase 1 IPI00555069.3 17 0.777 
DRP2 dystrophin related protein 2 IPI00830746.1 14 0.779 
WBP2 WW domain binding protein 2 IPI00648905.1 3 0.780 
ANXA3 annexin A3 IPI00132722.9 6 0.782 
HSPA4L heat shock 70kDa protein 4-like IPI00317711.1 8 0.786 
HSPA8 heat shock 70kDa protein 8  IPI00323357.3 25 0.786 
YWHAZ 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta 
polypeptide IPI00116498.1 11 0.786 
SNX6 sorting nexin 6 IPI00111827.5 2 0.789 
DAG1 dystroglycan 1 (dystrophin-associated glycoprotein 1) IPI00122273.1 7 0.790 
ANXA2 annexin A2 IPI00468203.3 25 0.790 
GSTM3 glutathione S-transferase mu 3 (brain) IPI00990550.1 3 0.791 
IDH1 isocitrate dehydrogenase 1 (NADP+), soluble IPI00762452.2 11 0.791 
RAP2A RAP2A, member of RAS oncogene family IPI00396701.3 2 0.795 
IDH3A isocitrate dehydrogenase 3 (NAD+) alpha IPI00608078.1 3 0.796 
MARCKS myristoylated alanine-rich protein kinase C substrate IPI00229534.5 4 0.798 
RAP1GDS1 RAP1, GTP-GDP dissociation stimulator 1 IPI00653794.2 21 0.798 
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PPP1R7 protein phosphatase 1, regulatory subunit 7 IPI00129319.3 2 0.799 
CAPNS1 calpain, small subunit 1 IPI00830335.1 3 0.799 
FSCN1 fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) IPI00353563.4 16 0.799 
PYGB phosphorylase, glycogen; brain IPI00229796.3 20 0.799 
ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) IPI00111218.1 13 0.799 
 
 
